{
  "0": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the lack of evidence for HER2-targeted therapy in SCC, guideline recommendations, and the prioritization of standard chemo/immunotherapy, with no major omissions or errors."
  },
  "1": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and appropriate justification without omissions or errors."
  },
  "2": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the rationale for prioritizing FDG-PET/CT and enhanced brain MRI, and considerations for renal function. However, it slightly overstates the priority of brain MRI (should be based on suspicion of metastasis) and does not explicitly mention that these modalities are recommended only when there is suspicion of recurrence or metastasis, as emphasized in the reference answer."
  },
  "3": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细阐述了放疗风险、指南建议及替代方案，无重大遗漏或错误。"
  },
  "4": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guideline recommendations, and the necessity of EGFR testing before considering osimertinib, with no major omissions or errors."
  },
  "5": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need for pulmonary function assessment and alternative non-surgical treatments if the patient is not a surgical candidate. No major omissions or errors."
  },
  "6": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional rationale and guideline references without deviating from the core recommendation."
  },
  "7": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the diagnostic criteria for OPBC and correctly excluding cases with skin or chest wall involvement, with no major omissions or errors."
  },
  "8": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and even adds relevant guideline references and specific regimen details."
  },
  "9": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including SRS and WBRT indications, the impact of brain edema, and guideline recommendations. However, it overemphasizes the need to avoid SRS in cases of steroid-refractory edema, whereas the reference answer allows for SRS if vital signs are stable, leading to a minor omission in nuance."
  },
  "10": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even provides additional relevant details and guideline references."
  },
  "11": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing orthopedic stabilization plus postoperative radiotherapy over radiotherapy alone, with no major omissions or errors."
  },
  "12": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes radiotherapy, and provides detailed justification consistent with the reference answer, with no major omissions or errors."
  },
  "13": {
    "score": 5.0,
    "explanation": "5: The model answer accurately reflects current guidelines and provides a detailed rationale for preferring chemotherapy over continued endocrine therapy in this clinical scenario, with no major omissions or errors."
  },
  "14": {
    "score": 3.0,
    "explanation": "3: The model answer provides a generally correct follow-up frequency for surgical patients but inaccurately states that the frequency is the same for those who received adjuvant radiotherapy, missing the key point that radiotherapy patients require more frequent follow-up (every 3–6 months for the first 3 years). It also omits the transition to less frequent follow-up after 2–3 years and does not distinguish the nuanced differences in follow-up protocols based on treatment modality."
  },
  "15": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including surgical candidacy, the role of multidisciplinary evaluation, and alternative treatments if surgery is not feasible. No major omissions or errors are present."
  },
  "16": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why surgery is not preferred, referencing guidelines, and recommending chemoradiotherapy, with no major omissions or errors."
  },
  "17": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, guideline recommendations, and appropriate indications, with no major omissions or errors. It is comprehensive and aligns closely with the reference answer."
  },
  "18": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical content from the reference answer, clearly stating the implicit assumption regarding the absence of other actionable driver mutations and providing appropriate rationale without omissions or errors."
  },
  "19": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including drug indications, PS score considerations, guideline recommendations, and the need for individualized assessment, with no major omissions or errors."
  },
  "20": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of molecular testing, the low mutation rate in squamous cell carcinoma, and appropriate standard treatments, with no major omissions or errors."
  },
  "21": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed reasoning, but it diverges from the reference answer by stating that mediastinal lymph node pathological evaluation is not always mandatory if imaging is negative, whereas the reference answer recommends routine evaluation regardless. This constitutes a minor but important omission."
  },
  "22": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to avoid contrast-enhanced CT in chronic renal insufficiency, providing rationale, guideline support, and appropriate exceptions, with no major omissions or errors."
  },
  "23": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of pathological confirmation, relevant guidelines, and the rare exceptions, with no major omissions or errors."
  },
  "24": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of pathological confirmation for N3 status before initiating stage III treatment, with no major omissions or errors."
  },
  "25": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale for using head MRI and FDG-PET/CT in the context of a new suspicious lesion, but incorrectly recommends their \"routine\" use rather than emphasizing their use only when recurrence is suspected, as per the reference answer. This represents a significant inaccuracy regarding the timing and indication for these imaging modalities."
  },
  "26": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including guideline recommendations, treatment options, and risk considerations, but it could more explicitly emphasize that this approach is a compromise due to contraindications and is not the standard recommendation for such high-risk patients."
  },
  "27": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with comprehensive explanation, supporting evidence, and no major omissions or errors."
  },
  "28": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides guideline references and rationale."
  },
  "29": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, contraindications, and alternative management options, matching the reference answer in content and detail without omissions or errors."
  },
  "30": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and includes all key clinical points without omissions or errors. It even provides additional relevant context and guideline references, fully supporting the clinical reasoning."
  },
  "31": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly delineating the boundary conditions for neoadjuvant therapy in TNBC, and accurately excludes cT1a/bN0 cases, with no major omissions or errors."
  },
  "32": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the lack of benefit from EGFR-TKI in KRAS-mutant patients, guideline recommendations, and appropriate alternative treatments, with no major omissions or errors."
  },
  "33": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need to prioritize local management of pleural effusion before or alongside prompt initiation of NTRK-targeted therapy, with no major omissions or errors."
  },
  "34": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, accurately explains the rationale, cites guidelines, and makes no major omissions or errors."
  },
  "35": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and emphasizing the priority of additional systemic therapy over immediate surgery without any major omissions or errors."
  },
  "36": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline citations, and practical recommendations without any major omissions or errors."
  },
  "37": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully covering the key points of the reference answer with no major omissions or errors. It elaborates on the diagnostic process, treatment principles, and guideline recommendations, matching the reference answer in clinical substance."
  },
  "38": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key points from the reference answer, clearly stating the exclusion of patients with prior radiotherapy or stage III disease and recommending appropriate follow-up imaging for those groups."
  },
  "39": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline references without omissions or errors."
  },
  "40": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need for more frequent imaging and further diagnostic workup, with no major omissions or errors."
  },
  "41": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the follow-up frequency should be the same for both groups, whereas the reference answer clearly distinguishes a more intensive follow-up for the radiotherapy group. This is a notable error, despite some correct general information about follow-up intervals."
  },
  "42": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the risks of EGFR-TKI and immunotherapy in ILD, the need for individualized decision-making, and the relative safety of chemotherapy, with no major omissions or errors."
  },
  "43": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, accurately explaining that the mixed ductal component does not affect the suitability of endocrine therapy with or without ovarian suppression/removal, and provides appropriate context and justification without any major omissions or errors."
  },
  "44": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key recommendations, rationale, and guideline support, with no major omissions or errors."
  },
  "45": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning and covering all key points without omissions or errors."
  },
  "46": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including guideline recommendations, rationale, and exceptions, with no major omissions or errors."
  },
  "47": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately addresses all key clinical considerations, and expands on the reference answer without introducing errors or omissions. It covers drug metabolism, guideline recommendations, alternative therapies, and the rationale for not recommending systemic chemotherapy, fully aligning with the reference content."
  },
  "48": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale against surveillance alone and emphasizing the standard recommendation for adjuvant radiotherapy, with no major omissions or errors."
  },
  "49": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, but it adds a conditional approach (only biopsy and mark if suspicious nodes are seen on ultrasound), whereas the reference answer implies a more routine approach for biopsy and marking. This is a minor omission, as current guidelines do support the model answer's approach, but it is not strictly identical to the reference."
  },
  "50": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the preference for non-surgical local therapies in high-risk patients and providing appropriate justification without omissions or errors."
  },
  "51": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough explanation, including supporting evidence and guideline recommendations, but it introduces the possibility of individualized consideration in special cases, which is not mentioned in the reference answer. This is a minor addition rather than an omission, but it slightly diverges from the strict recommendation in the reference."
  },
  "52": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the recommended follow-up frequency and providing appropriate justification without any major omissions or errors."
  },
  "53": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, providing detailed rationale, guideline support, and appropriate clinical caveats without any major omissions or errors."
  },
  "54": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, accurately reflects the reference answer, and adds relevant details about multidisciplinary evaluation and guideline recommendations without introducing errors or omissions."
  },
  "55": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing systemic therapy and specifying the limited indications for palliative surgery, with no major omissions or errors."
  },
  "56": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guideline recommendations, and the principle that ALK inhibitor therapy should be prioritized regardless of histology, with no major omissions or errors."
  },
  "57": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale for prioritizing RET-targeted therapy over immunotherapy in RET-rearranged NSCLC with high PD-L1, and even adds relevant guideline support without introducing errors or omissions."
  },
  "58": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including prioritizing local hemostatic intervention over reoperation in the context of life-threatening hemoptysis, and subsequent reassessment for definitive therapy. No major omissions or errors are present."
  },
  "59": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that routine FDG-PET/CT or brain MRI is not recommended without evidence of recurrence, and provides appropriate rationale and guideline references without omissions or errors."
  },
  "60": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that completion of all recommended molecular tests is not required before using fam-trastuzumab deruxtecan-nxki, provided HER2 mutation is confirmed. It also appropriately contextualizes guideline recommendations and clinical practice, with no major omissions or errors."
  },
  "61": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "62": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the contraindications of bevacizumab in high bleeding risk patients and correctly recommending EGFR-TKI monotherapy as first-line treatment, with no major omissions or errors."
  },
  "63": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, supporting evidence, and guidelines for not using fam-trastuzumab deruxtecan-nxki in patients with a history of severe ILD, with no major omissions or errors."
  },
  "64": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides clear justification for the treatment choice."
  },
  "65": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, nuanced discussion, but it does not clearly state that常规再次局部放疗通常不推荐 and instead suggests it can be considered under certain conditions, which is a minor deviation from the reference answer’s more cautious stance."
  },
  "66": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the risks and recommendations for each drug in the context of significant hepatic impairment, and aligns fully with the reference answer without omissions or errors."
  },
  "67": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the high-risk status due to positive margins and the need for frequent CT follow-up, with no major omissions or errors."
  },
  "68": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案内容完全相反，且模型答案准确指出了AJCC第8版分期标准的更新，T4N0M0属于IIIB期而非IIIA期，反映了最新指南，内容完整且无误。"
  },
  "69": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, provides detailed justification, and aligns fully with the reference answer without omissions or errors."
  },
  "70": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed evidence and referencing guidelines, but it slightly narrows the recommended ECOG PS range to 0–1 rather than the reference answer's 0–2, which is a minor omission."
  },
  "71": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage, correctly stating that脑部 MRI不应常规进行，但对FDG-PET/CT的适应证表述不够准确，误导为新发结节时推荐常规PET/CT，而参考答案强调仅在高度怀疑复发或有症状时才考虑，存在一定的内容偏差和不严谨。"
  },
  "72": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the necessity of preoperative pulmonary function assessment, the risks of proceeding without it, and the need to consider alternative treatments. No major omissions or errors are present."
  },
  "73": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including staging, the role of preoperative systemic therapy, criteria for surgical resection, survival benefit, and the rationale for prioritizing surgery. It expands with guideline references and individualization, with no major omissions or errors."
  },
  "74": {
    "score": 2.0,
    "explanation": "2: The model answer directly contradicts the reference answer by recommending direct surgery as the preferred approach, whereas the reference answer prioritizes neoadjuvant systemic therapy before surgery. While the model answer is detailed and references guidelines, its core recommendation is notably different, constituting a significant error in clinical content."
  },
  "75": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive detail on standard treatment, guideline recommendations, and clarifying the role of local radical therapy versus systemic therapy, with no major omissions or errors."
  },
  "76": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors. It even expands on the rationale with guideline support and detailed explanation, fully aligning with the reference."
  },
  "77": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to use low-dose non-contrast CT for regular follow-up without delaying the surveillance interval, and provides additional guideline references without any omissions or errors."
  },
  "78": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points without omissions or errors, and even provides guideline references for support."
  },
  "79": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional supporting evidence and guideline references."
  },
  "80": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "81": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional guideline references and rationale without introducing inaccuracies."
  },
  "82": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, supporting evidence, and guideline recommendations without omissions or errors."
  },
  "83": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides additional guideline-based justification and safety considerations."
  },
  "84": {
    "score": 3.0,
    "explanation": "3: The model answer provides a partial but not fully accurate response; it incorrectly suggests that surgical removal of the dominant nodule can be considered for symptom control, which contradicts the reference answer's clear recommendation against surgery in this context. However, it does mention the need for multidisciplinary discussion and symptom-based decision-making, reflecting some relevant considerations."
  },
  "85": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need to prioritize internal medical interventions for hemostasis before considering external beam radiotherapy, with no major omissions or errors."
  },
  "86": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, indications, and rationale for palliative external beam radiotherapy in this scenario, with no major omissions or errors."
  },
  "87": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides appropriate justification and references."
  },
  "88": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, supporting evidence, and appropriate sequencing of EGFR-TKI and whole-brain radiotherapy, with no major omissions or errors."
  },
  "89": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and expands on the specific boundaries and considerations for postoperative radiotherapy, with no major omissions or errors."
  },
  "90": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects all key clinical points from the reference answer, and provides additional guideline-based detail without introducing errors or omissions."
  },
  "91": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including indications, drug metabolism, safety in renal impairment, and the rationale for not recommending chemotherapy, with no major omissions or errors."
  },
  "92": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guideline recommendations, and appropriate imaging choice, with no major omissions or errors."
  },
  "93": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed guideline-based recommendations, but it introduces some nuance about potentially stopping surveillance after 5 years, whereas the reference answer recommends indefinite annual CT regardless of symptoms. This is a minor omission."
  },
  "94": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage but diverges from the reference answer by recommending brain MRI based on persistent headache alone, whereas the reference answer states MRI is not standard unless symptoms are highly suggestive of intracranial disease. The model overstates the indication for MRI, missing the nuance that mild symptoms without focal signs do not routinely warrant imaging."
  },
  "95": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediate FDG-PET/CT, which contradicts current guidelines and the reference answer that prioritize regular enhanced chest CT follow-up in asymptomatic, isolated lesions post-R0 resection for stage IA NSCLC. The model answer provides rationale but contains a notable error in management approach."
  },
  "96": {
    "score": 2.0,
    "explanation": "2: The model answer provides a reasonable clinical rationale but directly contradicts the reference answer’s key point that systemic therapy decisions are not rigorously established without pathological confirmation of metastases. It overstates the acceptability of proceeding without pathology, omitting the emphasis on the necessity of pathological confirmation to avoid misdiagnosis and guide molecular profiling."
  },
  "97": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, contraindications, and alternative approaches, with no major omissions or errors."
  },
  "98": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including the rationale for ALK inhibitor use regardless of histology or prior treatment, and cites relevant guidelines. No major omissions or errors are present."
  },
  "99": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "100": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors. It provides a thorough explanation, includes guideline recommendations, and emphasizes individualized assessment and alternative treatment options."
  },
  "101": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline citations, and supporting evidence, with no major omissions or errors."
  },
  "102": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, referencing guidelines and correctly prioritizing local treatment in the absence of distant metastasis, with no major omissions or errors."
  },
  "103": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and provides appropriate justification and guideline references."
  },
  "104": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides additional rationale and guideline references, but the core clinical recommendation is the same."
  },
  "105": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of pathological confirmation, the limitations of imaging, guideline recommendations, and the impact on treatment decisions, with no major omissions or errors."
  },
  "106": {
    "score": 3.0,
    "explanation": "3: The model answer provides relevant background and references key studies and guidelines, but its conclusion contradicts the reference answer by recommending chemotherapy, whereas the reference answer clearly states it is not indicated for a score of 25. This is a significant inaccuracy."
  },
  "107": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the contraindication of T-DM1 in severe hepatic impairment, and suggests alternative management, with no major omissions or errors."
  },
  "108": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, addresses the risks, metabolism, and recommendations for HER2-targeted therapy in severe hepatic dysfunction, and provides appropriate references. No major omissions or errors are present."
  },
  "109": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and provides additional relevant details without introducing inaccuracies."
  },
  "110": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing支气管内支架置入 for rapid relief and providing clear reasoning without omissions or errors."
  },
  "111": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully aligning with the reference answer and current guidelines, with no major omissions or errors."
  },
  "112": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the preferred regimen, exceptions, rationale, and guideline support, with no major omissions or errors."
  },
  "113": {
    "score": 4.0,
    "explanation": "4: The model answer provides a comprehensive and accurate discussion, correctly stating that dual anti-HER2 therapy is not mandatory and should be individualized, but it slightly overemphasizes the lack of a \"must\" and introduces considerations (e.g., economic factors) not central to the reference answer, which focuses on HER2 positivity and nodal status as the main prerequisites."
  },
  "114": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining the rationale for systemic therapy in the presence of distant metastasis, with no major omissions or errors."
  },
  "115": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It clearly prioritizes SVC stenting, explains the rationale, and addresses the limitations of additional radiotherapy."
  },
  "116": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and even adds relevant guideline references and rationale."
  },
  "117": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "118": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing pharmacokinetics, guideline recommendations, and alternative management, with no major omissions or errors."
  },
  "119": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical reasoning, includes all key points from the reference answer, and adds relevant guideline and evidence context without introducing errors or omissions."
  },
  "120": {
    "score": 3.0,
    "explanation": "3: The model answer provides a more nuanced and detailed discussion, including patient selection and technical considerations, but it omits the clear recommendation against routine re-irradiation due to high risk, as emphasized in the reference answer. It may give the impression that re-irradiation is more commonly considered than guidelines suggest."
  },
  "121": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, with additional guideline details and a clear rationale, without any major omissions or errors."
  },
  "122": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, priority, and supporting evidence for prioritizing local therapy over systemic therapy, with no major omissions or errors."
  },
  "123": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why surgery is not preferred and recommending SBRT/SABR as the first-line alternative, with no major omissions or errors."
  },
  "124": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides appropriate justification and references."
  },
  "125": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of both local and systemic therapies, but it incorrectly prioritizes local treatment over systemic therapy, which contradicts the reference answer's emphasis on systemic therapy as the priority after local control. There are also some minor inaccuracies and omissions regarding the rationale for systemic therapy."
  },
  "126": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including prioritizing local treatment for brain metastasis, consideration of systemic therapy, and referencing relevant guidelines, with no major omissions or errors."
  },
  "127": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the sequence and rationale for completing chemotherapy before starting endocrine therapy, with no major omissions or errors."
  },
  "128": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the staging, management implications, and referencing authoritative guidelines, with no major omissions or errors."
  },
  "129": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the increased toxicity risk, the need for individualized assessment, and guideline recommendations against direct concurrent chemoradiotherapy after prior thoracic radiotherapy, with no major omissions or errors."
  },
  "130": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including PS score interpretation, lack of actionable mutations, PD-L1 status, guideline recommendations, and the rationale for systemic therapy over supportive care. No major omissions or errors are present."
  },
  "131": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and follow-up recommendations without omissions or errors."
  },
  "132": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the use of non-contrast CT and MRI as alternatives, and acknowledges the reduced sensitivity. However, it emphasizes漏诊风险 (missed diagnosis risk) more than the reference, which states that basic clinical needs are met without the need to delay or cancel follow-up, making the model answer slightly more cautious than the reference. Minor differences in emphasis and detail account for the deduction."
  },
  "133": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing crizotinib’s hepatotoxicity, guideline recommendations, and the need to optimize liver function before considering its use, with no major omissions or errors."
  },
  "134": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and recommended management without omissions or errors."
  },
  "135": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage of guideline recommendations, risk stratification, and individualized decision-making, with no major omissions or errors."
  },
  "136": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors, and even expands on the rationale in a manner consistent with the reference."
  },
  "137": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "138": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for systemic therapy over surgery in N2–N3 disease, and referencing relevant guidelines without any major omissions or errors."
  },
  "139": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale but contradicts the reference answer by stating T-DXd should not be prioritized in SCC with HER2 mutation, whereas the reference answer affirms its use regardless of histology. This represents a notable error in clinical content."
  },
  "140": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines, with no major omissions or errors."
  },
  "141": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the contraindication to surgery due to severe pulmonary dysfunction and appropriately recommending non-surgical local therapies such as SBRT. No major omissions or errors are present."
  },
  "142": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and recommending non-surgical management as initial therapy, with no major omissions or errors."
  },
  "143": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "144": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and addressing both efficacy and the role of molecular profiling, with no major omissions or errors."
  },
  "145": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional guideline references and rationale supporting the recommendation."
  },
  "146": {
    "score": 5.0,
    "explanation": "5: The model answer accurately reflects the reference answer, including the recommended frequency and duration for chest CT follow-up, with no significant omissions or errors."
  },
  "147": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and evidence for using afatinib or osimertinib after discovery of the EGFR S768I mutation, with no major omissions or errors."
  },
  "148": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "149": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and evidence, with no major omissions or errors."
  },
  "150": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully aligning with the reference answer. It correctly emphasizes the priority of chemotherapy plus trastuzumab and endocrine therapy, while also acknowledging rare exceptions, with no major omissions or errors."
  },
  "151": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the need for pathological confirmation, restaging, and the appropriateness of surgery based on updated staging and absence of distant metastasis, with no major omissions or errors."
  },
  "152": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "153": {
    "score": 2.0,
    "explanation": "2: The model answer recommends routine FDG-PET/CT for asymptomatic patients with only imaging abnormalities, which contradicts the reference answer stating these are not routinely indicated unless recurrence is clinically or radiologically suspected. This is a notable error, despite some correct background and guideline references."
  },
  "154": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even expanding with guideline references and practical considerations, without any major omissions or errors."
  },
  "155": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline references without omissions or errors."
  },
  "156": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly states that conventional surgery is not the first choice, suggesting alternative treatments. However, it introduces options like wedge or segmental resection and ablation, which are not mentioned in the reference answer, making it slightly broader but not inaccurate."
  },
  "157": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning and no major omissions or errors. It fully supports the recommendation for concurrent chemoradiotherapy and appropriately addresses exceptions."
  },
  "158": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly prioritizes interventional embolization for life-threatening hemoptysis, with appropriate reasoning. However, it underemphasizes that bronchoscopic laser therapy is also a rapid local hemostatic option, as highlighted in the reference answer."
  },
  "159": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional relevant details, and correctly addresses the limitations and alternatives, with no major omissions or errors."
  },
  "160": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable summary but incorrectly states that PD-L1 testing has a higher priority than comprehensive molecular testing, which contradicts the reference answer and current guidelines. It omits the recommendation that both tests should be performed in parallel and that comprehensive molecular testing is equally important for guiding initial therapy."
  },
  "161": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, providing detailed rationale and no major omissions or errors."
  },
  "162": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, emphasizing individualized assessment and the general avoidance of routine chemotherapy in patients over 75. However, it slightly overstates the recommendation against chemotherapy by suggesting it is \"not recommended in most cases,\" whereas the reference answer leaves more room for considering chemotherapy if the patient is fit and the expected benefit is significant."
  },
  "163": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for not prioritizing BRAF-targeted therapy in the context of severe hepatic impairment and appropriately recommending conventional chemotherapy, with no major omissions or errors."
  },
  "164": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the indications for FDG-PET/CT, referencing guidelines, and providing appropriate rationale without omissions or errors."
  },
  "165": {
    "score": 2.0,
    "explanation": "2: The model answer provides a guideline-based rationale for sequencing therapy but directly contradicts the reference answer, which focuses on the independence of KRAS G12C-targeted therapy from PD-L1 testing. The model answer introduces notable errors regarding the necessity of PD-L1 testing before targeted therapy, thus demonstrating limited coverage of the reference content."
  },
  "166": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity, rationale, and implications of preoperative pulmonary function testing in this context, with no major omissions or errors."
  },
  "167": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed reasoning, but it overemphasizes SBRT as the preferred option without sufficiently highlighting that surgery remains the first choice if the patient is deemed operable after risk assessment, as stated in the reference answer."
  },
  "168": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional supporting evidence and rationale, and no major omissions or errors."
  },
  "169": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive guideline-based justification and explicitly stating that COPD history does not alter management for a 5 mm pure ground-glass nodule. No major omissions or errors are present."
  },
  "170": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient selection, rationale, guideline support, and specific endocrine therapy options, with no major omissions or errors."
  },
  "171": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, indications, and exceptions, with no major omissions or errors."
  },
  "172": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses all key points, cites supporting evidence, and includes appropriate caveats without any major omissions or errors."
  },
  "173": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the necessity of orthopedic fixation and palliative radiotherapy in the presence of fracture risk, and clearly states that systemic therapy alone is insufficient. It also provides additional rationale and guideline references without introducing errors or omissions."
  },
  "174": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully aligning with the reference answer, and includes relevant guideline citations without any major omissions or errors."
  },
  "175": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points with additional relevant justification and no major omissions or errors."
  },
  "176": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of FDG-PET/CT and brain MRI for complete staging and referencing relevant guidelines, with no major omissions or errors."
  },
  "177": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline references, and correct recommendations without omissions or errors."
  },
  "178": {
    "score": 3.0,
    "explanation": "3: The model answer correctly identifies that the presence of a same-side, different-lobe nodule upgrades the T stage to T4, but it inaccurately states that T4N1M0 is stage IIIB, when according to the reference answer and current TNM staging, T4N1M0 is still stage IIIA. This is a significant inaccuracy."
  },
  "179": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It even adds relevant guideline support, fully justifying the recommendation."
  },
  "180": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the rationale for PD-L1 testing, its role in immunotherapy decision-making, and guideline recommendations, with no major omissions or errors."
  },
  "181": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points, correctly prioritizing systemic therapy and appropriately discussing the role of local radiotherapy, with no major omissions or errors."
  },
  "182": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides additional rationale and guideline references, but the core clinical recommendation and reasoning are fully aligned."
  },
  "183": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the exclusion of targetable mutations, the role of PD-L1 expression, and the use of immunotherapy as first-line systemic treatment, with appropriate detail and no major omissions."
  },
  "184": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need for routine FDG-PET/CT and brain MRI to exclude distant metastases before local or perioperative treatment, with no major omissions or errors."
  },
  "185": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately states that routine FDG-PET/CT or brain MRI is not recommended for follow-up in this scenario and provides appropriate justification and guideline references."
  },
  "186": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, provides accurate rationale, and even cites relevant guidelines, with no major omissions or errors."
  },
  "187": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the impact of severe hepatic dysfunction on treatment choice, the need for individualized therapy, and the deprioritization of standard systemic plus HER2-targeted therapy, with no major omissions or errors."
  },
  "188": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need for increased imaging and individualized follow-up in the presence of new radiological abnormalities, with no major omissions or errors."
  },
  "189": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with comprehensive coverage, clear rationale, and no major omissions or errors. It even provides additional guideline references and practical follow-up advice, fully aligning with the reference content."
  },
  "190": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including the rationale for not recommending first-line systemic therapy, guideline references, and the emphasis on best supportive care due to poor performance status. No major omissions or errors are present."
  },
  "191": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the prioritization of targeted therapy, rationale, guideline recommendations, and the role of immunotherapy, with no major omissions or errors."
  },
  "192": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that molecular testing must be completed before starting systemic therapy, which contradicts the reference answer. The reference answer clearly states that systemic therapy can be initiated based on histology and disease progression, with molecular testing as an adjunct, not a prerequisite."
  },
  "193": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the rationale for PET/CT and brain MRI, and referencing guidelines, with no major omissions or errors."
  },
  "194": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "195": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing palliative radiotherapy and correctly addressing the limitations of systemic therapy in this context, with no major omissions or errors."
  },
  "196": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the increased surgical risk, guideline recommendations, and the preference for SBRT in patients with significant pulmonary impairment, with no major omissions or errors."
  },
  "197": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, provides accurate recommendations, and even cites relevant guidelines, with no major omissions or errors."
  },
  "198": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the rationale for avoiding enhanced CT in moderate renal insufficiency, and correctly recommends non-contrast CT for routine surveillance, with no major omissions or errors."
  },
  "199": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "200": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors, and even provides additional rationale and guideline references."
  },
  "201": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a good understanding of the differences in follow-up between the two groups, including rationale and practical adjustments. However, it does not specify the exact frequency differences in chest CT follow-up as clearly as the reference answer, which is a minor omission."
  },
  "202": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides supporting guideline references and rationale."
  },
  "203": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key points from the reference answer, clearly distinguishing between first-line and subsequent-line use of MET抑制剂 based on timing of molecular results, and provides appropriate guideline references without any major omissions or errors."
  },
  "204": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and appropriate caveats without any major omissions or errors."
  },
  "205": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of FDG-PET/CT before perioperative treatment and providing guideline-based justification without omissions or errors."
  },
  "206": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the evidence base, guideline recommendations, and the rationale for limiting HER2-targeted therapy to non-squamous NSCLC, with no major omissions or errors."
  },
  "207": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It accurately reflects guideline recommendations and provides additional rationale without introducing inaccuracies."
  },
  "208": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including rationale, guideline support, efficacy evidence, and applicability to squamous cell carcinoma, with no major omissions or errors."
  },
  "209": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need for comprehensive molecular testing and the rationale for not starting immunotherapy plus chemotherapy without excluding all actionable driver mutations. No major omissions or errors are present."
  },
  "210": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately addresses the treatment choice, provides rationale, and aligns with guideline recommendations."
  },
  "211": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "212": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive guideline-based justification and no major omissions or errors. It fully supports switching to annual low-dose non-contrast CT after 3 years, matching the reference."
  },
  "213": {
    "score": 5.0,
    "explanation": "5: The model answer fully matches the reference answer in clinical content, clearly explaining the necessity of tumor bed marking before neoadjuvant therapy and the consequences of omission, with no major omissions or errors."
  },
  "214": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the criteria for omitting ALND and clearly stating that 3 positive sentinel lymph nodes exceed the threshold, thus requiring ALND. No major omissions or errors are present."
  },
  "215": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing imaging modality and frequency, and correctly stating that low-dose non-contrast chest CT is sufficient for follow-up in this patient population. No major omissions or errors are present."
  },
  "216": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately addresses the lack of indication for adjuvant therapy and provides appropriate rationale and follow-up recommendations."
  },
  "217": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and practical recommendations without omissions or errors."
  },
  "218": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and provides additional rationale and guideline support."
  },
  "219": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional relevant rationale supporting the prioritization of local intervention."
  },
  "220": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that brain MRI is not routinely required for T2aN0M0 NSCLC unless neurological symptoms are present, and provides appropriate guideline references without any major omissions or errors."
  },
  "221": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and provides additional relevant detail and guideline references."
  },
  "222": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately explaining the need for adjuvant systemic therapy and referencing relevant guidelines, with no major omissions or errors."
  },
  "223": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, elaborates on the diagnostic and management rationale, and includes relevant guideline recommendations without introducing errors or major omissions."
  },
  "224": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the key points, and even expands on perioperative assessment and multidisciplinary management without any major omissions or errors."
  },
  "225": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and emphasizing the need for structural or clinical evidence before altering follow-up or treatment. No major omissions or errors are present."
  },
  "226": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main clinical points, including surgical options and considerations for WBRT. However, it slightly overemphasizes the routine use of WBRT postoperatively, whereas the reference answer notes that WBRT can sometimes be omitted (2B recommendation), which is a minor omission."
  },
  "227": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "228": {
    "score": 4.0,
    "explanation": "4: The model answer provides a comprehensive and accurate discussion, including diagnostic principles and guideline references, but introduces additional detail and conditionality not explicitly present in the reference answer, which may slightly detract from directness and completeness relative to the reference."
  },
  "229": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the rationale, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "230": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, correctly referencing the AJCC 8th edition TNM staging, and clearly explains the implications for staging and treatment, with no major omissions or errors."
  },
  "231": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the stage, rationale, and standard of care (concurrent chemoradiotherapy), with no major omissions or errors."
  },
  "232": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for concurrent chemoradiotherapy (with or without stenting), the role of stenting for symptom relief, and the use of radiotherapy alone only if chemoradiotherapy is not tolerated. No major omissions or errors are present."
  },
  "233": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key clinical considerations, and expands on the reference answer without introducing errors or omissions. It addresses surgical candidacy, risk assessment, further evaluation, and the need for multidisciplinary discussion, fully aligning with the reference content."
  },
  "234": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, nuanced discussion, including diagnostic criteria and treatment principles. However, it is more conservative than the reference answer, emphasizing that most cases should be treated as metastatic unless strict criteria for double primaries are met, which is a minor deviation from the reference's more direct affirmation."
  },
  "235": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the indication for thoracic radiotherapy, references guidelines, discusses treatment options (including chemoradiotherapy), and emphasizes individualized assessment and technical considerations, with no major omissions or errors."
  },
  "236": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately describes the indication for concurrent chemoradiotherapy, and even adds relevant guideline references and alternative options, with no major omissions or errors."
  },
  "237": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale and references but inaccurately states that molecular testing is not routinely recommended for squamous NSCLC, whereas current guidelines advocate broad molecular testing for all NSCLC subtypes, including squamous. This represents a significant omission and inaccuracy compared to the reference answer."
  },
  "238": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guideline support, and correct follow-up imaging modality, with no major omissions or errors."
  },
  "239": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and includes all key clinical points without omissions or errors."
  },
  "240": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "241": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, indications, and limitations of using plasma cfDNA for molecular testing in this scenario, matching the reference answer in content and rationale."
  },
  "242": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guidelines, and risk-benefit considerations without omissions or errors."
  },
  "243": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and appropriate rationale, with no major omissions or errors."
  },
  "244": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical points from the reference answer, including the risks of standard chemoradiotherapy, the need for individualized assessment, and alternative strategies such as reduced-dose therapy, supportive care, and multidisciplinary evaluation, with no major omissions or errors."
  },
  "245": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline references, and appropriate alternative recommendations without any major omissions or errors."
  },
  "246": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the avoidance of bisphosphonates in renal impairment, the preference for denosumab, and the need for calcium monitoring, with no major omissions or errors."
  },
  "247": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and alternative treatments, with no major omissions or errors."
  },
  "248": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately distinguishes between the two groups, referencing guideline recommendations and providing appropriate follow-up intervals. However, it introduces some minor variations in the specific timing of follow-up compared to the reference answer and is slightly less concise in directly contrasting the two regimens."
  },
  "249": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, provides additional rationale, and contains no major omissions or errors."
  },
  "250": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale against surgery and emphasizing non-surgical management, with no major omissions or errors."
  },
  "251": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the timing and rationale for switching to ROS1-targeted therapy, and includes relevant guidelines and practical considerations without any major omissions or errors."
  },
  "252": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, emphasizes the need for individualized treatment, and correctly states that observation alone is not generally appropriate, matching the reference answer in content and detail."
  },
  "253": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "254": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "255": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification, guideline references, and no major omissions or errors."
  },
  "256": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly prioritizing fam-trastuzumab deruxtecan-nxki and providing additional supporting evidence and rationale without introducing errors or omissions."
  },
  "257": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the management principles and providing appropriate guideline references, with no major omissions or errors."
  },
  "258": {
    "score": 3.0,
    "explanation": "3: The model answer provides guideline-based recommendations supporting annual CT after 2 years, which conflicts with the reference answer that recommends continuing 6-monthly CT until 3 years post-op. While the model answer is well-reasoned and cites guidelines, it omits the specific recommendation to continue 6-monthly CT through year 3, representing a significant clinical deviation."
  },
  "259": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，并补充了具体药物和指南依据，内容完整准确。"
  },
  "260": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guideline support, and appropriate sequencing of therapy without omissions or errors."
  },
  "261": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the prerequisite of excluding other actionable driver mutations (EGFR, ALK, etc.) before selecting MET inhibitors, and provides accurate, guideline-based justification without omissions or errors."
  },
  "262": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, citing the KATHERINE study, and clearly explaining why T-DM1 is preferred over continued trastuzumab plus endocrine therapy in this scenario. No major omissions or errors are present."
  },
  "263": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and even adds relevant guideline references and rationale without introducing inaccuracies."
  },
  "264": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion but contains notable inaccuracies, particularly overstating the limitations of larotrectinib's CNS activity and incorrectly suggesting it should not be first-line in untreated brain metastases, which contradicts the reference answer and current guidelines."
  },
  "265": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and even provides additional guideline references and rationale."
  },
  "266": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need for immediate airway relief with interventional procedures and correctly noting the slower onset of radiotherapy, with no major omissions or errors."
  },
  "267": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including guideline support, rationale, and the acceptability of non-contrast CT for follow-up in patients with severe renal insufficiency. No major omissions or errors are present."
  },
  "268": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, covering all key clinical points without omissions or errors."
  },
  "269": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing systemic therapy, referencing guidelines, and appropriately noting exceptions for select cases. No major omissions or errors are present."
  },
  "270": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the indication, rationale, and practical considerations for palliative radiotherapy in this scenario, with no major omissions or errors."
  },
  "271": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors, and even provides supporting guidelines and rationale."
  },
  "272": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides clear justification for the treatment sequence."
  },
  "273": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and emphasizing the need for adjuvant chemoradiotherapy rather than direct follow-up. No major omissions or errors."
  },
  "274": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale for choosing chest contrast-enhanced CT as the first-line assessment and appropriately describing the role of PET/CT, with no major omissions or errors."
  },
  "275": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing whole-brain radiotherapy, the lack of actionable mutations, and the limitations of systemic therapy, with no major omissions or errors."
  },
  "276": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在临床内容上完全一致，详细阐述了局部治疗的重要性及系统治疗的适应证，无明显遗漏或错误。"
  },
  "277": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including guideline recommendations, rationale for endocrine therapy, and the indications for chemotherapy, with no major omissions or errors."
  },
  "278": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the need for individualized assessment in patients with severe pulmonary dysfunction and the consideration of non-surgical therapies if surgical risk is high. However, it initially overemphasizes surgery as the default without immediately clarifying that severe pulmonary dysfunction generally precludes surgery as first choice, which is more clearly stated in the reference answer."
  },
  "279": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately addressing the timing and modality of follow-up CT scans, and provides appropriate justification without any major omissions or errors."
  },
  "280": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors. It provides detailed justification consistent with current guidelines and clinical practice."
  },
  "281": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the impact of limited pulmonary reserve on treatment choice and correctly outlining alternative options without omissions or errors."
  },
  "282": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points and providing appropriate justification and guideline references, with no major omissions or errors."
  },
  "283": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive detail, guideline references, and appropriate caveats, with no major omissions or errors."
  },
  "284": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based discussion, but it is more conservative than the reference answer and emphasizes the need for strict pathological and molecular confirmation before treating as multiple primaries. It covers all key points but slightly overstates the need for molecular distinction, whereas the reference answer allows for separate treatment if both lesions are resectable and no other metastases are present."
  },
  "285": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding the necessity of FDG-PET/CT and bronchoscopy in preoperative assessment, and provides appropriate rationale and guideline references without omissions or errors."
  },
  "286": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, provides detailed justification, and contains no major omissions or errors."
  },
  "287": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale but directly contradicts the reference answer by stating that RET抑制剂 are not recommended as first-line therapy for squamous NSCLC with RET rearrangement, whereas the reference answer affirms their use regardless of histology. This is a notable error in clinical content."
  },
  "288": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "289": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the requirement for other driver mutations to be negative before using NTRK inhibitors, and provides appropriate rationale and guideline references without any major omissions or errors."
  },
  "290": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for systemic therapy and addressing the role of observation, with no major omissions or errors."
  },
  "291": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive discussion of both systemic and local therapies and emphasizes a combined approach, but it does not directly answer the question of which should be prioritized. It omits the clear prioritization of local therapy for solitary brain metastasis as stated in the reference answer, leading to some inaccuracy regarding the recommended sequence."
  },
  "292": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need to wait for molecular and PD-L1 results unless the patient is critically ill, and referencing relevant guidelines. No major omissions or errors are present."
  },
  "293": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and references relevant guidelines, but it inaccurately suggests that osimertinib can be started before completing the current first-line regimen based on efficacy or toxicity, which contradicts the reference answer's clear recommendation to wait until the current treatment is finished or interrupted."
  },
  "294": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides a thorough explanation consistent with the reference."
  },
  "295": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the insufficiency of only EGFR/ALK testing, the need for comprehensive molecular and PD-L1 testing, guideline recommendations, and practical considerations when samples are limited, with no major omissions or errors."
  },
  "296": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately explaining that H&P is required in addition to imaging and citing relevant guidelines, with no major omissions or errors."
  },
  "297": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes local therapy, addresses relevant patient factors, and appropriately discusses the role of systemic therapy, fully matching the reference answer with no major omissions or errors."
  },
  "298": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the appropriateness of low-dose non-contrast CT for follow-up, guideline support, and specific patient considerations, with no major omissions or errors."
  },
  "299": {
    "score": 5.0,
    "explanation": "5: The model answer provides identical clinical content to the reference answer, clearly outlining the decision-making process based on the presence or absence of neurological symptoms, and referencing relevant guidelines. There are no major omissions or errors."
  },
  "300": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately addresses the question, and provides additional relevant details without introducing errors or omissions."
  },
  "301": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the inability to exclude distant metastases without FDG-PET/CT and brain MRI, and providing clear reasoning and appropriate clinical context without omissions or errors."
  },
  "302": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including guideline recommendations, risk stratification, and the need for individualized decision-making without major omissions or errors."
  },
  "303": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical reasoning, correctly emphasizing the need for immunotherapy combined with chemotherapy (rather than monotherapy) in PD-L1 1–49% and target-negative cases, and clearly links the decision to both PD-L1 status and absence of actionable mutations, matching the reference answer in clinical content."
  },
  "304": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, guideline basis, and justification for systemic therapy alone in this scenario, with no major omissions or errors. It is comprehensive and aligns closely with the reference answer."
  },
  "305": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines for prioritizing re-resection over immediate radiotherapy or chemotherapy, with no major omissions or errors."
  },
  "306": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, contraindication of contrast CT in severe renal insufficiency, and provides appropriate alternative imaging options, matching the reference answer in content and accuracy."
  },
  "307": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, adds relevant guideline support, and provides appropriate detail without omissions or errors."
  },
  "308": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and emphasizing the importance of combined local and systemic therapy, with no major omissions or errors."
  },
  "309": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully addressing the impact of severe renal insufficiency on adjuvant chemotherapy, the rationale for favoring radiotherapy, and the need for multidisciplinary evaluation, with no major omissions or errors."
  },
  "310": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, current evidence, and guideline recommendations, with no major omissions or errors."
  },
  "311": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes systemic therapy, and clearly explains the rationale, with no major omissions or errors compared to the reference answer."
  },
  "312": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and clinical implications without any omissions or errors."
  },
  "313": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and guideline-based discussion but directly contradicts the reference answer, which states ALND can be omitted, while the model answer argues ALND is generally still recommended. This represents a notable error in clinical content."
  },
  "314": {
    "score": 3.0,
    "explanation": "3: The model answer provides a generally accurate overview but incorrectly states that there is no significant difference in follow-up frequency, which contradicts the reference answer. It omits the specific differences in recommended CT intervals between the two groups, leading to partial coverage with some inaccuracies."
  },
  "315": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that ALND cannot be omitted when 3 SLNs are positive and providing clear justification and references without any omissions or errors."
  },
  "316": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides additional supporting evidence and rationale, but the core recommendation and reasoning are the same."
  },
  "317": {
    "score": 3.0,
    "explanation": "3: The model answer provides a partial and nuanced discussion, emphasizing individualized treatment and multidisciplinary assessment, but omits the reference answer’s clear recommendation that orthopedic stabilization and palliative radiotherapy should be routinely considered in parallel with systemic therapy, not replaced by it. This constitutes a significant omission of the standard of care emphasized in the reference answer."
  },
  "318": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach but deviates from the reference by recommending a shortened CT follow-up interval (3–6 months), which is not supported by the reference answer or guidelines for asymptomatic, non-specific findings. It otherwise correctly advises against routine PET/CT and covers key considerations."
  },
  "319": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the standard of care, the impact of severe lung dysfunction, and the need for individualized assessment, with no major omissions or errors."
  },
  "320": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating with supporting evidence and guideline recommendations, without introducing any errors or omissions."
  },
  "321": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the TNM classification, stage, and surgical eligibility, with no major omissions or errors."
  },
  "322": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the criteria for omitting ALND and clearly stating that ALND should not be omitted in this case due to three positive sentinel lymph nodes. No major omissions or errors are present."
  },
  "323": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion but incorrectly prioritizes concurrent chemoradiotherapy over reoperation, which is contrary to the reference answer and current guidelines. It also overstates the limitations of reoperation, leading to a significant inaccuracy."
  },
  "324": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and appropriate recommendations without omissions or errors."
  },
  "325": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the rationale, recommended management, and alternatives, with no major omissions or errors."
  },
  "326": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, including current guidelines, diagnostic criteria, and management strategies, with no major omissions or errors compared to the reference answer."
  },
  "327": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, provides accurate rationale, and includes relevant guideline support without any major omissions or errors."
  },
  "328": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and limitations of other imaging, with no major omissions or errors."
  },
  "329": {
    "score": 3.0,
    "explanation": "3: The model answer incorrectly states that low-dose non-contrast CT is the standard for the first 2–3 years, omitting that guidelines recommend routine (not low-dose) chest CT during this period. This is a significant inaccuracy, though the rest of the answer is generally relevant."
  },
  "330": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，且补充了指南依据和具体理由，无重大遗漏或错误。"
  },
  "331": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully covers the clinical content of the reference answer, with no major omissions or errors. It also provides additional guideline-based justification and practical considerations, all of which are correct and relevant."
  },
  "332": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing tumor staging, COPD comorbidity, perioperative indications, and the need for multidisciplinary evaluation, with no major omissions or errors."
  },
  "333": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive, guideline-based reasoning that fully aligns with the reference answer, with no major omissions or errors. It even adds relevant details and references, maintaining identical clinical content."
  },
  "334": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the necessity of broad molecular testing in addition to histological subtyping, and correctly explaining the rationale and guideline recommendations without omissions or errors."
  },
  "335": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly prioritizing骨科固定手术 for immediate stabilization and appropriately sequencing骨改良制剂 use, with no major omissions or errors."
  },
  "336": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a nuanced, guideline-based discussion, but it introduces a distinction between 16–20 and 21–25分的患者, suggesting omission of chemotherapy for 16–20分, which is more permissive than the reference answer that generally recommends chemotherapy for all 16–25分 in premenopausal women. This constitutes a minor omission relative to the reference standard."
  },
  "337": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides appropriate guideline-based rationale."
  },
  "338": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with no major omissions or errors. It even provides additional rationale and references, fully aligning with current clinical practice."
  },
  "339": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive detail on pharmacokinetics, guideline recommendations, and clinical practice, with no major omissions or errors."
  },
  "340": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content, accurately explains the rationale, and references relevant studies and guidelines, with no major omissions or errors."
  },
  "341": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including the need for thorough pulmonary function assessment, the risks of surgery, alternative treatments, and the requirement for MDT evaluation, with no major omissions or errors."
  },
  "342": {
    "score": 5.0,
    "explanation": "5: The model answer accurately reflects the reference answer, clearly stating that systemic therapy can be considered directly instead of perioperative strategies, and provides appropriate clinical reasoning without omissions or errors."
  },
  "343": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional rationale consistent with guidelines."
  },
  "344": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional rationale and guideline support without introducing inaccuracies."
  },
  "345": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why surgery is not preferred and recommending alternative treatments, with no major omissions or errors."
  },
  "346": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，无重大遗漏或错误，准确说明了无增强CT可满足随访要求，并补充了监测复发的作用。"
  },
  "347": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining the implicit assumption and providing accurate, relevant details without omissions or errors."
  },
  "348": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining the rationale for prioritizing SVC stent placement and accurately comparing the onset of symptom relief with radiotherapy, with no major omissions or errors."
  },
  "349": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, referencing guidelines and indications, and covers all key points from the reference answer without omissions or errors."
  },
  "350": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediately switching to BRAF/MEK inhibitors upon detection of the mutation, which contradicts the reference answer that advises completing the current systemic therapy unless there is unacceptable toxicity or clear progression. This is a notable error in clinical management."
  },
  "351": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the differences in sensitivity between low-dose non-contrast and contrast-enhanced CT, guideline recommendations, and the rationale for using enhanced CT in high-risk patients. However, it is somewhat lengthy and could be more concise, and it does not explicitly state that enhanced CT remains the preferred tool for early recurrence detection in the first 2–3 years, as emphasized in the reference answer."
  },
  "352": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the evidence and guidelines, with no major omissions or errors."
  },
  "353": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and appropriate clinical nuance regarding the prioritization of EGFR-TKI over whole-brain radiotherapy, with no major omissions or errors."
  },
  "354": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing concurrent chemoradiotherapy over reoperation, and referencing guidelines. No major omissions or errors are present."
  },
  "355": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately updates the staging to T4, discusses both surgical and systemic treatment options, emphasizes MDT decision-making, and references current guidelines, with no major omissions or errors."
  },
  "356": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even expanding with guideline references and detailed follow-up intervals, without introducing any errors or omissions."
  },
  "357": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and references guidelines, but it incorrectly states that routine follow-up is sufficient despite new radiologic abnormalities. It omits the key point that new or residual radiologic findings warrant increased surveillance, as emphasized in the reference answer."
  },
  "358": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly outlining the priority of orthopedic fixation and radiotherapy before bone-modifying agents, with no major omissions or errors."
  },
  "359": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately explains the rationale, and references relevant guidelines, with no major omissions or errors."
  },
  "360": {
    "score": 2.0,
    "explanation": "2: The model answer provides a rationale based on general guidelines for early-stage NSCLC but incorrectly concludes that brain MRI is not routinely recommended, missing the specific higher risk associated with central tumors as highlighted in the reference answer. This represents a notable error in clinical judgment for this scenario."
  },
  "361": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and even provides additional guideline-based details without introducing errors or omissions."
  },
  "362": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and some accurate discussion of the clinical scenario, but it incorrectly states that radiotherapy exceeds the standard indication boundaries, whereas guidelines (NCCN 2B) allow its use in inoperable patients, making this a notable inaccuracy."
  },
  "363": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing tumor size, risk stratification, guideline recommendations, and the rationale for endocrine therapy alone, with no major omissions or errors."
  },
  "364": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale for prioritizing SVC stenting for rapid symptom relief, but it omits the guideline-supported recommendation for concurrent chemoradiotherapy with stenting as the preferred approach in eligible patients. It overemphasizes sequential therapy and does not clearly state that combined chemoradiotherapy with stenting is first-line unless contraindicated, which is a key point in the reference answer."
  },
  "365": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately stating that low-dose non-contrast chest CT is the preferred annual follow-up imaging for these patients, and provides additional rationale consistent with guidelines."
  },
  "366": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering all key points with no major omissions or errors. It even provides additional rationale and guideline references, enhancing completeness without introducing inaccuracies."
  },
  "367": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion and references guidelines, but it inaccurately concludes that 1.1 cm tumors can routinely be included for neoadjuvant therapy, omitting the key point that most guidelines and clinical practice set a higher threshold (≥1.5 cm) for TNBC, as highlighted in the reference answer."
  },
  "368": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating with guideline references and rationale, without any major omissions or errors."
  },
  "369": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing orthopedic fixation over radiotherapy, and includes all key points without omissions or errors."
  },
  "370": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to avoid routine contrast-enhanced CT in chronic kidney disease patients and recommending non-contrast CT for surveillance, with no major omissions or errors."
  },
  "371": {
    "score": 3.0,
    "explanation": "3: The model answer provides comprehensive guideline references and rationale but directly contradicts the reference answer’s key point—that 6-monthly CT should continue for 2–3 years before switching to annual scans. This is a significant inaccuracy regarding the timing of frequency adjustment."
  },
  "372": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, provides detailed reasoning, and includes relevant diagnostic and management considerations without major omissions or errors."
  },
  "373": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, clearly stating that olaparib cannot be used without confirmed germline BRCA1/2 mutation and emphasizing the need for genetic testing first, with no major omissions or errors."
  },
  "374": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and guideline references, and no major omissions or errors."
  },
  "375": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, provides clear reasoning, and includes no major omissions or errors."
  },
  "376": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides appropriate rationale and guideline references."
  },
  "377": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors. It clearly states that PET/CT cannot replace standard chest CT for routine follow-up, provides guideline-based reasoning, and addresses the appropriate use of PET/CT."
  },
  "378": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including the rationale for systemic therapy, the role of local treatment, and guideline recommendations, with no major omissions or errors."
  },
  "379": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the need for continued broad molecular testing, and provides appropriate guideline-based justification without any major omissions or errors."
  },
  "380": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects the reference answer, and includes all key points without major omissions or errors. It even provides additional detail and references, fully supporting the clinical reasoning."
  },
  "381": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed rationale, but it places more emphasis on afatinib over osimertinib, whereas the reference answer gives both as preferred options without prioritization. This is a minor omission, as both drugs are acceptable choices per the reference."
  },
  "382": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the essential clinical content, emphasizing the necessity of PFTs and the generally recommended use of bronchoscopy, but introduces a nuanced, individualized approach to bronchoscopy that is not explicitly stated in the reference answer. This is a minor omission, as the reference answer asserts both are mandatory regardless of comorbidity."
  },
  "383": {
    "score": 2.0,
    "explanation": "2: The model answer contains notable errors, as it incorrectly broadens the indication for neoadjuvant systemic therapy in cT1cN0M0 patients to include hormone receptor-positive, HER2-negative subtypes, which is not standard practice. The reference answer correctly states that, for this stage, neoadjuvant therapy is only indicated for HER2-positive or triple-negative subtypes, making the model answer's core assertion inaccurate."
  },
  "384": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly prioritizing whole-brain radiotherapy for symptomatic brain edema and providing sound justification without omissions or errors."
  },
  "385": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly stating that pathological confirmation and staging take priority over biomarker testing, and providing logical justification for the sequence. No major omissions or errors are present."
  },
  "386": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indications, rationale, and guideline recommendations for FDG-PET/CT in this scenario, with no major omissions or errors."
  },
  "387": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the rationale, guideline recommendations, and clinical management suggestions, with no major omissions or errors."
  },
  "388": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion but inverts the priority compared to the reference answer, recommending systemic therapy first rather than initial local management for malignant effusion without acute distress. This is a significant deviation from the reference, though the rest of the content is relevant and accurate."
  },
  "389": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive, guideline-based information consistent with the reference answer, with no major omissions or errors. It accurately reflects the current recommendations and nuances for this clinical scenario."
  },
  "390": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points and providing appropriate justification without omissions or errors."
  },
  "391": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the necessity of pathological confirmation for N3 staging and referencing appropriate guidelines, with no major omissions or errors."
  },
  "392": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of R1/R2 margins and suggests a more intensive follow-up schedule, but this contradicts the reference answer, which states that the follow-up frequency remains the same regardless of margin status. The model answer contains some inaccuracies regarding guideline recommendations for follow-up frequency in R1/R2 cases."
  },
  "393": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, risks, and guideline recommendations, with no major omissions or errors."
  },
  "394": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional guideline context, and accurately discusses individualized decision-making without introducing errors or omissions."
  },
  "395": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the contraindication of standard chemoradiotherapy in severe renal insufficiency, the rationale, guideline recommendations, and the need for individualized, multidisciplinary decision-making. No major omissions or errors are present."
  },
  "396": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including guideline recommendations, cognitive protection, indications, and the limitations of WBRT, with no major omissions or errors."
  },
  "397": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of histological confirmation before proceeding with treatment, and even expands with guideline references and rationale without introducing errors or omissions."
  },
  "398": {
    "score": 4.0,
    "explanation": "4: The model answer provides a comprehensive and nuanced discussion, covering key considerations and emphasizing individualized assessment, but it does not clearly state that re-irradiation is generally not recommended and should only be considered in highly selected cases, as highlighted in the reference answer."
  },
  "399": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "400": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the necessity of postoperative radiotherapy for R1 margins, guideline recommendations, and the risks of omitting adjuvant therapy, with no significant omissions or errors."
  },
  "401": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including the need to start chemotherapy if urgent, the importance of obtaining molecular testing as soon as possible, and adjusting treatment based on results. It also provides additional rationale and references, with no major omissions or errors."
  },
  "402": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It covers all key points, including the rationale for surgical preference, supporting evidence, and indications for radiotherapy."
  },
  "403": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides additional guideline-based justification and references."
  },
  "404": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining that ALND cannot be omitted when 3 positive sentinel lymph nodes are found, and provides appropriate guideline and trial context without any major omissions or errors."
  },
  "405": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical content from the reference answer, with additional relevant details and supporting evidence, without any major omissions or errors."
  },
  "406": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and clear indications for both endocrine therapy and chemotherapy, with no major omissions or errors."
  },
  "407": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage, correctly referencing guidelines and the standard follow-up interval, but it omits the reference answer’s emphasis on increasing imaging frequency in the presence of repeated or new radiological abnormalities, even if asymptomatic. This is a significant omission that affects clinical decision-making."
  },
  "408": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It covers all key points, provides guideline-based justification, and clearly states that axillary micrometastasis is not a contraindication."
  },
  "409": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including guideline support, the validity of plasma cfDNA testing, and the appropriateness of BRAF-targeted therapy without requiring repeat tissue biopsy. No major omissions or errors are present."
  },
  "410": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, relevant study evidence, and guideline recommendations, with no major omissions or errors."
  },
  "411": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical decision points, including the distinction between multiple primary lung cancers and metastatic disease, as well as the management implications. However, it is more detailed and includes additional discussion on diagnostic criteria and guidelines, which, while accurate, slightly diverges from the concise principle-based approach of the reference answer."
  },
  "412": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering all key points with no major omissions or errors. It even provides additional guideline references and clear reasoning, matching the reference answer's intent and content."
  },
  "413": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including drug selection, metabolism, safety in renal impairment, and guideline recommendations, with no major omissions or errors."
  },
  "414": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need to increase imaging frequency in the presence of new or residual abnormalities, and adds appropriate detail about individualized assessment and further diagnostic steps. There are no major omissions or errors."
  },
  "415": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindications for surgery and preoperative chemoradiotherapy in the context of severely impaired lung function, and appropriately recommending non-surgical management."
  },
  "416": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects all key clinical content from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "417": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, covering all key points from the reference answer and adding relevant details without introducing errors or omissions."
  },
  "418": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and supporting evidence without omissions or errors."
  },
  "419": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it introduces additional detail about molecular and PD-L1 status and suggests initial systemic therapy before local treatment, which is a nuanced but slightly different emphasis from the reference answer's clear prioritization of local ablative therapy in eligible oligometastatic patients."
  },
  "420": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the follow-up interval, imaging modality, and rationale for non-contrast CT in patients with renal insufficiency, with no major omissions or errors."
  },
  "421": {
    "score": 4.0,
    "explanation": "4: The model answer provides a comprehensive and nuanced discussion, referencing guidelines and clinical scenarios, but introduces some ambiguity and extra detail not present in the reference answer, which may cause minor confusion. The core recommendation—that ALND can be omitted in cN0 patients with only micrometastases after NAST—is present, but the answer is less direct and slightly more equivocal than the reference."
  },
  "422": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even provides additional guideline references and rationale, fully supporting the correct approach."
  },
  "423": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale and references guidelines, but it incorrectly prioritizes chemotherapy over further endocrine therapy, missing the guideline-based recommendation to continue endocrine therapy unless there is clear endocrine resistance or visceral crisis. This is a significant clinical inaccuracy."
  },
  "424": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the rationale for prioritizing surgery, detailing the risks of re-irradiation, and referencing guidelines, with no major omissions or errors."
  },
  "425": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough explanation, including rationale and guideline references. However, it is slightly more conservative than the reference answer, emphasizing that ctDNA should not fully replace tissue testing, whereas the reference allows ctDNA as a substitute when tissue is insufficient. Minor differences in emphasis account for the deduction."
  },
  "426": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including guideline recommendations, clinical value, and limitations of ctDNA testing. However, it overstates ctDNA as a \"首选手段替代\" (primary replacement), whereas the reference emphasizes that tissue remains the gold standard and ctDNA is a substitute only when tissue is unavailable, making this a minor but important omission."
  },
  "427": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including staging, guideline recommendations, the impact of severe lung dysfunction, and the preferred non-surgical treatment approach, with no major omissions or errors."
  },
  "428": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive coverage, referencing current guidelines, management options, and the need for individualized assessment, fully aligning with the reference answer without omissions or errors."
  },
  "429": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the prioritization of SBRT or RFA over parenchyma-sparing resection in patients with significant pulmonary dysfunction, and provides appropriate guideline references without any major omissions or errors."
  },
  "430": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides appropriate rationale and guideline references."
  },
  "431": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the priority of postoperative radiotherapy over systemic therapy, with no major omissions or errors. It even provides guideline references and a clear summary, fully matching the reference content."
  },
  "432": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with detailed reasoning, guideline references, and appropriate caveats, without any major omissions or errors."
  },
  "433": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the question with no major omissions or errors, and provides clear justification and guideline support."
  },
  "434": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale and covers some relevant guidelines, but it incorrectly prioritizes surgery over concurrent chemoradiotherapy, which is not consistent with standard recommendations for stage IIIA NSCLC. This is a significant inaccuracy, though the answer is otherwise detailed."
  },
  "435": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points, and provides detailed justification consistent with the reference answer, with no major omissions or errors."
  },
  "436": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed rationale, guideline references, and supporting evidence, but it overemphasizes化疗联合HER2靶向药物 as the default without充分强调病程进展速度和内脏危象等临床分层决策要点，略有偏离参考答案的分层思路。"
  },
  "437": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding, but it allows for proceeding to preoperative therapy without PET/CT if other imaging excludes metastasis, which is a minor deviation from the reference answer's stricter requirement for PET/CT before treatment."
  },
  "438": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately reflects the key clinical recommendations, but it specifies the 3–6 month interval for only the first 2 years rather than the 3 years stated in the reference answer, which is a minor omission."
  },
  "439": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, accurately reflecting current guidelines and including relevant details about standard first-line therapy and the role of PD-L1, with no major omissions or errors."
  },
  "440": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification, guideline references, and appropriate follow-up recommendations without any major omissions or errors."
  },
  "441": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant detail supporting the reasoning."
  },
  "442": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the rationale for treating as two primaries when appropriate, the distinction from metastatic disease, and the importance of MDT evaluation. No major omissions or errors are present."
  },
  "443": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline citations, and no major omissions or errors. It fully supports annual low-dose non-contrast CT after 3 years without recurrence, matching the reference answer."
  },
  "444": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It accurately explains the indications, provides guideline references, and clearly states that cT1cN0 TNBC fits the criteria for neoadjuvant systemic therapy."
  },
  "445": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the risks of contrast in severe renal insufficiency, recommending non-contrast CT for routine follow-up, and appropriately discussing exceptions and multidisciplinary decision-making."
  },
  "446": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the rationale for local treatment first, the role of systemic therapy, and guideline recommendations. However, it introduces more detail than the reference and slightly shifts emphasis to a combined approach, which is a minor deviation from the reference's clear prioritization of local therapy first."
  },
  "447": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and appropriate recommendations without any omissions or errors."
  },
  "448": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the necessity of bronchoscopy, its impact on surgical planning, and guideline recommendations, with no major omissions or errors."
  },
  "449": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of molecular testing before initiating immunotherapy, referencing guidelines, and outlining appropriate next steps without omissions or errors."
  },
  "450": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately explains the rationale, and matches the reference answer with no major omissions or errors."
  },
  "451": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses each drug, details the impact of hepatic impairment, and reaches the same conclusion as the reference answer with no major omissions or errors."
  },
  "452": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the increased toxicity risk of platinum-based chemotherapy in severe renal insufficiency, the general recommendation against adjuvant systemic therapy in this context, and the preference for close observation. It also adds relevant guideline context and discusses alternative options, with no major omissions or errors."
  },
  "453": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides comprehensive justification, cites relevant guidelines and studies, and addresses all key points."
  },
  "454": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately explaining the rationale for SRS before molecular results, and even adds appropriate clinical considerations without introducing errors or omissions."
  },
  "455": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately explaining that MRI is sufficient for abdominal and pelvic imaging in patients with renal insufficiency, and that CT is not required. It also provides additional relevant details and references, with no major omissions or errors."
  },
  "456": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the need for careful pulmonary function assessment, the contraindication to perioperative therapy in the setting of severe impairment, and the consideration of alternative non-surgical treatments. No major omissions or errors are present."
  },
  "457": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing both the advanced tumor stage and the significant pulmonary dysfunction as contraindications to surgery, and correctly recommending non-surgical local therapies."
  },
  "458": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points without omissions or errors, and even provides supporting guideline references."
  },
  "459": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, supporting evidence, and guideline recommendations without any major omissions or errors."
  },
  "460": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, guideline recommendations, supporting evidence, and a clear conclusion without omissions or errors."
  },
  "461": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors. It clearly states that ICI monotherapy is not recommended, provides supporting evidence, and aligns with guideline recommendations."
  },
  "462": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need to avoid routine enhanced CT in patients with renal insufficiency and emphasizing the preference for non-contrast CT, with no major omissions or errors."
  },
  "463": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer by recommending routine follow-up intervals rather than increased imaging frequency in the presence of new or residual radiological abnormalities, even without symptoms or clear progression. This is a major clinical error."
  },
  "464": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the clinical scenario, including all relevant staging distinctions and management implications, with no major omissions or errors."
  },
  "465": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and including all key points without omissions or errors."
  },
  "466": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and provides a clear rationale for prioritizing systemic targeted therapy over local treatment."
  },
  "467": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for adjuvant chemotherapy, the inapplicability of endocrine therapy, and referencing relevant guidelines, with no major omissions or errors."
  },
  "468": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating on the rationale and supporting evidence without introducing errors or omissions."
  },
  "469": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, diagnostic steps, and emphasizing the importance of not excluding Paget disease based on negative mammography alone. No major omissions or errors are present."
  },
  "470": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors. It clearly prioritizes reoperation over adjuvant radiotherapy, provides rationale, and references guidelines, matching the reference answer in content and reasoning."
  },
  "471": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage of follow-up recommendations, appropriate use of imaging, and guideline references, with no major omissions or errors."
  },
  "472": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed and guideline-based rationale but directly contradicts the reference answer, which states that repeat pathological mediastinal lymph node assessment is not routinely required if it was done at initial diagnosis and imaging shows no progression. This is a notable error in clinical content."
  },
  "473": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, relevant guidelines, and the necessity of confirming molecular subtype before considering neoadjuvant therapy, with no major omissions or errors."
  },
  "474": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides appropriate justification and guideline references."
  },
  "475": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately addressing the ECOG status, guideline recommendations, and rationale for not recommending Fam-trastuzumab deruxtecan-nxki, with no major omissions or errors."
  },
  "476": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why EGFR-TKI is not appropriate and correctly recommending immunotherapy based on PD-L1 status, with no major omissions or errors."
  },
  "477": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the necessity of repeat biopsy for molecular testing regardless of imaging limitations or renal dysfunction, and even expands on guideline support and alternative imaging options without introducing errors or omissions."
  },
  "478": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the necessity of preoperative PFTs, the rationale, and the clinical guidelines, with no major omissions or errors."
  },
  "479": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "480": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the priority of local treatment for the solitary brain metastasis, the rationale, and the role of systemic therapy, with no major omissions or errors."
  },
  "481": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical points from the reference answer, with additional supporting evidence and guideline recommendations, without any major omissions or errors."
  },
  "482": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and appropriate use of FDG-PET/CT and brain MRI in this context, with no major omissions or errors."
  },
  "483": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the need for pathological confirmation, the insufficiency of imaging alone, and the impact on treatment decisions, with added guideline references and rationale."
  },
  "484": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the prioritization of NTRK inhibitors, rationale, and appropriate handling of symptomatic pericardial effusion, with no major omissions or errors."
  },
  "485": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately compares both treatment strategies, and clearly states the priority of combined therapy, fully aligning with the reference answer without omissions or errors."
  },
  "486": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and clear justification without omissions or errors."
  },
  "487": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of pathological confirmation before systemic therapy and referencing relevant guidelines, with no major omissions or errors."
  },
  "488": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It clearly explains the rationale and aligns with guideline recommendations."
  },
  "489": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, providing detailed information on both drugs’ metabolism, toxicity, and clinical recommendations. However, it does not as clearly state the clinical preference for Brigatinib over Alectinib in patients with chronic liver dysfunction, which is emphasized in the reference answer."
  },
  "490": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，理由充分，无明显遗漏或错误。"
  },
  "491": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately recommends following the imaging surveillance schedule for locally advanced (III) or early/intermediate-stage patients, and clearly distinguishes this from the approach for patients with multiple metastases. There are no major omissions or errors."
  },
  "492": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need to prioritize local control of bleeding before systemic therapy, and provides additional relevant details without introducing errors or omissions."
  },
  "493": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the appropriateness of concurrent chemoradiotherapy, the need for risk assessment, and individualized management based on bleeding risk, with no major omissions or errors."
  },
  "494": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a well-reasoned explanation, but it diverges from the reference answer by allowing omission of pulmonary function testing in certain cases, whereas the reference answer states it should always be performed preoperatively. This represents a minor but important difference in clinical approach."
  },
  "495": {
    "score": 5.0,
    "explanation": "5: The model answer accurately reflects all key clinical content from the reference answer, including the rationale for continued endocrine therapy, the assessment of endocrine resistance, and the clinical implications for treatment selection, with no major omissions or errors."
  },
  "496": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately explains why Durvalumab is not recommended, referencing relevant studies and guidelines. However, it does not explicitly state that Osimertinib is preferred as consolidation therapy, which is a key point in the reference answer."
  },
  "497": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based rationale, but it introduces additional stratification based on symptom severity, which, while accurate and clinically relevant, goes beyond the scope of the reference answer. There are no major errors, but the extra detail is not strictly required for full marks."
  },
  "498": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, provides detailed rationale, and includes relevant guideline recommendations and practical considerations, with no major omissions or errors."
  },
  "499": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "500": {
    "score": 2.0,
    "explanation": "2: The model answer recommends low-dose non-contrast CT every 6 months as the preferred follow-up, which contradicts the reference answer that specifies routine chest CT ± contrast every 3–6 months for the first 3 years. The model omits the need for more frequent and potentially contrast-enhanced imaging in the early post-treatment period, representing a notable error in clinical guidance."
  },
  "501": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "502": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, relevant guidelines, and explicitly stating that the absence of advanced imaging implies no symptoms or radiological evidence of recurrence."
  },
  "503": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of bisphosphonates and the cautious use of denosumab with appropriate monitoring, without any major omissions or errors."
  },
  "504": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately addresses the contraindications and risks of both bisphosphonates and denosumab in severe renal impairment, as well as the need for monitoring and alternative strategies. However, it omits explicit mention of surgical or radiotherapy alternatives for fracture management, which is present in the reference answer."
  },
  "505": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the necessity of postoperative radiotherapy and the correct treatment sequence, with no major omissions or errors."
  },
  "506": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even elaborates on emergency management options appropriately."
  },
  "507": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "508": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the impact of severe renal insufficiency on standard imaging modalities, discusses alternative assessments, and reaches the same conclusion as the reference answer with no major omissions or errors."
  },
  "509": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing both the staging and functional contraindications to surgery, and correctly recommending non-surgical multimodal therapy as the preferred approach."
  },
  "510": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "511": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and well-reasoned, correctly stating that PFTs are not mandatory before systemic therapy in N3 NSCLC patients who are not surgical candidates. However, it omits the potential value of PFTs in assessing overall treatment tolerance and risks, which is highlighted in the reference answer."
  },
  "512": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing postoperative radiotherapy and appropriately addressing the role of systemic therapy, with no major omissions or errors."
  },
  "513": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including drug metabolism, lack of contraindication in renal failure, guideline recommendations, and the need for monitoring, with no major omissions or errors."
  },
  "514": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "515": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why direct follow-up after R2 resection does not meet standard treatment boundaries and detailing the need for further therapy, with no major omissions or errors."
  },
  "516": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and alternative management, with no major omissions or errors."
  },
  "517": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need for additional local therapy and referencing guidelines, with no major omissions or errors."
  },
  "518": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of the clinical scenario and acknowledges the importance of lung function assessment, but it incorrectly states that PFTs are not necessary before starting chemoradiotherapy and suggests proceeding without them, which contradicts the reference answer’s emphasis on the necessity of PFTs to ensure treatment safety. This is a significant omission."
  },
  "519": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed justification, including guideline recommendations, efficacy, and safety data. However, it introduces an unnecessary discussion about the combination with拉泽替尼, which is not relevant for patients without RET mutations, and this could cause minor confusion. Otherwise, the clinical content aligns well with the reference answer."
  },
  "520": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the standard recommendation of concurrent chemoradiotherapy, the necessity of detailed pulmonary function assessment, and alternative treatments if the patient cannot tolerate chemoradiotherapy. There are no major omissions or errors."
  },
  "521": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed but incorrect recommendation, contradicting current guidelines and the reference answer by insisting on waiting for other driver gene results before initiating NTRK-targeted therapy, despite confirmed NTRK fusion positivity. This represents a notable clinical error and misinterpretation of treatment prioritization."
  },
  "522": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of driver gene testing before using PD-L1 as a basis for immunotherapy, and referencing guidelines and rationale without any major omissions or errors."
  },
  "523": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indications, rationale, and considerations for breast-conserving surgery versus mastectomy, with no major omissions or errors."
  },
  "524": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately addresses the question, and provides additional guideline references and rationale without introducing errors or omissions."
  },
  "525": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It clearly prioritizes interventional measures for acute bleeding, explains the rationale, and addresses subsequent radiotherapy considerations."
  },
  "526": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，且补充了具体的随访建议和进一步诊断措施，无重大遗漏或错误。"
  },
  "527": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "528": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even provides additional guideline references and alternative approaches if PET/CT is unavailable."
  },
  "529": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guideline recommendations, and implications of using low-dose non-contrast CT versus contrast-enhanced CT in this context, with no major omissions or errors."
  },
  "530": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "531": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully aligning with the reference answer and current guidelines, with no major omissions or errors."
  },
  "532": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of both lung function and FDG-PET/CT before proceeding, with no major omissions or errors."
  },
  "533": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, covering all key clinical points and rationale without omissions or errors."
  },
  "534": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the indication, rationale, and guideline support for radiotherapy as a salvage option in this scenario, with no major omissions or errors."
  },
  "535": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based discussion, but it differs from the reference answer by recommending postmastectomy radiotherapy even after pathological complete response, whereas the reference answer states it can be omitted. This represents a minor but important difference in clinical recommendation."
  },
  "536": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing chest CT over PET/CT and referencing guidelines, with no major omissions or errors."
  },
  "537": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering all key points with no major omissions or errors, and even provides additional guideline references and rationale."
  },
  "538": {
    "score": 5.0,
    "explanation": "5: The model answer not only covers all the key points of the reference answer but also provides additional relevant details and guideline references, with no major omissions or errors."
  },
  "539": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key criteria and providing appropriate justification without omissions or errors."
  },
  "540": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the need to wait for molecular and PD-L1 results before initiating individualized therapy, and even adds relevant guideline references and appropriate caveats without introducing errors or omissions."
  },
  "541": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the question with no major omissions or errors, and even provides additional rationale and guideline references."
  },
  "542": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need for comprehensive molecular profiling and PD-L1 testing before optimal first-line therapy selection, with no major omissions or errors."
  },
  "543": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "544": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and provides additional guideline-based rationale without introducing errors or omissions."
  },
  "545": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even adds appropriate detail and guideline references."
  },
  "546": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the primacy of systemic therapy and the possible role of local therapy in selected oligometastatic cases, but it adds extra detail and nuance not present in the reference answer. There are no major omissions, but the answer is more elaborate than required."
  },
  "547": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including survival equivalence, indications, and the rationale for prioritizing breast-conserving surgery plus radiotherapy, with no major omissions or errors."
  },
  "548": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of preoperative pulmonary function testing and referencing relevant guidelines, with no major omissions or errors."
  },
  "549": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion of the use of 21-gene RT-PCR in pN1mi patients and emphasizes the need for comprehensive clinical-pathological assessment, but it omits the critical point from the reference answer: the necessity to clarify the pathological type before relying on the test result, especially excluding inflammatory carcinoma, which is a key contraindication for using the assay in decision-making."
  },
  "550": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale for prioritizing SVC stenting for acute symptom control but omits the importance of combined chemoradiotherapy for both symptom and tumor control as emphasized in the reference answer. It also overstates the preference for stenting alone, which is only indicated for patients unable to tolerate systemic therapy or in emergency situations, leading to partial coverage and some inaccuracy."
  },
  "551": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately prioritizes local treatment, and provides detailed rationale consistent with the reference answer, with no major omissions or errors."
  },
  "552": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and appropriate justification without omissions or errors."
  },
  "553": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the recommendations, rationale, and guidelines, with no major omissions or errors."
  },
  "554": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and adds relevant clinical considerations without introducing errors or omissions. It fully covers the need for individualized assessment and the limitations of radiotherapy as a universal solution."
  },
  "555": {
    "score": 2.0,
    "explanation": "2: The model answer recommends ALND in cases of SLN micrometastases after neoadjuvant therapy, which contradicts the reference answer that states ALND is not needed in this scenario. The model answer provides detailed rationale but contains a notable clinical error, leading to a limited score."
  },
  "556": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates good clinical reasoning, but it prioritizes neoadjuvant therapy over surgery, whereas the reference answer states that surgery is preferred if the patient can tolerate it. The model answer underemphasizes that surgery remains first-line if feasible, which is a minor but important omission."
  },
  "557": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical content from the reference answer, with additional relevant guideline and evidence-based details. There are no major omissions or errors."
  },
  "558": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors. It even provides additional guideline references and rationale, fully supporting the correct recommendation."
  },
  "559": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical content from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "560": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive discussion but incorrectly prioritizes re-operation as the first choice, which contradicts the reference answer stating that systemic therapy and chemoradiotherapy are preferred over repeat surgery. This is a significant deviation, though the rest of the content is relevant and detailed."
  },
  "561": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing olaparib over abemaciclib, and includes all key details without omissions or errors."
  },
  "562": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline references, with no major omissions or errors."
  },
  "563": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and even elaborates on rationale, guidelines, and safety considerations."
  },
  "564": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer by recommending no increase in CT follow-up frequency, whereas the reference answer clearly states that frequency should be increased in the presence of persistent imaging abnormalities, regardless of their specificity."
  },
  "565": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, including guideline-based stratification by PD-L1 expression, and correctly prioritizes immunotherapy (alone or combined with chemotherapy) over chemotherapy alone, with no major omissions or errors."
  },
  "566": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing EGFR-TKI (osimertinib) as first-line therapy despite high PD-L1, and provides clear rationale and guideline support without omissions or errors."
  },
  "567": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, supporting evidence, and guideline recommendations without any major omissions or errors."
  },
  "568": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing external beam radiotherapy for rapid symptom control and providing appropriate rationale without omissions or errors."
  },
  "569": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the inapplicability of the regimen for squamous histology and providing additional rationale without introducing errors or omissions."
  },
  "570": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the impact of severe pulmonary dysfunction on surgical candidacy, perioperative management, and alternative treatments, with no major omissions or errors."
  },
  "571": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical reasoning, includes relevant guideline references, and fully supports the recommendation to prioritize systemic therapy over observation, matching the reference answer in clinical content without omissions or errors."
  },
  "572": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of need for immediate surgery, the importance of pathological confirmation, and the recommendation for follow-up. No major omissions or errors are present."
  },
  "573": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed reasoning, but it overemphasizes that both neoadjuvant therapy and direct surgery are equally recommended, whereas the reference answer suggests neoadjuvant therapy is preferred and direct surgery is not the first choice. Minor nuance is missing regarding the prioritization."
  },
  "574": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately prioritizing surgery for suitable patients and explaining the rationale, with no major omissions or errors."
  },
  "575": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "576": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the impact of COPD-related lung function impairment on treatment choice, emphasizing the need for multidisciplinary evaluation, and providing detailed criteria for decision-making without any major omissions or errors."
  },
  "577": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the risks of contrast in renal insufficiency, the sufficiency of non-contrast CT for follow-up, and guideline recommendations, with no major omissions or errors."
  },
  "578": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indications and rationale for not routinely performing FDG-PET/CT or brain MRI, and emphasizing chest CT as the mainstay of follow-up. No major omissions or errors are present."
  },
  "579": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately explains the rationale, and provides additional relevant details without introducing errors or omissions."
  },
  "580": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional supporting rationale consistent with current guidelines."
  },
  "581": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and cites guidelines, but it inaccurately states that adjuvant chemotherapy plus trastuzumab is recommended for tumors <0.6 cm with pN1mi, whereas the reference answer clearly states that evidence is insufficient and such treatment is generally not recommended. This is a significant clinical inaccuracy."
  },
  "582": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, providing detailed reasoning and referencing guidelines, but it introduces the option of immunotherapy combined with chemotherapy, which, while correct, slightly extends beyond the reference answer's focus on monotherapy versus chemotherapy. Minor expansion, but no major omissions or errors."
  },
  "583": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preferred use of low-dose chest CT, the indications for PET/CT, guideline recommendations, and the rationale for the diagnostic sequence, with no major omissions or errors."
  },
  "584": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the key recommendation and providing additional rationale and guideline support without any omissions or errors."
  },
  "585": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating with guideline references and rationale, without any major omissions or errors."
  },
  "586": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides comprehensive justification, cites supporting studies and guidelines, and clearly states that EGFR-TKI should be prioritized over chemotherapy in this scenario."
  },
  "587": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and provides additional rationale and guideline support."
  },
  "588": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining that endocrine therapy is not routinely recommended after mastectomy for ER-positive DCIS, and provides appropriate rationale and guideline references without major omissions or errors."
  },
  "589": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points without omissions or errors. It clearly states that routine FDG-PET/CT or brain MRI is not recommended in asymptomatic patients, even with a persistent smoking history, and provides appropriate rationale and guideline references."
  },
  "590": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the inapplicability of osimertinib without EGFR mutations and outlining appropriate standard treatments, with no major omissions or errors."
  },
  "591": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, diagnostic considerations, and management principles outlined in the reference answer, with no major omissions or errors. It even expands on the decision-making process, but remains entirely consistent with the reference."
  },
  "592": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the primacy of systemic therapy, the role of MDT assessment, criteria for local therapy, and the necessity of combining systemic and local treatments when appropriate, with no major omissions or errors."
  },
  "593": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale but omits the key standard that PET/CT is required for proper staging before surgery, as emphasized in the reference answer. It inaccurately suggests that surgery can proceed without PET/CT in early-stage cases, which is not consistent with standard guidelines."
  },
  "594": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and clearly stating that the combination regimen is not recommended for squamous NSCLC with EGFR mutation. No major omissions or errors are present."
  },
  "595": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and includes appropriate rationale and guideline references."
  },
  "596": {
    "score": 1.0,
    "explanation": "1: The model answer contradicts the reference answer by stating that neoadjuvant systemic therapy is not routinely recommended for cT1cN0M0 triple-negative breast cancer, whereas the reference answer affirms it is an indication. This represents a major clinical inaccuracy."
  },
  "597": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the scenario, rationale, and prioritization of reoperation over surveillance, with no major omissions or errors."
  },
  "598": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors. It accurately reflects current guidelines and provides clear justification."
  },
  "599": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors, and even provides supporting guidelines and rationale."
  },
  "600": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining why surgery is not preferred and appropriately recommending chemoradiotherapy as the first-line local treatment, with no major omissions or errors."
  },
  "601": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, provides additional guideline-based justification, and has no major omissions or errors."
  },
  "602": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including the risks of contrast agents in severe renal impairment and the preference for non-contrast imaging. However, it provides more detail than necessary and suggests possible exceptions (e.g., risk-benefit assessment for contrast use) that are not mentioned in the reference answer, which simply states that contrast studies are not suitable."
  },
  "603": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the rationale for concurrent chemoradiotherapy, the role of SVC stenting, and the limitations of radiotherapy alone, with no major omissions or errors."
  },
  "604": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the T4 classification and the possibility of curative treatment, with no significant omissions or errors."
  },
  "605": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of FDG-PET/CT and brain MRI for adequate staging, and referencing guidelines; there are no major omissions or errors."
  },
  "606": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including guideline recommendations, the role of non-contrast CT, and alternative imaging. However, it omits the specific caveat that for certain mediastinal structures or suspicious areas, non-contrast CT may have reduced sensitivity and specificity, and that enhanced imaging should be considered if clinically indicated and risk is acceptable."
  },
  "607": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and well-supported by evidence, but it places more emphasis on initial systemic therapy before local therapy, whereas the reference answer allows for local therapy to be prioritized in certain cases. Minor differences in sequencing and nuance account for the slight deduction."
  },
  "608": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer by recommending immediate FDG-PET/CT rather than increased imaging follow-up, which is a major clinical error and misinterpretation of guidelines."
  },
  "609": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale for prioritizing adjuvant pembrolizumab and references relevant studies and guidelines, but it omits the key point from the reference answer that both pembrolizumab and olaparib are options without a clear priority, and that the choice should be individualized based on patient tolerance. This represents a significant omission in clinical content."
  },
  "610": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and criteria for systemic and bone-targeted therapy, and clearly stating the implication regarding the absence of visceral crisis, with no major omissions or errors."
  },
  "611": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "612": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guidelines, and appropriate prioritization of concurrent chemoradiotherapy, with no major omissions or errors."
  },
  "613": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends more frequent (every 3–6 months) chest CT follow-up for I–II stage NSCLC patients treated with surgery alone, which contradicts the reference answer and guidelines; it also misapplies recommendations meant for higher-risk groups."
  },
  "614": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines and key studies, and making no major omissions or errors."
  },
  "615": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining that low-dose non-contrast chest CT does not require adjustment in frequency for patients with renal insufficiency, and provides appropriate guideline context without omissions or errors."
  },
  "616": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including evidence, guideline recommendations, and rationale for prioritizing osimertinib over durvalumab, with no major omissions or errors."
  },
  "617": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning and supporting evidence without any major omissions or errors."
  },
  "618": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "619": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the indication, rationale, and advantages of SABR for patients unsuitable for surgery, with no major omissions or errors."
  },
  "620": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately contrasts T3与T4分期，明确指出治疗原则需随分期提升调整，并补充了指南依据及具体处理建议，无重大遗漏或错误。"
  },
  "621": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends prioritizing RET inhibitors over standard chemotherapy in squamous NSCLC, which contradicts current guidelines and available evidence; while it provides rationale, it contains a notable clinical error and omits the guideline-based preference for chemotherapy in this context."
  },
  "622": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes concurrent chemoradiotherapy over chemotherapy alone, and provides detailed rationale and guideline support, with no major omissions or errors."
  },
  "623": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects the reference answer, and even expands with guideline references and management of special situations, without introducing errors or major omissions."
  },
  "624": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and even provides additional guideline references for support."
  },
  "625": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional supporting details and references without introducing inaccuracies."
  },
  "626": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, relevant rationale, and even additional context without introducing errors or omissions."
  },
  "627": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with accurate rationale and no major omissions or errors."
  },
  "628": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly prioritizing palliative local intervention for airway obstruction over curative surgery, and then systemic therapy, with no major omissions or errors."
  },
  "629": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly addressing both the sufficiency of molecular testing and the irrelevance of PD-L1 status in this context, with no major omissions or errors."
  },
  "630": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that neoadjuvant systemic therapy is not routinely recommended for tumors <1 cm, and provides additional guideline-based context without introducing errors or omissions."
  },
  "631": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the contraindication for adjuvant systemic therapy in this context and providing appropriate justification without omissions or errors."
  },
  "632": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing a thorough rationale for the lack of indication for both drugs and explicitly referencing their molecular targets and current guideline recommendations, with no major omissions or errors."
  },
  "633": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the question with no major omissions or errors, and even provides supporting guidelines and rationale."
  },
  "634": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why synchronous chemoradiotherapy is not recommended in patients with significant pulmonary dysfunction and suggesting appropriate alternative strategies, with no major omissions or errors."
  },
  "635": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points without omissions or errors. It clearly explains the rationale and guideline basis for choosing adjuvant endocrine therapy without 21-gene testing."
  },
  "636": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer, stating that routine molecular testing is not recommended, whereas the reference answer clearly states it is recommended by guidelines. This is a major error in clinical content."
  },
  "637": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors. It clearly explains the rationale and guidelines, matching the reference in content and recommendations."
  },
  "638": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional relevant details and guideline citations, without any major omissions or errors."
  },
  "639": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with clear reasoning and no major omissions or errors. It fully explains the necessity of completing FDG-PET/CT and brain MRI before proceeding with concurrent chemoradiotherapy."
  },
  "640": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of neoadjuvant therapy due to severe hepatic dysfunction, and appropriately emphasizing individualized treatment and prioritizing surgical management. No major omissions or errors are present."
  },
  "641": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，并补充了权威指南依据和注意事项，内容全面准确。"
  },
  "642": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the inapplicability of concurrent chemoradiotherapy in patients with severe chronic respiratory failure and appropriately suggesting alternative individualized treatments."
  },
  "643": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the question, and provides detailed rationale and guideline support without any major omissions or errors."
  },
  "644": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of staging and follow-up principles, but it incorrectly assumes that a history of metastasis (even if all lesions are radically treated) should default the patient to a higher follow-up intensity, which contradicts the reference answer. The reference answer clearly states that if all lesions are radically resected and the pathological stage is I–II, standard I–II follow-up is sufficient; the model answer introduces confusion and overstates the need for stricter surveillance."
  },
  "645": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides appropriate justification and references."
  },
  "646": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including the need for caution with standard systemic therapy in severe hepatic impairment, the rationale, and the importance of individualized treatment adjustment. No major omissions or errors are present."
  },
  "647": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that routine FDG-PET/CT or brain MRI is not recommended in asymptomatic IIB NSCLC patients post-R0 resection, and provides appropriate rationale and guideline references without any major omissions or errors."
  },
  "648": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive overview of the evidence and guidelines but inaccurately suggests abemaciclib can be considered as an alternative if olaparib is not tolerated, which is not supported by current recommendations; the reference answer clearly states abemaciclib is not a direct substitute due to different indications and lack of evidence."
  },
  "649": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors. It even adds relevant guideline references and further details, enhancing completeness."
  },
  "650": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, supporting evidence, and guideline recommendations for prioritizing surgical resection, with no major omissions or errors."
  },
  "651": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for systemic therapy over concurrent chemoradiotherapy in the presence of distant metastasis, with no major omissions or errors."
  },
  "652": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, indications, and rationale for preferring surgical resection over SRS in the presence of seizures, matching the reference answer in content and detail, with no major omissions or errors."
  },
  "653": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and correct recommendations without omissions or errors."
  },
  "654": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical considerations, and aligns closely with the reference answer without major omissions or errors. It details the rationale, guideline recommendations, and patient factors, fully addressing the question."
  },
  "655": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, providing detailed guideline-based reasoning and evidence. However, it introduces the possibility of omitting radiotherapy in select low-risk cases, which is not mentioned in the reference answer, representing a minor deviation."
  },
  "656": {
    "score": 5.0,
    "explanation": "5: The model answer fully matches the reference answer in clinical content, clearly stating that adequate tissue or plasma samples are assumed for molecular and PD-L1 testing, and provides additional relevant context without any omissions or errors."
  },
  "657": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, includes relevant guidelines, and reiterates all key points from the reference answer without omissions or errors."
  },
  "658": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the indication, rationale, and supporting guidelines for radiotherapy as the main salvage option, with no major omissions or errors."
  },
  "659": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the rationale, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "660": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a detailed, up-to-date rationale for prioritizing MET抑制剂靶向治疗, referencing recent evidence of intracranial efficacy. However, it omits the reference answer’s emphasis on the limited blood-brain barrier penetration of most MET inhibitors and the rapid symptom control offered by WBRT, which are important considerations."
  },
  "661": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, emphasizing the importance of axillary assessment before neoadjuvant therapy and referencing guidelines. However, it introduces some nuance about real-world practice that slightly dilutes the clear \"not appropriate\" stance of the reference answer, making it a minor omission."
  },
  "662": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guideline recommendations, and exceptions, with no major omissions or errors."
  },
  "663": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, relevant studies, and guideline recommendations without omissions or errors."
  },
  "664": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough and guideline-based discussion but directly contradicts the reference answer by prioritizing reoperation over chemoradiotherapy, which is not the recommended approach in the reference. This represents a significant clinical inaccuracy despite otherwise comprehensive coverage."
  },
  "665": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including the indications for T-DM1, the management of pCR patients, and the equivalence of treatment principles regardless of hormone receptor status, with no major omissions or errors."
  },
  "666": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of brain MRI for staging and its impact on treatment decisions, with no major omissions or errors."
  },
  "667": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional rationale and guideline support."
  },
  "668": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification and even elaborating on guideline recommendations, drug safety, and alternative treatments, with no major omissions or errors."
  },
  "669": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical points, including the change in staging, the role of surgery, and the need for adjuvant therapy. However, it places slightly more emphasis on surgery as the primary treatment, whereas the reference answer stresses that surgery is no longer the sole or primary option and that perioperative therapy should be prioritized, which is a subtle but important distinction."
  },
  "670": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, referencing guidelines and appropriate treatment modalities, with no major omissions or errors."
  },
  "671": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and provides additional supporting rationale consistent with guidelines."
  },
  "672": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately explains the rationale, and has no major omissions or errors."
  },
  "673": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides comprehensive reasoning, specific drug examples, and references to guidelines, fully covering the required content."
  },
  "674": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer by stating that increased imaging frequency is not recommended, whereas the reference answer clearly states that it is recommended. This is a major error in clinical content."
  },
  "675": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including guideline recommendations, the importance of waiting for all actionable driver gene results, and the rationale for not starting immunotherapy/chemotherapy prematurely. No major omissions or errors are present."
  },
  "676": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the risks of radiotherapy in severe COPD, guideline recommendations, and the prioritization of chemotherapy, with no major omissions or errors."
  },
  "677": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It provides comprehensive reasoning, guideline references, and aligns fully with current evidence and recommendations."
  },
  "678": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly identifies that标准辅助化疗（含蒽环类）不适用于严重心脏功能不全患者，但提出可考虑紫杉类等替代化疗方案，略超出参考答案的保守建议，未明确强调通常不推荐常规化疗，存在轻微扩展。"
  },
  "679": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the premise that observation assumes absence of high-risk features, and even expands with guideline references and additional examples of high-risk factors without introducing errors."
  },
  "680": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately addresses the risks of using EGFR TKIs in severe hepatic impairment, and aligns fully with the reference answer, with no major omissions or errors."
  },
  "681": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the limited benefit of Durvalumab in EGFR-mutant patients and the emerging evidence for Osimertinib. However, it is slightly more detailed than necessary and introduces some uncertainty regarding guideline updates, which is a minor omission compared to the more definitive stance in the reference answer."
  },
  "682": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the appropriateness of immune checkpoint inhibitors as first-line therapy regardless of prior radiotherapy, the need to assess for immune-related toxicity, and the importance of individualized evaluation. No major omissions or errors are present."
  },
  "683": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, relevant guidelines, and supporting evidence, with no major omissions or errors."
  },
  "684": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, adds relevant guideline support, and provides nuanced clinical considerations without introducing errors or omissions."
  },
  "685": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately explains the rationale, references guidelines, and matches the reference answer with no major omissions or errors."
  },
  "686": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including risk assessment, guideline recommendations, and the rationale for follow-up CT over PET/CT, with no significant omissions or errors."
  },
  "687": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "688": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without any major omissions or errors."
  },
  "689": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing postoperative chemoradiotherapy over systemic therapy alone, and includes relevant guideline recommendations without any major omissions or errors."
  },
  "690": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of brain MRI before systemic therapy, referencing guidelines, and providing clear justification without omissions or errors."
  },
  "691": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the necessity of PET/CT for accurate staging, exclusion of distant metastasis, and guideline recommendations, with no major omissions or errors."
  },
  "692": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for surgery, the role of chemoradiotherapy as an alternative, and the need for multidisciplinary evaluation, with no major omissions or errors."
  },
  "693": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides detailed rationale, guideline references, and does not omit any major content."
  },
  "694": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, recommendations, and rationale found in the reference answer, with additional guideline support and no major omissions or errors."
  },
  "695": {
    "score": 3.0,
    "explanation": "3: The model answer provides a well-reasoned and guideline-based approach but directly contradicts the reference answer regarding the preferred sequencing of therapies, recommending PD-1/PD-L1 inhibitors over KRAS G12C inhibitors. While the answer is detailed and accurate per some guidelines, it omits the reference answer’s emphasis on prioritizing KRAS G12C targeted therapy, resulting in a significant clinical discrepancy."
  },
  "696": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing staging, lung function, treatment options, and providing clear justification without omissions or errors."
  },
  "697": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of surgery in the context of severe pulmonary dysfunction, and appropriately recommending non-surgical management. No major omissions or errors are present."
  },
  "698": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately reflects the key clinical reasoning, emphasizing the need to exclude other actionable driver mutations before choosing crizotinib. However, it is slightly more conservative than the reference answer, stating \"不能直接合理选择,\" whereas the reference allows for crizotinib use if no other mutations are present, even if not yet confirmed, which is a minor nuance."
  },
  "699": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and some guideline references, but it contradicts the reference answer by recommending routine molecular testing in all such cases, whereas the reference answer states that molecular testing is not routinely indicated and has limited value in this context. This represents a significant inaccuracy."
  },
  "700": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors. It even provides additional guideline references and rationale, fully supporting the correct recommendation."
  },
  "701": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to increase imaging frequency upon detection of abnormal findings, and provides additional guideline-based rationale without any major omissions or errors."
  },
  "702": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including tumor biology, staging, guideline recommendations, and the rationale for adjuvant chemotherapy, with no major omissions or errors."
  },
  "703": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points, including guideline recommendations, evidence basis, and the rationale for using dual HER2 blockade based on initial nodal status rather than post-neoadjuvant pathology, with no major omissions or errors."
  },
  "704": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing concurrent chemoradiotherapy, the indications for systemic therapy, and guideline support, with no major omissions or errors."
  },
  "705": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed guideline-based reasoning, but it introduces additional qualifiers (e.g., high-risk factors, patient preference) that are not mentioned in the reference answer, which states more definitively that cT1cN0 TNBC is an indication for neoadjuvant therapy without such caveats."
  },
  "706": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately addresses the role of ECOG 3 status, and appropriately discusses the limited evidence and preference for supportive care, with no major omissions or errors."
  },
  "707": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the indication for palliative radiotherapy as initial intervention for symptom control, and correctly emphasizes subsequent systemic therapy, with no major omissions or errors."
  },
  "708": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of broad molecular testing (including rare driver mutations) in advanced squamous cell carcinoma, with no major omissions or errors."
  },
  "709": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately explains the rationale, and aligns fully with the reference answer without omissions or errors."
  },
  "710": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical reasoning, including the need for further evaluation and possible intervention, but it introduces a nuanced approach (e.g., observation for minor hemoptysis) that is not explicitly stated in the reference answer, which more strongly recommends intervention for any hemoptysis. Minor omissions and slight deviation from the reference's emphasis on safety account for the deduction."
  },
  "711": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the follow-up frequency after surgery is the same as after radiotherapy, missing the key point that surgical patients are generally followed every 6 months (not every 3–6 months) in the first 2–3 years. This is a notable error in clinical content."
  },
  "712": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the increased risks of combined therapy in patients with severe pulmonary dysfunction and emphasizing individualized, less toxic treatment strategies, with no major omissions or errors."
  },
  "713": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, risks, and guideline recommendations, with no major omissions or errors."
  },
  "714": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough discussion, but it overemphasizes N3作为广泛转移的排除标准，未充分体现参考答案中“符合有限转移定义，可考虑局部加全身治疗”的观点，结论与参考答案不一致。"
  },
  "715": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides clear justification based on guidelines and clinical reasoning."
  },
  "716": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the prioritization of selective RET inhibitors, the non-preference for Cabozantinib as first-line, and the exception for special circumstances. No major omissions or errors are present."
  },
  "717": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including prioritizing palliative radiotherapy for focal symptoms, the rationale for rapid symptom relief, and the role of systemic therapy, with no major omissions or errors."
  },
  "718": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and references relevant studies, but it inaccurately extends the Z0011 criteria to include 3 positive SLNs, which is not supported by the reference answer or standard guidelines; this is a significant clinical inaccuracy."
  },
  "719": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification and no major omissions or errors. It covers all key points, including guideline recommendations, risks of contrast in renal insufficiency, and the appropriateness of low-dose non-contrast CT for follow-up."
  },
  "720": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the rationale for prioritizing surgery over re-irradiation and providing appropriate detail without omissions or errors."
  },
  "721": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "722": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately reflects current guideline recommendations, emphasizing that immunotherapy monotherapy is generally reserved for PD-L1 ≥50%. However, it omits that monotherapy is still an option per some guidelines for PD-L1 ≥1% when chemotherapy is contraindicated, which is a minor omission."
  },
  "723": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, relevant study support, and guideline references, with no major omissions or errors."
  },
  "724": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content, accurately explains both the staging system and clinical practice considerations, and includes appropriate caveats and references. There are no major omissions or errors."
  },
  "725": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the lack of safety data, increased toxicity risk, and the recommendation against using dabrafenib plus trametinib as first-line therapy in severe hepatic impairment, with no major omissions or errors."
  },
  "726": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including prioritizing hemostasis with radiotherapy or interventional measures, deferring surgery until stabilization, and providing clear rationale and sequence. No major omissions or errors are present."
  },
  "727": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the need for urgent local intervention for high-risk bone metastases without waiting for molecular results, and provides additional relevant details without any omissions or errors."
  },
  "728": {
    "score": 4.0,
    "explanation": "4: The model answer is comprehensive and clinically accurate, but it adds较多指南和实际操作细节，强调需明确双原发诊断后方可根治性治疗，略多于参考答案的简明表述，且对“若无法区分”时的处理强调较多，属于细节扩展而非遗漏，整体内容无重大遗漏或错误。"
  },
  "729": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and guideline-based discussion but contradicts the reference answer by recommending against primary surgery, whereas the reference answer supports surgery as the preferred initial treatment in this scenario. This represents a significant inaccuracy in clinical content."
  },
  "730": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the risks of postoperative radiotherapy in patients with poor lung function, referencing guidelines, and emphasizing individualized decision-making and quality of life. No major omissions or errors are present."
  },
  "731": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points without omissions or errors, and appropriately referencing guidelines."
  },
  "732": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately explains the rationale, and covers all key points from the reference answer without omissions or errors."
  },
  "733": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the necessity of EGFR mutation confirmation before using osimertinib, the standard of care in the absence of mutation data, and relevant guideline recommendations, with no major omissions or errors."
  },
  "734": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the clinical priorities, including both local and systemic treatment, their sequencing, and the rationale, with no major omissions or errors compared to the reference answer."
  },
  "735": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, providing detailed rationale and guideline support without any omissions or errors."
  },
  "736": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with accurate reasoning and no major omissions or errors. It thoroughly explains the rationale and aligns with current guidelines."
  },
  "737": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the lack of evidence for BRAF inhibitors in active CNS metastases, guideline recommendations to prioritize local control, and the need to avoid these agents as initial therapy in this context. There are no major omissions or errors."
  },
  "738": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately explains the rationale, and even provides guideline references and possible exceptions, with no major omissions or errors."
  },
  "739": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and provides additional supporting rationale consistent with current guidelines."
  },
  "740": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that patients can directly enter neoadjuvant therapy without a complete axillary evaluation, omitting the essential step of pre-treatment axillary ultrasound assessment emphasized in the reference answer. This is a notable error in clinical workflow."
  },
  "741": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that the dual anti-HER2 regimen (trastuzumab + pertuzumab) is more highly recommended than single-agent trastuzumab, and provides appropriate guideline and evidence references without any major omissions or errors."
  },
  "742": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors, and provides detailed justification and guideline references."
  },
  "743": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly recommending low-dose non-contrast CT for follow-up and providing appropriate rationale without any major omissions or errors."
  },
  "744": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It covers all key points, provides rationale, and even adds relevant guidelines and process steps, fully aligning with the reference answer."
  },
  "745": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing systemic therapy and appropriately describing the role of local therapy as adjunctive, with no major omissions or errors."
  },
  "746": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, risks, and guideline recommendations, with no major omissions or errors."
  },
  "747": {
    "score": 5.0,
    "explanation": "5: The model answer fully matches the reference answer in clinical content, clearly explaining that the follow-up strategy assumes no radiotherapy was included in the primary treatment, with no major omissions or errors."
  },
  "748": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale but directly contradicts current guideline recommendations, which support interrupting existing therapy and prioritizing osimertinib for EGFR S768I mutations even in squamous NSCLC. This represents a notable error in clinical content despite the thorough discussion."
  },
  "749": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the role of imaging in follow-up, and correctly states that FDG-PET/CT or brain MRI should not be routinely added even in COPD patients, unless there is suspicion of recurrence. No major omissions or errors."
  },
  "750": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, adds relevant clinical context, and accurately discusses guideline recommendations and alternative testing strategies without any major omissions or errors."
  },
  "751": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the contraindication due to poor lung function and chronic respiratory failure, and appropriately discussing alternative management."
  },
  "752": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that severe pulmonary dysfunction precludes surgery as the first-line curative option and that radiotherapy should be prioritized, with no major omissions or errors."
  },
  "753": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of surgery due to severe pulmonary dysfunction, and appropriately recommending non-surgical treatments as first-line therapy, with no major omissions or errors."
  },
  "754": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and appropriate follow-up, with no major omissions or errors."
  },
  "755": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides detailed justification, and correctly concludes that adjuvant chemotherapy can be omitted in favor of endocrine therapy alone, with no major omissions or errors."
  },
  "756": {
    "score": 5.0,
    "explanation": "5: The model answer fully matches the reference answer in clinical content, clearly stating that surgery is not appropriate in patients with poor lung function and recommending non-surgical treatments, with no major omissions or errors."
  },
  "757": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the general non-recommendation of routine molecular testing in squamous cell carcinoma except in special clinical scenarios. However, it introduces some ambiguity regarding staging and the significance of brain metastases, which could cause minor confusion compared to the more concise reference answer."
  },
  "758": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and evidence, with no major omissions or errors."
  },
  "759": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline references, and supporting evidence without any major omissions or errors."
  },
  "760": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines, with no major omissions or errors."
  },
  "761": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional guideline-based context, and addresses safety considerations, with no major omissions or errors."
  },
  "762": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional guideline references for support."
  },
  "763": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, with no major omissions or errors, and even provides additional relevant details without introducing inaccuracies."
  },
  "764": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and provides detailed rationale and guideline support without any major omissions or errors."
  },
  "765": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to avoid contrast-enhanced CT in chronic renal insufficiency and recommending non-contrast CT for follow-up, with no major omissions or errors."
  },
  "766": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, providing detailed reasoning and referencing guidelines, but it does not explicitly mention PD-L1 or the need for broad molecular testing beyond EGFR/ALK, which is a minor omission compared to the reference answer."
  },
  "767": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the rationale, guideline recommendations, and appropriate follow-up, with no major omissions or errors."
  },
  "768": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the need for pathological confirmation before classifying as stage IV and initiating systemic therapy, with no major omissions or errors."
  },
  "769": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the increased surgical risk, the preference for SBRT, and the rare consideration of surgery, with no major omissions or errors."
  },
  "770": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline references without omissions or errors."
  },
  "771": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even provides additional guideline-based justification."
  },
  "772": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, supporting evidence, and guideline recommendations without omissions or errors."
  },
  "773": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing all key points, including the sufficiency of ultrasound-guided biopsy and marking, the non-essential nature of enhanced imaging in this context, and guideline support. No major omissions or errors are present."
  },
  "774": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately states that a history of severe bleeding is not an absolute contraindication to immunotherapy, and emphasizes the need for individualized risk assessment."
  },
  "775": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional supporting evidence and guideline recommendations."
  },
  "776": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides comprehensive reasoning, guideline references, and a clear conclusion consistent with the reference."
  },
  "777": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the role of brain MRI, alternative imaging options, risk of missed brain metastases, and the need for careful follow-up and patient communication, with no major omissions or errors."
  },
  "778": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, includes additional relevant details, and contains no major omissions or errors."
  },
  "779": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points with additional relevant details and clear justification, without any omissions or errors."
  },
  "780": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides additional relevant details and context, but fully covers the key clinical decision points."
  },
  "781": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately addresses the key clinical reasoning, emphasizing the importance of removing the marked node and referencing relevant guidelines. However, it could be more explicit in stating that axillary dissection cannot be omitted unless the marked node is removed, as the reference answer does."
  },
  "782": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need for further functional assessment before surgery, detailing specific evaluation methods, and providing guideline references, with no major omissions or errors."
  },
  "783": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional relevant details and guideline citations, without any major omissions or errors."
  },
  "784": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers most key points, including standard treatment, the role of neoadjuvant therapy, and the impact of liver dysfunction on chemotherapy choice. However, it suggests that neoadjuvant therapy can still be considered with non-anthracycline regimens, whereas the reference answer emphasizes that, due to lack of standard alternatives and uncertain efficacy/safety, neoadjuvant therapy is not routinely recommended and surgery should be prioritized. This is a minor but important difference."
  },
  "785": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and provides additional supporting rationale consistent with guidelines."
  },
  "786": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even referencing relevant guidelines, with no major omissions or errors."
  },
  "787": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It restates the key recommendation, provides supporting rationale, and aligns fully with current guidelines."
  },
  "788": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including guideline recommendations, rationale, and practical considerations, with no major omissions or errors."
  },
  "789": {
    "score": 1.0,
    "explanation": "1: The model answer contradicts the reference answer by stating that direct surgery is an option, whereas the reference answer clearly states that neoadjuvant therapy is required before surgery. This is a major error in clinical content."
  },
  "790": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the clinical content of the reference answer, provides detailed guideline support, and has no major omissions or errors. It is comprehensive and accurate."
  },
  "791": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediate switching to an ALK inhibitor, which contradicts the reference answer that advises completing the current systemic therapy before switching. While the model answer provides rationale and guideline references, it contains a notable error in clinical recommendation."
  },
  "792": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the prioritization of RET inhibitors, the limited role of Cabozantinib, and the indication boundaries based on RET rearrangement status, with no major omissions or errors."
  },
  "793": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including guideline recommendations, rationale for low-dose non-contrast CT, and the reasoning against routine use of contrast-enhanced CT, with no major omissions or errors."
  },
  "794": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and addressing possible exceptions without any major omissions or errors."
  },
  "795": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline references, with no major omissions or errors."
  },
  "796": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "797": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of FDG-PET/CT staging before systemic therapy and covering all key points without omissions or errors."
  },
  "798": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of complete staging and functional assessment before initiating systemic therapy, with no major omissions or errors."
  },
  "799": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "800": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and covering all key points without omissions or errors."
  },
  "801": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including guideline recommendations, the importance of brain MRI, risks of missing asymptomatic brain metastases, and the need for preoperative brain imaging. There are no major omissions or errors."
  },
  "802": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the rationale, guideline support, and practical considerations, with no major omissions or errors."
  },
  "803": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, correctly recommending bone-targeted agents regardless of symptoms. However, it introduces nuance about \"not absolutely required,\" which is a minor deviation from the unequivocal guideline-based recommendation in the reference answer."
  },
  "804": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately explains the rationale, and references relevant guidelines, with no major omissions or errors."
  },
  "805": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for not routinely repeating molecular testing and appropriately noting exceptions, with no major omissions or errors."
  },
  "806": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately explains the rationale, outlines standard management, and cites guideline recommendations, with no major omissions or errors compared to the reference answer."
  },
  "807": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, alternative treatment options, and guideline support, with no major omissions or errors."
  },
  "808": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the necessity of completing FDG-PET/CT and brain MRI before local treatment, the rationale, and the guideline-based recommendation, with no major omissions or errors."
  },
  "809": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, evidence, and recommendations found in the reference answer, with no major omissions or errors. It even adds appropriate clinical considerations and caveats, maintaining accuracy and completeness."
  },
  "810": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the rationale, mechanism, and guideline recommendations, with no major omissions or errors."
  },
  "811": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the need to increase imaging frequency and providing detailed rationale and guideline support, with no major omissions or errors."
  },
  "812": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the indication, molecular prerequisite, and supporting evidence, with no major omissions or errors."
  },
  "813": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the increased surgical risk, preference for SBRT, and guideline recommendations, with no major omissions or errors."
  },
  "814": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, accurately explaining that HR status is not decisive for neoadjuvant therapy decisions in HER2-positive cT1cN0 breast cancer, and adds relevant details without introducing errors or omissions."
  },
  "815": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "816": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing orthopedic intervention and/or radiotherapy before systemic targeted therapy, with no major omissions or errors."
  },
  "817": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides appropriate rationale and guideline references."
  },
  "818": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the indication for MET抑制剂优先, referencing guidelines, listing appropriate agents, and considering bone metastasis management without omissions or errors."
  },
  "819": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including guideline recommendations, drug metabolism, safety in renal impairment, and a clear conclusion. No major omissions or errors are present."
  },
  "820": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors, and even provides additional rationale and guideline support."
  },
  "821": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale for not using chemotherapy as first-line treatment and specifying the indications for endocrine therapy, with no major omissions or errors."
  },
  "822": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the indication for chemotherapy in visceral crisis, providing rationale, and referencing guidelines, with no major omissions or errors."
  },
  "823": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining that systemic therapy is the mainstay and local radiotherapy is reserved for palliation, with no major omissions or errors."
  },
  "824": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed information on dose adjustment and monitoring, but it omits the reference answer’s emphasis on the limited safety data and the need to consider alternative regimens with more established renal safety profiles."
  },
  "825": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing bone fixation and palliative radiotherapy, and clearly stating that systemic therapy alone is insufficient for local control and fracture prevention. No major omissions or errors are present."
  },
  "826": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points without omissions or errors, and provides additional guideline-based justification."
  },
  "827": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining that osimertinib is only indicated with confirmed EGFR mutations and that durvalumab is preferred when EGFR status is unknown, with no major omissions or errors."
  },
  "828": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of both local and systemic treatments, but it prioritizes local therapy as the initial strategy, which is contrary to the reference answer that recommends systemic therapy as the primary initial approach. This represents a significant deviation from current guidelines and the reference answer, though the answer is otherwise detailed."
  },
  "829": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guideline recommendations, and exceptions, with no major omissions or errors."
  },
  "830": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and includes all key clinical points without omissions or errors. It even provides additional relevant details and clarifications, fully supporting the recommendation."
  },
  "831": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a nuanced discussion, but it overstates guideline recommendations by implying BRAF靶向治疗 is equally recommended for鳞状细胞癌 as for腺癌, whereas the reference answer emphasizes its standard use is limited to腺癌. Minor overgeneralization is present."
  },
  "832": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including rationale for prioritizing whole-brain radiotherapy, limitations of EGFR exon 20-targeted therapy, and a clear, guideline-based conclusion, with no major omissions or errors."
  },
  "833": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing staging, standard treatment, the impact of reduced lung function, and the rationale against prioritizing surgery, with no major omissions or errors."
  },
  "834": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the necessity of pathological mediastinal lymph node assessment and the insufficiency of PET/CT alone, with no major omissions or errors."
  },
  "835": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and appropriate mention of exceptions, with no major omissions or errors."
  },
  "836": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, management options, and rationale, matching the reference answer in content and detail, with no significant omissions or errors."
  },
  "837": {
    "score": 5.0,
    "explanation": "5: The model answer accurately reflects current clinical guidelines, correctly noting that KRAS G12C inhibitors are not standard first-line therapy for squamous NSCLC and that chemotherapy (± immunotherapy) remains the preferred option, with clear justification and no major omissions."
  },
  "838": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even adds relevant guideline references and practical considerations."
  },
  "839": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately states that platinum-based chemotherapy is preferred over immunotherapy monotherapy in this scenario and provides appropriate rationale and supporting evidence."
  },
  "840": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and appropriate management, with no major omissions or errors."
  },
  "841": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes systemic therapy over local treatment for limited brain metastases, which contradicts standard guidelines and the reference answer. While it provides rationale and cites guidelines, it contains a notable error in initial management recommendation, leading to limited but not entirely incorrect coverage."
  },
  "842": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, relevant pharmacological details, and appropriate recommendations without omissions or errors."
  },
  "843": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细阐述了低剂量非增强胸部CT的适应性、安全性及指南依据，无明显遗漏或错误。"
  },
  "844": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content, accurately identifies the molecular subtype, and correctly explains the rationale for the treatment regimen without omissions or errors."
  },
  "845": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, providing detailed rationale, guideline support, and evidence, with no major omissions or errors."
  },
  "846": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based approach, but it introduces additional details (e.g., molecular features, MDT discussion) not explicitly required by the reference answer, and slightly complicates the core message. However, it does not omit any major clinical content."
  },
  "847": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the rationale, guidelines, and appropriate use of FDG-PET/CT and brain MRI in this scenario, with no major omissions or errors."
  },
  "848": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points, including guideline recommendations, lack of evidence in PS 3–4 patients, and the rationale for best supportive care, with no major omissions or errors."
  },
  "849": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and provides additional guideline and evidence-based justification."
  },
  "850": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the need to complete 1 year of HER2-targeted therapy and specifying the use of trastuzumab if T-DM1 is discontinued, with no major omissions or errors."
  },
  "851": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细阐述了随访频率、CT类型及其理由，无重大遗漏或错误。"
  },
  "852": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that FDG-PET/CT and brain MRI are not first-line for routine follow-up, and providing appropriate details on when these modalities are indicated, with no major omissions or errors."
  },
  "853": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, standard guidelines, and the necessity of EGFR testing before considering osimertinib, with no major omissions or errors."
  },
  "854": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to increase imaging frequency, providing rationale, and referencing guidelines, with no major omissions or errors."
  },
  "855": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including guideline recommendations, rationale for high-frequency follow-up, and appropriate timing for transitioning to annual low-dose CT. No major omissions or errors are present."
  },
  "856": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need to assess cardiac tolerance, the risks of standard chemotherapy, guideline recommendations, and the preference for endocrine therapy alone in significant heart failure, with no major omissions or errors."
  },
  "857": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "858": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, including rationale, guideline support, and specific radiotherapy modalities, with no major omissions or errors."
  },
  "859": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to maintain standard follow-up frequency with non-contrast CT and emphasizing that renal dysfunction only alters the imaging modality, not the surveillance schedule. No major omissions or errors are present."
  },
  "860": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the risks of contrast in renal insufficiency, the recommendation for non-contrast CT, and the exceptions for enhanced CT use. No major omissions or errors."
  },
  "861": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and even elaborates on guideline support and rationale."
  },
  "862": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and well-referenced, but it slightly overstates the priority of radiotherapy by implying it is within the \"优选边界\" (preferred boundary), whereas the reference answer clarifies that surgery remains preferred and radiotherapy is a 2B recommendation. Minor nuance is lost regarding the lower priority of radiotherapy compared to reoperation."
  },
  "863": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a well-reasoned, guideline-based rationale for preferring platinum-based chemotherapy over BRAF inhibitors in this context, which differs from the reference answer. However, it omits the reference answer’s emphasis on the proven efficacy of BRAF-targeted therapy in BRAF V600E mutant NSCLC and the principle of precision medicine, focusing instead on the lack of evidence and guideline support for squamous histology."
  },
  "864": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the prioritization of EGFR exon 20 targeted therapy over immunotherapy, the rationale, guideline support, drug examples, and safety considerations, with no major omissions or errors."
  },
  "865": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it slightly overstates the necessity of brain MRI for all IB期 patients, whereas the reference answer notes it as optional for stage I. Otherwise, clinical content is accurate and comprehensive."
  },
  "866": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key points from the reference answer, with no major omissions or errors, and even adds relevant guideline references and rationale."
  },
  "867": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the specific recommendation of osimertinib, rationale, supporting evidence, and explicit exclusion of durvalumab, with no major omissions or errors."
  },
  "868": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the risks of full-course radiotherapy in severe COPD, the need for individualized treatment, multidisciplinary evaluation, and guideline references, with no major omissions or errors."
  },
  "869": {
    "score": 5.0,
    "explanation": "5: The model answer fully matches the reference answer in clinical content, clearly explaining why simple follow-up is insufficient and detailing appropriate guideline-based management for R1/R2 resection in stage IIA NSCLC. No major omissions or errors."
  },
  "870": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a detailed, guideline-based approach, but it introduces additional stratification (如ⅢA、ⅢB、ⅢC) and discusses同步放化疗及巩固免疫治疗等内容，虽有一定扩展，但未完全聚焦于“局部干预优先于系统治疗”这一核心，且未明确强调系统治疗优先级低于局部干预，存在轻微偏离。"
  },
  "871": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the contraindication of concurrent chemoradiotherapy in severe hepatic dysfunction, and appropriately recommends individualized or radiotherapy-based approaches, with no major omissions or errors."
  },
  "872": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even expanding with guideline support and specific radiotherapy modalities, without any major omissions or errors."
  },
  "873": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the need for multidisciplinary evaluation, R0 resection, and consideration of vascular involvement and surgical expertise, with no major omissions or errors."
  },
  "874": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based reasoning, including nuances about ECOG PS 3 and possible individualized treatment. However, it introduces the possibility of off-label, individualized use in select PS 3 patients, which is not mentioned in the reference answer, making it slightly more permissive than the strict \"not appropriate\" stance of the reference."
  },
  "875": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and appropriate prioritization of immunotherapy as first-line, with KRAS inhibitors reserved for later lines. No major omissions or errors are present."
  },
  "876": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and appropriate recommendations without omissions or errors."
  },
  "877": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and appropriate sequencing of therapy, with no major omissions or errors."
  },
  "878": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, rationale, and guideline recommendations without omissions or errors."
  },
  "879": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately recommending the correct follow-up frequency and providing appropriate justification without any major omissions or errors."
  },
  "880": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends routine follow-up for a patient with a history of colorectal cancer and a new lung nodule, which is a notable error. The reference answer emphasizes the need for heightened suspicion and further evaluation rather than routine surveillance alone in this high-risk context."
  },
  "881": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach to acute SVCS management and explains the rationale for initial radiotherapy and possible stenting, but it omits that concurrent chemoradiotherapy is the preferred definitive treatment for stage IIIB NSCLC and overemphasizes acute symptom relief as the primary decision factor, which is a significant deviation from the reference answer."
  },
  "882": {
    "score": 5.0,
    "explanation": "5: The model answer provides identical clinical content to the reference answer, clearly stating that olaparib is only indicated for patients with confirmed germline BRCA mutations and should not be used without this information, with no major omissions or errors."
  },
  "883": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately citing the Z0011 criteria and clearly explaining why axillary dissection cannot be omitted in this case. No major omissions or errors."
  },
  "884": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of prioritizing pulmonary function assessment before proceeding with further staging or intraoperative evaluation in NSCLC patients with COPD, with no major omissions or errors."
  },
  "885": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the prioritization of palliative radiotherapy for urgent symptom relief, the central role of systemic targeted therapy, and the need for individualized, coordinated treatment. No major omissions or errors are present."
  },
  "886": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining that routine head MRI is not recommended in asymptomatic, R0-resected stage IIB NSCLC patients without prior radiotherapy, and provides supporting guideline references without any major omissions or errors."
  },
  "887": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, covers all key clinical points from the reference answer, and provides additional relevant details without any major omissions or errors."
  },
  "888": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of efficacy of traditional EGFR-TKIs, the recommendation for chemotherapy or specific targeted agents, and referencing relevant guidelines. No major omissions or errors are present."
  },
  "889": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of PET/CT and PFTs before surgery and clearly stating that proceeding without them does not meet standard decision-making protocols. No major omissions or errors are present."
  },
  "890": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, guideline recommendations, and rationale for not choosing surveillance alone, matching the reference answer in content and accuracy."
  },
  "891": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need for further evaluation, differential diagnosis, appropriate imaging, and only considering systemic therapy if widespread metastasis is confirmed. No major omissions or errors are present."
  },
  "892": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, guideline recommendations, and distinctions between local and whole-brain radiotherapy, with no major omissions or errors."
  },
  "893": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "894": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that routine FDG-PET/CT or brain MRI is not recommended without suspicious findings, and provides appropriate justification without omissions or errors."
  },
  "895": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the indication for radical external-beam RT or SABR in this patient group, and even adds relevant guideline support and practical considerations without introducing errors or omissions."
  },
  "896": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, referencing key studies and guidelines, and covers all relevant aspects without omissions or errors. It even adds clarifying notes about surgical type, fully aligning with the reference answer."
  },
  "897": {
    "score": 4.0,
    "explanation": "4: The model answer correctly prioritizes chemoradiation over chemotherapy alone and provides appropriate rationale, but it does not specifically emphasize \"concurrent\" chemoradiation as the first choice, instead mentioning both concurrent and sequential approaches, which is a minor omission compared to the reference answer."
  },
  "898": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the timing and rationale for local and systemic therapy, the importance of molecular/PD-L1 results, and appropriate exceptions, with no major omissions or errors."
  },
  "899": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing surgical contraindications due to poor lung function, referencing guidelines, and appropriately recommending systemic therapy over surgery, with no major omissions or errors."
  },
  "900": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully addressing the differences in follow-up protocols between early and late-stage NSCLC, and correctly emphasizes the need for individualized, more intensive surveillance in advanced cases, with no major omissions or errors."
  },
  "901": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, clinically accurate, and covers all key points in the reference answer, with additional relevant details and no major omissions or errors."
  },
  "902": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the need for further imaging, the significance of brain metastasis (stage IV), and the shift from surgery to systemic therapy. However, it introduces the concept of \"oligometastatic\" treatment, which, while accurate, is a nuanced addition not present in the reference answer and could be seen as a minor deviation."
  },
  "903": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and evidence for prioritizing RET-targeted TKI over immunotherapy monotherapy, with no major omissions or errors."
  },
  "904": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately describes the follow-up schedule, and correctly addresses the classification of these patients, with no major omissions or errors."
  },
  "905": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points, accurately references current guidelines, and provides appropriate justification without omissions or errors."
  },
  "906": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key recommendations and supporting rationale, with no major omissions or errors."
  },
  "907": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，并补充了理由和指南依据，内容更为详实。"
  },
  "908": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，并补充了循证依据和指南推荐，内容更为详实。"
  },
  "909": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and provides appropriate justification and references."
  },
  "910": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the rationale for prioritizing SVC stent placement over radiotherapy, and elaborating on the urgency, mechanism, and guideline recommendations without any major omissions or errors."
  },
  "911": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional guideline support and rationale."
  },
  "912": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding, emphasizing the need to distinguish between双原发 and寡转移，并指出管理方式的不同。唯一的轻微不足是未明确强调在N0、M1a且两处均具治愈潜力时，推荐按两个原发分别管理，而非以寡转移处理，表述略显复杂。"
  },
  "913": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive guideline-based rationale, appropriate recommendations, and no major omissions or errors."
  },
  "914": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly prioritizes repeat surgical resection over concurrent chemoradiotherapy, which contradicts the reference answer and current guidelines. While it covers relevant options, the primary recommendation is notably incorrect."
  },
  "915": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer by stating that routine pathological mediastinal lymph node evaluation is not needed, whereas the reference answer recommends it. This is a major clinical error."
  },
  "916": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points, including guideline recommendations, rationale, and rare exceptions, with no major omissions or errors."
  },
  "917": {
    "score": 4.0,
    "explanation": "4: The model答案内容全面，涵盖了指南依据、亚实性结节的特殊性、结核史的影响，并给出实际临床建议，但相比参考答案，增加了对“可考虑随访”的讨论，略有超出指南推荐，存在轻微偏差。"
  },
  "918": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why close surveillance alone is not appropriate, referencing guidelines, and addressing both local and systemic treatment considerations without any major omissions or errors."
  },
  "919": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the rationale for prioritizing local palliative radiotherapy, and includes all key considerations without omissions or errors."
  },
  "920": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity and rationale for both FDG-PET/CT and contrast-enhanced brain MRI in staging, with no major omissions or errors."
  },
  "921": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, providing detailed discussion on both brain metastases and ECOG 2 status, but it adds extra caution regarding ECOG 2 (noting limited trial data) and emphasizes individualized decision-making, which, while appropriate, is a minor elaboration beyond the reference answer. No major omissions or errors are present."
  },
  "922": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of Dabrafenib plus Trametinib in severe hepatic impairment, and includes all key points without omissions or errors."
  },
  "923": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification and referencing guidelines, with no major omissions or errors."
  },
  "924": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that imaging follow-up frequency should be the same regardless of whether adjuvant radiotherapy or chemotherapy is used, which contradicts the reference answer that specifies more frequent imaging for patients primarily treated with radiotherapy. This is a notable error, despite otherwise comprehensive content."
  },
  "925": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of FDG-PET/CT for accurate staging and treatment planning, with no major omissions or errors."
  },
  "926": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion and correctly excludes concurrent chemoradiotherapy, but it inaccurately prioritizes definitive (curative) radiotherapy over palliative radiotherapy, which is not supported by the reference answer given the patient's severe COPD and likely poor tolerance of high-dose radiotherapy. This represents a significant clinical inaccuracy."
  },
  "927": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines for prioritizing best supportive care over immunotherapy in PS 3 patients, with no major omissions or errors."
  },
  "928": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "929": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "930": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, indications, and supporting guidelines, with no major omissions or errors compared to the reference answer."
  },
  "931": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of preoperative brain MRI, referencing guidelines, and addressing the limitations of PET/CT, with no major omissions or errors."
  },
  "932": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly prioritizing reoperation for R0 resection and providing appropriate rationale and guideline references, with no major omissions or errors."
  },
  "933": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification, guideline references, and supporting evidence, with no major omissions or errors."
  },
  "934": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly prioritizing surgical resection and appropriately mentioning radiotherapy as an alternative if surgery is not feasible, with no major omissions or errors."
  },
  "935": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, but it introduces additional discussion about patient preference and high-risk factors, which, while relevant, are not emphasized in the reference answer. The core recommendation aligns, but the answer could be more concise and focused on the standard indications."
  },
  "936": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, accurately explains the rationale, and details the appropriate follow-up schedule, matching the reference answer without omissions or errors."
  },
  "937": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to avoid routine enhanced CT in patients with chronic renal insufficiency and recommending non-contrast CT, with no major omissions or errors."
  },
  "938": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of guideline-recommended imaging follow-up, correctly identifies both frequency and modality issues, and offers detailed justification consistent with the reference answer."
  },
  "939": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, including the need for comprehensive molecular profiling and the insufficiency of RET-only testing, with no major omissions or errors."
  },
  "940": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, emphasizing that systemic chemotherapy is not routinely required and observation is reasonable. However, it slightly overstates the recommendation against systemic therapy and does not explicitly mention that both options (chemotherapy or observation) are reasonable choices depending on individual assessment, as the reference answer does."
  },
  "941": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, correctly emphasizing the need to increase imaging follow-up frequency in the presence of new or residual abnormalities, and provides additional guideline-based context without introducing errors or omissions."
  },
  "942": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, risks, and guideline recommendations, with no major omissions or errors."
  },
  "943": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and adds relevant guideline and evidence-based details without introducing errors or omissions."
  },
  "944": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including contraindication of bisphosphonates in severe renal impairment, rationale, alternative use of denosumab, and the need to monitor for hypocalcemia."
  },
  "945": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including the need for systemic therapy as first-line treatment, the role of MDT evaluation, and the conditional consideration of local therapy, with no major omissions or errors."
  },
  "946": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, supporting evidence, and guideline references, with no major omissions or errors."
  },
  "947": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale for using FDG-PET/CT and brain MRI in the context of new suspicious findings, but it incorrectly recommends routine use in the absence of clear evidence of recurrence or symptoms, which contradicts the reference answer. This represents a significant inaccuracy, though the answer is otherwise detailed."
  },
  "948": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the indication for endocrine therapy, the definition of visceral crisis, relevant guidelines, and the safety considerations, with no major omissions or errors."
  },
  "949": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the risks of contrast agents in renal insufficiency and providing appropriate alternative imaging strategies without major omissions or errors."
  },
  "950": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the indications, rationale, and guidelines for follow-up, with no major omissions or errors."
  },
  "951": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors. It accurately reflects current guidelines and provides appropriate rationale."
  },
  "952": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and standard treatment sequence without omissions or errors."
  },
  "953": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors. It accurately reflects current guidelines and provides clear justification."
  },
  "954": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurate, correctly stating that follow-up should follow protocols for limited-stage patients rather than advanced metastatic cases. However, it slightly diverges by referencing \"局限期\" (limited-stage) rather than specifically \"III期或根治性放疗后\" as in the reference, and includes some extra rationale, but overall clinical content is appropriate with only minor omissions."
  },
  "955": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indication for palliative local therapy, the need for individualized risk-benefit assessment, and the importance of careful selection and perioperative management, with additional detail but no major omissions or errors."
  },
  "956": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides comprehensive reasoning and guideline support for switching to crizotinib upon detection of ALK rearrangement."
  },
  "957": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and well-structured, referencing guidelines and providing detailed reasoning. However, it recommends primary surgery over neoadjuvant therapy, which is contrary to the reference answer's emphasis on neoadjuvant systemic therapy as the preferred approach, representing a minor but important difference in clinical recommendation."
  },
  "958": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need to weigh surgical risks in severe COPD, highlighting SBRT as a preferred alternative, and referencing current guidelines. No major omissions or errors are present."
  },
  "959": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the risks of cCRT in patients with severe pulmonary dysfunction, guideline recommendations, and the need for individualized treatment. There are no major omissions or errors."
  },
  "960": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "961": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately addressing the inappropriateness of Sotorasib or Adagrasib in ECOG 3-4 patients and emphasizing best supportive care, with no major omissions or errors."
  },
  "962": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of克唑替尼 in severe hepatic impairment, the need for caution or alternative therapies, and provides appropriate references. No major omissions or errors are present."
  },
  "963": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the rationale, guideline references, and practical considerations. However, it is more verbose than necessary and introduces some nuance (e.g., about high-risk patients and equipment) that, while accurate, slightly complicates the clear, direct recommendation found in the reference answer. No major omissions or errors."
  },
  "964": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional detail and appropriate caveats, and no major omissions or errors."
  },
  "965": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including the role of PFTs, indications for adjuvant therapy, and the importance of current functional status. However, it adds extra detail and slightly overemphasizes the need for further evaluation in cases of severe dysfunction, which is not explicitly required per the reference answer. Minor omissions in directly stating that the lack of preoperative PFTs does not affect the initiation of adjuvant therapy."
  },
  "966": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including guideline recommendations, the limited evidence for osimertinib in G719X mutations, and the preference for first- or second-generation EGFR TKIs over osimertinib or chemotherapy. It also adds relevant clinical context without introducing errors or omissions."
  },
  "967": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately stating that concurrent chemoradiotherapy is not recommended for patients with severe pulmonary dysfunction and suggesting appropriate alternative treatments, with no major omissions or errors."
  },
  "968": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of annual low-dose non-contrast chest CT in follow-up, referencing guidelines, and providing rationale without any major omissions or errors."
  },
  "969": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indications for reoperation versus chemoradiotherapy, referencing guidelines, and emphasizing that not all R2 patients should directly receive chemoradiotherapy. No major omissions or errors are present."
  },
  "970": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在临床内容上完全一致，且补充了更多细节和注意事项，无重大遗漏或错误。"
  },
  "971": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including guideline recommendations, interpretation of positive and negative ctDNA results, and the need for tissue testing if ctDNA is negative. No major omissions or errors are present."
  },
  "972": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the risk of missing occult distant metastases, and clearly states that the follow-up strategy assumes no high-risk factors or symptoms, fully matching the reference answer with no major omissions or errors."
  },
  "973": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it adds extra context about exceptional circumstances and references guidelines, which, while informative, slightly diverges from the concise focus of the reference answer. No major omissions or errors are present."
  },
  "974": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough discussion, including alternative imaging strategies and guideline references, but it introduces nuanced management options (e.g., proceeding with treatment after risk assessment and communication) that go beyond the reference answer’s strict stance, making it slightly divergent from the reference."
  },
  "975": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately prioritizing surgery over SABR and providing additional relevant details without introducing errors or omissions."
  },
  "976": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, accurately distinguishing between the two scenarios and emphasizing the need for comprehensive evaluation before considering independent treatment for multiple primaries. No major omissions or errors are present."
  },
  "977": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "978": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, correctly prioritizing EGFR-TKI over NTRK inhibitors in the presence of classic EGFR mutations, but it adds extra context and nuances not strictly necessary, which could introduce minor ambiguity. No major omissions or errors are present."
  },
  "979": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional guideline-based justification without introducing inaccuracies."
  },
  "980": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It accurately addresses the contraindication to surgery and recommends appropriate alternative treatment."
  },
  "981": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, emphasizing the need for adjuvant therapy and not direct surveillance. However, it omits the step of considering salvage re-resection before adjuvant therapy, which is a minor but important detail."
  },
  "982": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of SRS and surgery, but it incorrectly prioritizes SRS as the first-line treatment, whereas the reference answer clearly states surgery is preferred if feasible. There are also some omissions regarding the role of surgery in symptomatic patients or for pathological diagnosis."
  },
  "983": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for CT follow-up over immediate biopsy in high-risk patients with severe COPD and 6–8 mm solid nodules, with no major omissions or errors."
  },
  "984": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "985": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and references authoritative guidelines, but it does not specifically emphasize the use of low-dose, non-contrast CT as in the reference answer, and suggests a possible 6–12 month interval rather than clearly recommending annual follow-up after 3 years."
  },
  "986": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and appropriate prioritization without omissions or errors."
  },
  "987": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the prioritization of orthopedic intervention and palliative radiotherapy before BRAF-targeted therapy, with no major omissions or errors."
  },
  "988": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including endocrine therapy as the sole systemic treatment, no chemotherapy, and radiotherapy decisions based on surgical method, with no major omissions or errors."
  },
  "989": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive detail without omissions or errors, and even expands on the rationale and multidisciplinary approach, fully aligning with the reference content."
  },
  "990": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "991": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the exceptions to systemic therapy in the presence of severe organ dysfunction and emphasizing supportive care, with no major omissions or errors."
  },
  "992": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification, guideline support, and addressing all relevant aspects without omissions or errors."
  },
  "993": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, evidence, and guideline recommendations for prioritizing concurrent chemoradiotherapy, with no major omissions or errors."
  },
  "994": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it adds extra emphasis on individualized assessment and risk-benefit analysis, which, while clinically relevant, slightly dilutes the clear recommendation that reoperation is the first choice if feasible. Minor omissions in the directness of the recommendation account for the deduction."
  },
  "995": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with no major omissions or errors. It provides clear justification and aligns fully with current guidelines."
  },
  "996": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing radiotherapy over chemotherapy due to significant renal impairment, with no major omissions or errors."
  },
  "997": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of PET/CT and brain MRI for accurate staging and treatment planning, with no major omissions or errors."
  },
  "998": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately stating that cT1cN0 HER2阳性乳腺癌患者（肿瘤1.1 cm）可以纳入术前系统治疗适应证，并不局限于更高分期或腋窝淋巴结阳性，同时补充了指南依据和临床实际，内容无重大遗漏或错误。"
  },
  "999": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the contraindication to surgery due to poor lung function, the preference for non-surgical treatment, and the rationale behind these recommendations, with no major omissions or errors."
  },
  "1000": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately states that routine follow-up does not include FDG-PET/CT or brain MRI, provides rationale, and cites relevant guidelines."
  },
  "1001": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately recommending every 6 months H&P and chest CT, and provides appropriate guideline-based justification without major omissions or errors."
  },
  "1002": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant details supporting the rationale."
  },
  "1003": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and even supporting evidence, with no major omissions or errors."
  },
  "1004": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a nuanced, guideline-based approach, but it introduces additional considerations (如术后瘢痕、纤维化等) and conditional recommendations not explicitly stated in the reference answer, which could be seen as minor omissions or deviations from the reference's clear directive to increase imaging frequency for any residual or new abnormality."
  },
  "1005": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, prioritizes post-op radiotherapy (or re-resection if feasible), and correctly excludes chemotherapy or observation as first-line options, matching the reference answer in content and rationale."
  },
  "1006": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based reasoning, but it omits the clear recommendation that neoadjuvant therapy should be prioritized due to high recurrence risk, as stated in the reference answer. Instead, it presents both options as equally reasonable, which is a minor but important omission."
  },
  "1007": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points regarding increased risk of complications with moderate to severe pulmonary dysfunction, the need for multidisciplinary evaluation, and individualized decision-making. However, it is slightly more detailed and conditional than the reference answer, which more clearly states that conventional chest radiotherapy is generally not suitable in this context."
  },
  "1008": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why severe pulmonary dysfunction precludes concurrent chemoradiotherapy, referencing guidelines, and suggesting alternative treatments without any major omissions or errors."
  },
  "1009": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，准确阐述了分期、肿瘤大小和分子分型的隐含临床判断。"
  },
  "1010": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including guideline recommendations, evidence limitations, and practical considerations. However, it introduces additional nuance and caution not present in the reference answer, such as the limited data in squamous cell carcinoma and the need for individualized decision-making, which, while accurate, slightly diverges from the more direct recommendation in the reference."
  },
  "1011": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale and covers the imaging modalities, but incorrectly prioritizes FDG-PET/CT over contrast-enhanced chest CT, which is the recommended first-line investigation for a new focal chest abnormality postoperatively without evidence of distant metastasis. This represents a significant deviation from standard practice, though the rest of the content is accurate."
  },
  "1012": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guideline support, and appropriate management without omissions or errors."
  },
  "1013": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional guideline references and rationale without introducing inaccuracies."
  },
  "1014": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete, providing detailed reasoning and appropriate clinical recommendations, but it slightly softens the conclusion by stating \"不完全满足\" rather than the reference's more definitive \"不满足,\" and includes some additional suggestions not explicitly in the reference answer."
  },
  "1015": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, sequence, and practical steps for prioritizing local intervention before systemic RET-targeted therapy, with no major omissions or errors."
  },
  "1016": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and references guidelines, but it inaccurately states that capmatinib and tepotinib are suitable for all NSCLC subtypes with METex14 skipping, including squamous cell carcinoma, whereas the reference answer correctly notes that evidence and recommendations do not support use in squamous cell carcinoma. This is a significant omission."
  },
  "1017": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "1018": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of management and surveillance but omits the key recommendation from the reference answer—that increased imaging frequency is advised even in asymptomatic patients with new or residual imaging abnormalities postoperatively. This is a significant omission, as the model answer suggests maintaining the original frequency unless progression or symptoms occur."
  },
  "1019": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the rarity of EGFR mutations in squamous cell carcinoma, guideline recommendations, and the priority of EGFR-TKI therapy, with no major omissions or errors."
  },
  "1020": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and a clear recommendation without omissions or errors."
  },
  "1021": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, guideline recommendations, and specific treatment details without any major omissions or errors."
  },
  "1022": {
    "score": 3.0,
    "explanation": "3: The model answer covers the importance of surgery and discusses considerations for adjuvant systemic therapy, but it incorrectly states that direct observation is not recommended, whereas the reference answer allows for close observation if there is no residual tumor or distant spread. This represents a significant deviation from the reference standard."
  },
  "1023": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly stating that PORT should not be routinely considered in these patients and providing appropriate justification without omissions or errors."
  },
  "1024": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline citations, and supporting evidence, with no major omissions or errors."
  },
  "1025": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1026": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even provides additional guideline references and rationale."
  },
  "1027": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, supporting evidence, and guideline recommendations without omissions or errors."
  },
  "1028": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that adjuvant endocrine therapy is not preferred, which contradicts the reference answer and current guidelines; while it correctly notes the need for caution and dose adjustment, it omits that endocrine therapy remains the first-line recommendation even with severe hepatic impairment, leading to a notable error in clinical content."
  },
  "1029": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without major omissions or errors, and even provides additional relevant details and rationale."
  },
  "1030": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindications to surgery, alternative local therapies, and the rationale for non-surgical management, with no major omissions or errors."
  },
  "1031": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including contraindication of zoledronic acid and pamidronate in severe renal impairment, rationale, alternative therapy with denosumab, and the need to monitor for hypocalcemia. No major omissions or errors."
  },
  "1032": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically accurate, aligns with major guidelines, and provides a clear rationale for not routinely performing brain MRI in asymptomatic stage II NSCLC patients, matching current evidence and recommendations."
  },
  "1033": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，明确指出SBRT（SABR）为首选，并补充了适应证、优点及与常规放疗的对比，无重大遗漏或错误。"
  },
  "1034": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even referencing guidelines, with no major omissions or errors."
  },
  "1035": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for preferring neoadjuvant systemic therapy over direct surgery, with no major omissions or errors."
  },
  "1036": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant details and justification."
  },
  "1037": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of both systemic and local therapies, but it incorrectly prioritizes systemic therapy as the initial step, whereas the reference answer and guidelines recommend prioritizing local treatment for all resectable/amenable oligometastatic lesions. There are also some unnecessary details and minor inaccuracies regarding the sequence of therapy."
  },
  "1038": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "1039": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the necessity of pre-treatment PFTs, their role in risk assessment and treatment planning, and referencing relevant guidelines, with no major omissions or errors."
  },
  "1040": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, correctly prioritizing osimertinib over chemotherapy and providing additional guideline-based justification without introducing errors or omissions."
  },
  "1041": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately describing the recommended follow-up frequency and imaging modalities, and provides appropriate rationale and references without any major omissions or errors."
  },
  "1042": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the standard recommendation, the impact of poor lung function, and the rationale for not routinely recommending adjuvant therapy, with no major omissions or errors."
  },
  "1043": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, clearly stating that routine FDG-PET/CT or brain MRI is not recommended in asymptomatic patients with new small nodules, and emphasizing chest CT as the main follow-up. However, it is slightly more detailed and could be more concise, with a minor omission in not explicitly stating that PET/CT and brain MRI are not part of routine surveillance."
  },
  "1044": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional supporting rationale and guideline references, and no major omissions or errors."
  },
  "1045": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based reasoning, but it diverges from the reference answer by emphasizing that not all un-dissected axillary regions must be irradiated if adequate axillary dissection has been performed. This introduces nuance not present in the reference, which unequivocally recommends comprehensive regional nodal irradiation, including all at-risk undissected axillary areas."
  },
  "1046": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and aligns with current guidelines, providing detailed justification for preferring direct surgery over neoadjuvant therapy in cT1cN0 TNBC patients, with no major omissions or errors."
  },
  "1047": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points without omissions or errors, and provides clear justification consistent with current guidelines."
  },
  "1048": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale for not repeating molecular testing, referencing guidelines, and appropriately noting rare exceptions, with no major omissions or errors."
  },
  "1049": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，明确指出严重肺功能障碍为手术禁忌，并建议优先考虑非手术治疗，无重大遗漏或错误。"
  },
  "1050": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion but overemphasizes the lack of data and guideline support for squamous NSCLC, suggesting Sotorasib/Adagrasib are not standard options, which is more restrictive than the reference answer. The reference answer affirms their use as standard choices post-progression in KRAS G12C-mutant squamous NSCLC with ECOG 0–2, so the model answer contains some omissions and inaccuracies regarding current standard practice."
  },
  "1051": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based discussion, but it introduces more nuance and conditionality than the reference answer, which could be seen as a minor omission of decisiveness. The core clinical content aligns well with the reference."
  },
  "1052": {
    "score": 5.0,
    "explanation": "5: The model answer fully matches the reference answer in clinical content, clearly stating that prior EGFR TKI therapy for sensitizing mutations is not required, and provides accurate rationale and supporting details without omissions or errors."
  },
  "1053": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1054": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the prioritization of SVC stenting in severe cases and the rationale for treatment sequencing, with no major omissions or errors."
  },
  "1055": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the indication for EGFR-TKI in squamous cell carcinoma with EGFR exon 19 deletion, and even adds relevant guideline references and clinical caveats without any major omissions or errors."
  },
  "1056": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, relevant guidelines, and addressing the key points without omissions or errors."
  },
  "1057": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing FDG-PET/CT, including sensitivity, specificity, whole-body staging, and guideline recommendations, with no major omissions or errors."
  },
  "1058": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage, appropriate guideline citations, and clear reasoning without omissions or errors."
  },
  "1059": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, indications, and guideline support for prioritizing orthopedic fixation plus palliative radiotherapy, with no major omissions or errors."
  },
  "1060": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale including efficacy data, guideline recommendations, and approval status, with no major omissions or errors."
  },
  "1061": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and emphasizing best supportive care, with no major omissions or errors."
  },
  "1062": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive guideline-based reasoning and no major omissions or errors. It even elaborates on the rationale and cites authoritative guidelines, fully supporting the conclusion."
  },
  "1063": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need for good cardiopulmonary function and treatment tolerance, and providing detailed rationale without omissions or errors."
  },
  "1064": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，涵盖了手术禁忌、根治性同步放化疗为首选及后续可考虑durvalumab巩固治疗，无重大遗漏或错误。"
  },
  "1065": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, supporting evidence, and appropriate recommendations without any major omissions or errors."
  },
  "1066": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the standard recommendation for PORT, the increased risk with severe pulmonary dysfunction, and the need for individualized, multidisciplinary assessment. No major omissions or errors are present."
  },
  "1067": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that there is no absolute indication for adjuvant systemic therapy in this scenario and providing appropriate guideline context and rationale without major omissions or errors."
  },
  "1068": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and appropriate recommendations without omissions or errors."
  },
  "1069": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage of the rationale, specific local control methods, and guideline support, with no major omissions or errors."
  },
  "1070": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it provides more detail than necessary and suggests PET/CT can be considered more broadly, whereas the reference answer emphasizes chest CT as the first choice and PET/CT or brain MRI only if recurrence is suspected. Minor overstatement and extra detail prevent a perfect score."
  },
  "1071": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It clearly states selpercatinib as the preferred first-line therapy, provides rationale, and references guidelines, fully covering the required content."
  },
  "1072": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guideline support, and sequencing of targeted therapies, with no major omissions or errors."
  },
  "1073": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key aspects, including the need for prompt initiation of both systemic therapy and bone-targeted interventions, but it introduces a slight prioritization of systemic therapy, whereas the reference emphasizes true simultaneity and no fixed order; this is a minor deviation."
  },
  "1074": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately explains the rationale, and even provides supporting guidelines, with no major omissions or errors."
  },
  "1075": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed rationale, referencing clinical trials and guidelines, but it introduces the possibility of individualized treatment in select ECOG PS 3 patients, which is a minor deviation from the reference answer's clear-cut recommendation against use."
  },
  "1076": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that prior radiotherapy does not affect follow-up frequency, which contradicts the reference answer. It also omits the specific frequency adjustments based on treatment modality, representing a notable error in clinical content."
  },
  "1077": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning and supporting guidelines, with no major omissions or errors."
  },
  "1078": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points without omissions or errors, and even provides additional guideline references for completeness."
  },
  "1079": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and includes relevant guidelines, but it incorrectly recommends routine FDG-PET/CT for all new radiological abnormalities, whereas the reference answer states that such advanced imaging should not be routinely performed unless there is high suspicion of recurrence or symptoms. This is a significant deviation from the reference answer."
  },
  "1080": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of胸部CT in标准随访 and the limited role of头部MRI, with no major omissions or errors."
  },
  "1081": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key considerations, including toxicity risks, prior radiation, and alternative strategies, but it does not state as clearly and definitively as the reference answer that standard concurrent chemoradiotherapy is generally contraindicated in this scenario. Minor ambiguity remains regarding the appropriateness of concurrent chemoradiotherapy."
  },
  "1082": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining why surgery is not preferred and recommending chemoradiotherapy, with no major omissions or errors."
  },
  "1083": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the rationale for continued 6-monthly CT follow-up and the lack of need to change imaging modality or frequency. However, it introduces additional discussion about high-risk factors and guidelines, which, while accurate, are not strictly necessary per the reference answer and could be seen as minor extraneous detail."
  },
  "1084": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of bevacizumab in high bleeding risk and recommending EGFR-TKI monotherapy, with no major omissions or errors."
  },
  "1085": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the issue of contrast allergy, and correctly recommends non-contrast CT for follow-up, with no major omissions or errors."
  },
  "1086": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides supporting guideline references and rationale."
  },
  "1087": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides detailed justification with guideline citations and clinical rationale, with no major omissions or errors."
  },
  "1088": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors. It clearly states that endocrine therapy cannot be omitted, details the rationale, and references relevant guidelines."
  },
  "1089": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer, recommending immediate initiation of ALK inhibitors and skipping the remainder of chemotherapy, whereas the reference answer states this is not appropriate. The model answer is detailed but fundamentally incorrect in clinical content."
  },
  "1090": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the necessity of molecular testing before systemic therapy, the rationale, and exceptions for urgent cases, with no major omissions or errors."
  },
  "1091": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that ALND cannot be omitted when there are 3 positive SLNs and providing appropriate guideline and evidence-based justification without any major omissions or errors."
  },
  "1092": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately reflects current guidelines, elaborates on treatment options, and clearly states the indications for chemotherapy."
  },
  "1093": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the inappropriateness of standard concurrent chemoradiotherapy in patients with severe pulmonary dysfunction, and appropriately emphasizing individualized treatment and guideline recommendations."
  },
  "1094": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points from the reference answer, including the use of non-contrast CT, unchanged follow-up intervals, and the limitations of non-contrast imaging. It adds extra details (ultrasound, MRI, PET-CT) that are reasonable but not strictly required, and does not omit any major clinical content."
  },
  "1095": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the rationale for choosing enhanced brain MRI over FDG-PET/CT and referencing relevant guidelines, with no major omissions or errors."
  },
  "1096": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the risks of contrast in severe renal insufficiency, recommending non-contrast CT, and mentioning alternative imaging when necessary. No major omissions or errors."
  },
  "1097": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content from the reference answer, including the indication for radiotherapy, guideline support, and appropriate context, with no major omissions or errors."
  },
  "1098": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly identifies the lesion as a single lung metastasis (M1a) rather than two primary lung cancers, which is a significant clinical error. While it provides some relevant staging and treatment information, it fundamentally misinterprets the scenario, leading to a notable error in clinical reasoning."
  },
  "1099": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and guideline-based reasoning, accurately identifying the staging, standard treatment sequence, and the rationale for preoperative systemic therapy, with no major omissions or errors."
  },
  "1100": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, guideline-based approach, including risk stratification by nodule size and features. However, it introduces additional nuance (e.g., size thresholds, short期复查) not explicitly mentioned in the reference answer, which could be seen as a minor deviation from the direct recommendation to perform PET/CT for any new nodule."
  },
  "1101": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately compares the risks of both contrast agents in CKD 3, and clearly concludes that enhanced MRI is preferred, fully aligning with the reference answer without omissions or errors."
  },
  "1102": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main recommendation of chemoradiotherapy, but it introduces surgical resection and other local therapies as possible options, which are not mentioned in the reference answer and may not be standard unless in highly selected cases. Minor overextension beyond the reference answer's scope."
  },
  "1103": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1104": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification with guideline recommendations, efficacy data, and safety profile, with no major omissions or errors."
  },
  "1105": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately explains the rationale, and includes relevant guidelines, with no major omissions or errors."
  },
  "1106": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, correctly emphasizing chemoradiotherapy as the mainstay and noting surgery is generally not recommended. However, it introduces the possibility of surgery in rare cases, which is not mentioned in the reference, and slightly overstates the term \"radical local therapy,\" which could be misleading. Minor differences prevent a perfect score."
  },
  "1107": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately addressing the follow-up timing and rationale, with no major omissions or errors."
  },
  "1108": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully aligning with the reference answer and including additional relevant details without any major omissions or errors."
  },
  "1109": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed guideline-based reasoning, but it suggests that switching to annual low-dose CT in the second year is acceptable, whereas the reference answer recommends maintaining 6-monthly CT for the first 2–3 years before switching. This is a minor but important omission."
  },
  "1110": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully aligning with the reference answer. It elaborates on the rationale, exceptions, and guideline recommendations without omitting any major points."
  },
  "1111": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the rationale for not delaying concurrent chemoradiotherapy, the role and timing of molecular testing, and guideline recommendations, with no major omissions or errors."
  },
  "1112": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with clear justification and no major omissions or errors."
  },
  "1113": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of axillary imaging and biopsy before neoadjuvant therapy, with no major omissions or errors."
  },
  "1114": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1115": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant detail supporting the recommendation."
  },
  "1116": {
    "score": 3.0,
    "explanation": "3: The model answer provides a partial and guideline-based perspective but omits the current consensus that recommends broad molecular testing for all advanced NSCLC, including squamous cell carcinoma, regardless of clinical features, as stated in the reference answer."
  },
  "1117": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional guideline-based context, and emphasizes individualized decision-making without introducing errors or omissions."
  },
  "1118": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1119": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining why MRI is preferred over CT in this scenario, with no major omissions or errors."
  },
  "1120": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines for systemic therapy in cT1c, cN0 TNBC, with no major omissions or errors."
  },
  "1121": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects current guidelines, and includes all key points from the reference answer with additional relevant details and supporting evidence. No major omissions or errors."
  },
  "1122": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant details and rationale."
  },
  "1123": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the metabolic pathway, safety concerns, lack of data, and guideline recommendations, with no major omissions or errors."
  },
  "1124": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the role of PORT, the impact of severe pulmonary dysfunction, and the need for individualized risk-benefit assessment, with no major omissions or errors."
  },
  "1125": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the prioritization of orthopedic fixation plus palliative radiotherapy over antiresorptive agents, and clearly stating the indications and limitations for each approach without omissions or errors."
  },
  "1126": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends routine imaging restaging and brain MRI in all cases of positive margins post-resection without clinical or imaging evidence of residual disease, which contradicts the reference answer stating these are not routinely indicated unless new abnormalities are found. This represents a notable error in clinical content."
  },
  "1127": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly stating that enhanced CT should not be routinely used in follow-up for these patients, and provides appropriate rationale and guideline references without any major omissions or errors."
  },
  "1128": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "1129": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive guideline-based justification and including all key details without omissions or errors."
  },
  "1130": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，并补充了最新指南和相关研究依据，未有遗漏或错误。"
  },
  "1131": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the increased surgical risk, the role of SBRT, and guideline recommendations, with no major omissions or errors."
  },
  "1132": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly explaining why cT1c excludes inflammatory breast cancer and M0 excludes distant metastasis, with no major omissions or errors."
  },
  "1133": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately addressing the staging, surgical considerations, and the need for multidisciplinary evaluation, with no major omissions or errors."
  },
  "1134": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the inappropriateness of perioperative therapy and emphasizing non-surgical management, with no major omissions or errors."
  },
  "1135": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage, appropriate rationale, and guideline references, with no major omissions or errors."
  },
  "1136": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，无重大遗漏或错误，详细说明了手术风险、替代治疗选择及多学科评估。"
  },
  "1137": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed rationale, but it introduces the possibility of individualizing treatment duration in low-risk patients, which is not standard per current guidelines and not mentioned in the reference answer. This constitutes a minor deviation from the reference."
  },
  "1138": {
    "score": 5.0,
    "explanation": "5: 临床内容与参考答案完全一致，详细说明了影像学不能直接确诊N3期，强调了需病理学证实，并补充了影像学假阳性/假阴性的原因，无重大遗漏或错误。"
  },
  "1139": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides comprehensive reasoning, guideline references, and clear recommendations consistent with the reference."
  },
  "1140": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the acceptability of observation, the persistent risk of minimal residual disease, and the rationale for not routinely recommending adjuvant therapy, with no major omissions or errors."
  },
  "1141": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately addressing the use of non-contrast CT for follow-up in patients with renal insufficiency and providing appropriate rationale without omissions or errors."
  },
  "1142": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points, including rationale, guidelines, and recommended management, with no significant omissions or errors."
  },
  "1143": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need for more frequent imaging follow-up in the presence of new or residual radiological abnormalities, even in asymptomatic patients, and provides appropriate rationale and guideline references."
  },
  "1144": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, with no major omissions or errors. It correctly explains the staging and distinction between locally advanced and metastatic disease."
  },
  "1145": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points without omissions or errors, and provides appropriate rationale and guideline references."
  },
  "1146": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, elaborates on the rationale, and provides appropriate management options without omissions or errors."
  },
  "1147": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer, stating selpercatinib should not be used before progression, whereas the reference answer affirms it can be used without waiting for progression. This is a major clinical error."
  },
  "1148": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines for preferring palliative care over systemic therapy in this scenario, with no major omissions or errors."
  },
  "1149": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for increasing imaging frequency, referencing guidelines, and providing appropriate recommendations without omissions or errors."
  },
  "1150": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately addresses the risks of radiotherapy in severe pulmonary dysfunction, and appropriately recommends against adjuvant radiotherapy, with no major omissions or errors."
  },
  "1151": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the inappropriateness of standard surgical resection in severe COPD with limited respiratory reserve and recommending alternative local therapies. No major omissions or errors are present."
  },
  "1152": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and recommending alternative treatments without omissions or errors."
  },
  "1153": {
    "score": 3.0,
    "explanation": "3: The model answer provides a well-argued rationale for prioritizing targeted therapy, referencing drug efficacy, toxicity, and guidelines, but it contradicts the reference answer's clear recommendation to prioritize whole-brain radiotherapy for rapid symptom control in the setting of extensive brain metastases. This represents a significant clinical divergence."
  },
  "1154": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It provides a thorough rationale and aligns fully with current guidelines and evidence."
  },
  "1155": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale but contradicts the reference answer by stating ceritinib is not a standard or equally prioritized ROS1 inhibitor, omitting that it is an approved option with equal priority in this context. It covers relevant considerations but contains significant inaccuracies regarding ceritinib’s status and priority."
  },
  "1156": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional guideline-based justification."
  },
  "1157": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including patient selection, treatment prioritization, and boundaries for local therapy. However, it places slightly more emphasis on systemic therapy as the initial step, whereas the reference answer prioritizes local control of limited brain metastasis first in suitable patients, which is a minor deviation."
  },
  "1158": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediate advanced imaging (FDG-PET/CT and brain MRI) for any new or residual lesion, which contradicts the reference answer's guidance to prioritize close imaging follow-up unless there are clear signs of recurrence. This represents a notable error in clinical approach, despite some accurate background information."
  },
  "1159": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and recommended management without omissions or errors."
  },
  "1160": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately explains the rationale, and matches the reference answer without omissions or errors."
  },
  "1161": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing postoperative chemoradiotherapy over chemotherapy alone, and includes guideline support and specific regimen details without any major omissions or errors."
  },
  "1162": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects guideline recommendations, and covers all key points from the reference answer without omissions or errors."
  },
  "1163": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the risks, lack of evidence, and alternative recommendations for patients with moderate to severe hepatic impairment, with no major omissions or errors."
  },
  "1164": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering all key points without omissions or errors, and provides appropriate justification for not routinely using FDG-PET/CT or brain MRI in this context."
  },
  "1165": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the indications for surgery without preoperative radiotherapy, referencing guidelines, and providing appropriate clinical reasoning without omissions or errors."
  },
  "1166": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale but directly contradicts the reference answer by stating that CT随访与观察不能作为系统治疗的等同可选方案, whereas the reference answer affirms it can be an acceptable alternative in selected patients. This is a notable error in clinical content."
  },
  "1167": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including the correct staging distinction, treatment implications, and rationale, with no major omissions or errors."
  },
  "1168": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including surgical indications, survival equivalence, quality of life, and the lack of contraindications for breast-conserving surgery in this scenario. No major omissions or errors are present."
  },
  "1169": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a nuanced, guideline-based discussion, but it introduces the concept of individualization and high-risk factors, which, while clinically relevant, slightly diverges from the reference answer’s more categorical recommendation to consider adjuvant chemotherapy for all pT1bN0 triple-negative cases. Minor omission of the reference answer’s clear boundary that 0.6 cm is already beyond the threshold for not recommending chemotherapy."
  },
  "1170": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and appropriate follow-up, with no major omissions or errors."
  },
  "1171": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the scenario, and provides detailed justification consistent with the reference answer, with no major omissions or errors."
  },
  "1172": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and emphasizing that FDG-PET/CT is not recommended as a routine follow-up in asymptomatic patients with only local imaging abnormalities. No major omissions or errors are present."
  },
  "1173": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It even adds relevant details about MDT评估和指南依据, fully supporting the correct management approach."
  },
  "1174": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical content from the reference answer, including the need for risk stratification, the role of multigene assays, and the possibility of omitting chemotherapy in low-risk cases. It provides additional detail without introducing errors or omissions."
  },
  "1175": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and references guidelines, but it inaccurately suggests that systemic therapy can be directly considered without prioritizing local treatment options for resectable disease, which contradicts the reference answer's emphasis on evaluating for surgery or local therapy first."
  },
  "1176": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with clear justification and no major omissions or errors."
  },
  "1177": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need for surgical and pathological evaluation, the differences in staging and treatment, and referencing relevant guidelines, with no major omissions or errors."
  },
  "1178": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully addressing the staging, surgical considerations, and multidisciplinary evaluation, with no major omissions or errors compared to the reference answer."
  },
  "1179": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately explains the rationale, and cites guideline recommendations, with no major omissions or errors."
  },
  "1180": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the need for further imaging and pathological evaluation before staging, and accurately distinguishing between multiple primaries and metastases. No major omissions or errors are present."
  },
  "1181": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with detailed explanations and no major omissions or errors."
  },
  "1182": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification, referencing guidelines and studies, and correctly concluding that adjuvant chemotherapy alone is a standard and reasonable approach when radiotherapy is contraindicated."
  },
  "1183": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, emphasizing that FDG-PET/CT is not routinely required and should be considered based on risk assessment. However, it introduces more detail about risk stratification and decision-making, which, while accurate, slightly expands beyond the concise focus of the reference answer."
  },
  "1184": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing systemic therapy over local radiotherapy in the context of severe pulmonary dysfunction, with no major omissions or errors."
  },
  "1185": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference, covering all key points including guideline recommendations, exceptions for testing, sample limitations, and the limited impact on treatment decisions, with no major omissions or errors."
  },
  "1186": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, appropriate exceptions, and guideline references, with no major omissions or errors."
  },
  "1187": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline references without omissions or errors."
  },
  "1188": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the necessity of preoperative FDG-PET/CT, its rationale, and exceptions, with no major omissions or errors."
  },
  "1189": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the contraindication to surgery due to poor pulmonary function and appropriately recommending non-surgical options such as radiotherapy or combined therapy, with no major omissions or errors."
  },
  "1190": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing SVC stenting for acute symptom relief and correctly sequencing definitive chemoradiotherapy after stabilization, with no major omissions or errors."
  },
  "1191": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the necessity of PET/CT for staging, guideline recommendations, and the risks of occult metastasis, with no significant omissions or errors."
  },
  "1192": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the necessity of driver gene mutation testing and the limitations of relying solely on PD-L1 expression, with no major omissions or errors."
  },
  "1193": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough rationale and guideline references but recommends a higher follow-up frequency (every 3–6 months) than the reference answer (every 6 months), which is not aligned with the standard for this specific patient group (post-surgery ± chemotherapy, not radiotherapy or more advanced stage). This constitutes a significant inaccuracy despite otherwise comprehensive coverage."
  },
  "1194": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and standard practice, with no major omissions or errors."
  },
  "1195": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It clearly states that targeted therapy is not recommended, explains the rationale, outlines appropriate alternatives, and cites relevant guidelines."
  },
  "1196": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including patient characteristics, preference for endocrine therapy, and the role of risk assessment (including gene profiling). However, it is slightly more verbose and does not explicitly state that gene expression profiling (如21基因RT-PCR)是化疗决策的主要依据，略有细节遗漏。"
  },
  "1197": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects guideline recommendations, and covers all key points from the reference answer without omissions or errors."
  },
  "1198": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of bronchoscopy, its diagnostic and therapeutic roles, and the rare exceptions, with no major omissions or errors."
  },
  "1199": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that routine CT follow-up is not recommended for single pure ground-glass nodules <6 mm, and only indicated for nodules ≥6 mm, with no major omissions or errors."
  },
  "1200": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing guideline recommendations, the rationale for avoiding contrast in renal insufficiency, and the sufficiency of non-contrast CT for routine surveillance, with no major omissions or errors."
  },
  "1201": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the decision-making process, diagnostic steps, and treatment implications without any major omissions or errors."
  },
  "1202": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and rationale without omissions or errors."
  },
  "1203": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing systemic therapy, the role of local ablation, and guideline recommendations, with no major omissions or errors."
  },
  "1204": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly prioritizing urgent pericardial drainage for cardiac tamponade and explaining the rationale, with no major omissions or errors."
  },
  "1205": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the preference for standard chest CT in the first years post-surgery and the limited role of low-dose CT. However, it slightly overemphasizes the use of standard CT beyond 2 years and does not clearly state that after 2–3 years without recurrence, annual low-dose CT is appropriate, as per the reference answer."
  },
  "1206": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the prioritization of local symptomatic treatment, the timing of systemic therapy, and the need to await molecular results before initiating targeted therapy, with no major omissions or errors."
  },
  "1207": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides clear justification based on guidelines."
  },
  "1208": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive staging rationale, treatment principles, and guideline support without omissions or errors."
  },
  "1209": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, aligns fully with the reference answer, and adds relevant guideline support and practical considerations without introducing errors or omissions."
  },
  "1210": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and practical recommendations without omissions or errors."
  },
  "1211": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the risks of contrast in renal insufficiency and correctly recommending non-contrast CT for routine follow-up, with no major omissions or errors."
  },
  "1212": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "1213": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the inappropriateness of systemic therapy for PS 3–4 patients, the rationale, exceptions, and guideline references, with no major omissions or errors."
  },
  "1214": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the indication, appropriateness, and guideline support for SABR in this patient population, with no major omissions or errors."
  },
  "1215": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional guideline references and context without introducing inaccuracies."
  },
  "1216": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the question, and includes relevant evidence and guidelines without any major omissions or errors."
  },
  "1217": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive, guideline-based reasoning and reaches the same clinical recommendation as the reference answer, with no major omissions or errors."
  },
  "1218": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical content from the reference answer, with no major omissions or errors. It also provides supporting evidence and guideline references, fully justifying the recommendation for ALND."
  },
  "1219": {
    "score": 2.0,
    "explanation": "2: The model answer provides a guideline-based preference for neoadjuvant therapy, which is accurate, but incorrectly states that adjuvant chemotherapy plus trastuzumab cannot be directly recommended, contradicting the reference answer and omitting that adjuvant therapy remains a standard option if neoadjuvant therapy was not given."
  },
  "1220": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive, guideline-based reasoning and covers all key points, including the rationale for reoperation as first choice and chemoradiotherapy as second line, with supporting evidence and references. No major omissions or errors."
  },
  "1221": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and appropriate management without omissions or errors."
  },
  "1222": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately prioritizes treatment strategies, addresses both acute symptom management and long-term tumor control, and aligns fully with the reference answer without omissions or errors."
  },
  "1223": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the necessity of known BRCA mutation status, referencing relevant studies, and outlining the correct clinical approach without omissions or errors."
  },
  "1224": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the need for comprehensive staging with FDG-PET/CT and brain MRI before confirming systemic metastasis or initiating systemic therapy, with no major omissions or errors."
  },
  "1225": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately reflects guideline recommendations, emphasizing the \"borderline\" nature of 0.6 cm tumors for 21-gene testing and the need for individualized decision-making. However, it is slightly more permissive than the reference answer, which more clearly states that 0.6 cm is not routinely recommended, leading to a minor omission in emphasis."
  },
  "1226": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need for more frequent imaging follow-up in the presence of residual radiological abnormalities, rationale, guideline references, and adjustment of frequency based on findings, with no major omissions or errors."
  },
  "1227": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately addresses the role of molecular subtype in neoadjuvant therapy decisions for cT1c, cN0, M0 breast cancer, but it introduces some nuance about high-risk hormone receptor-positive cases that is not present in the reference answer, making it slightly more detailed but not strictly identical."
  },
  "1228": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1229": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning and no major omissions or errors. It accurately explains why PD-L1 status is not relevant when an EGFR S768I mutation is present and osimertinib is indicated."
  },
  "1230": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, provides guideline-based justification, and has no major omissions or errors."
  },
  "1231": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering all key points with no major omissions or errors, and even provides additional guideline references for completeness."
  },
  "1232": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need for urgent local intervention before systemic immunotherapy, with no major omissions or errors."
  },
  "1233": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of pathological mediastinal lymph node assessment, the limitations of imaging, and referencing relevant guidelines, with no major omissions or errors."
  },
  "1234": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points regarding recurrence risk, guideline recommendations, and the applicability of annual CT follow-up after 2 years for I–II stage patients. However, it introduces some extra detail (e.g., high-risk subgroups) and is slightly less concise than the reference, but there are no major omissions or errors."
  },
  "1235": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides detailed justification for each step, and contains no major omissions or errors. It is comprehensive and accurate."
  },
  "1236": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately describes the differences in CT follow-up frequency, but it omits the specific recommendation for years 3–5 after radiotherapy (i.e., every 6 months in years 4–5), and slightly generalizes the later follow-up interval. Otherwise, the clinical content is correct and well explained."
  },
  "1237": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the necessity of pulmonary function testing and the role of abnormal results in surgical decision-making. However, it slightly overemphasizes the need for comprehensive assessment beyond pulmonary function, whereas the reference answer states more definitively that abnormal pulmonary function is a hard contraindication to surgery."
  },
  "1238": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors, and even provides additional guideline references and rationale."
  },
  "1239": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors. It even elaborates on the evidence and approvals, fully aligning with current practice."
  },
  "1240": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It even provides additional guideline references and rationale, fully supporting the correct management approach."
  },
  "1241": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately reflecting guideline recommendations, and provides additional context without introducing errors or omissions."
  },
  "1242": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a detailed explanation, including the possibility of multiple primary lung cancers and the need for pathological and molecular differentiation. However, the reference answer clearly states that in this scenario, the default is to treat as T4 (single tumor with multiple foci), whereas the model answer introduces the alternative of separate primaries, which, while accurate in some contexts, is a minor deviation from the reference's more definitive approach."
  },
  "1243": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion and references but ultimately recommends immunotherapy over HER2-targeted therapy, which contradicts the reference answer's clear recommendation to prioritize targeted therapy based on molecular subtype. This is a significant clinical divergence, despite the answer's detailed rationale."
  },
  "1244": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately explains the rationale, and adds relevant guideline references without introducing errors or omissions."
  },
  "1245": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and references but incorrectly prioritizes EGFR-TKI over MET抑制剂, which contradicts the reference answer and current recommendations for METex14突变在鳞癌中的优先性。 This represents a significant inaccuracy despite otherwise comprehensive coverage."
  },
  "1246": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, standard options, and the impact of liver dysfunction, with no major omissions or errors."
  },
  "1247": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key recommendations, rationale, and guideline support, with no major omissions or errors."
  },
  "1248": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and emphasizing the need for closer follow-up and further evaluation in the presence of new imaging abnormalities. No major omissions or errors are present."
  },
  "1249": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the impact of severe COPD on surgical risk, the need for alternative therapies, and the importance of multidisciplinary evaluation, with no major omissions or errors."
  },
  "1250": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and emphasizing the necessity of mediastinal lymph node pathological assessment before perioperative treatment. No major omissions or errors are present."
  },
  "1251": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately explaining the higher recurrence risk and need for more intensive follow-up, and even adds appropriate detail about follow-up intervals and assessments. No major omissions or errors are present."
  },
  "1252": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reiterates the clinical scenario, provides supporting evidence, references guidelines, and covers all key points without omissions or errors."
  },
  "1253": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and some accurate rationale, but it overstates guideline support for amivantamab-vmjw monotherapy as initial treatment, which is not recommended by current evidence or guidelines. It omits the need for multidisciplinary evaluation and alternative strategies, and incorrectly presents monotherapy as a standard, rather than an exceptional, option."
  },
  "1254": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately prioritizing osimertinib over chemotherapy, and provides appropriate rationale and guideline references, with no major omissions or errors."
  },
  "1255": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides appropriate reasoning for more frequent follow-up due to high-risk features, but it diverges from the reference answer's recommendation of every 6 months and instead recommends every 3–6 months, reflecting a minor difference in guideline interpretation."
  },
  "1256": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the risks of both bisphosphonates and denosumab in severe renal impairment, and appropriately prioritizes local treatments, fully matching the reference answer with additional relevant detail."
  },
  "1257": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and provides additional guideline-based rationale and supporting evidence without introducing errors or omissions."
  },
  "1258": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need for non-contrast CT at standard intervals and providing appropriate rationale without major omissions or errors."
  },
  "1259": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough discussion, but it omits the clear endorsement of osimertinib as a preferred first-line therapy based on molecular features, as stated in the reference answer. Instead, it prioritizes afatinib, which is a minor but important deviation."
  },
  "1260": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the prioritization of systemic therapy and the specific indications for palliative radiotherapy, with no major omissions or errors."
  },
  "1261": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细阐述了严重肝功能障碍下不推荐系统性化疗的原因，并补充了指南依据和具体药物代谢机制，无重大遗漏或错误。"
  },
  "1262": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends RET抑制剂 as first-line therapy for鳞状NSCLC with RET重排, contrary to current evidence and guidelines, which only support this approach in非鳞状亚型; this is a notable error, despite some correct background information."
  },
  "1263": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and well-referenced, accurately summarizing both国内外指南 and providing rationale. However, it slightly overstates指南对2年后即可降为每年一次低剂量CT的推荐，未强调部分指南建议2–3年后才可降频，略有提前降频的倾向，属于小幅度遗漏。"
  },
  "1264": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of both systemic and local therapies, referencing guidelines and the need for MDT assessment, but it incorrectly prioritizes systemic therapy as first-line, which contradicts the reference answer's emphasis on local therapy for oligometastatic (single liver metastasis) NSCLC. This represents a significant clinical inaccuracy."
  },
  "1265": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1266": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and appropriate prioritization of single radiotherapy over concurrent chemoradiotherapy in patients with severe pulmonary dysfunction. No major omissions or errors are present."
  },
  "1267": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, guideline references, and rationale without omissions or errors."
  },
  "1268": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and addressing both efficacy and safety, with no major omissions or errors."
  },
  "1269": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points without omissions or errors."
  },
  "1270": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately reflects current guidelines and evidence, and addresses relevant caveats and exceptions without any major omissions or errors."
  },
  "1271": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and well-referenced, but it slightly overemphasizes direct surgery as the \"first choice\" and underplays that neoadjuvant therapy is also a standard, reasonable option for this group, as stated in the reference answer. Minor nuance is missing regarding the equivalence of both approaches."
  },
  "1272": {
    "score": 5.0,
    "explanation": "5: The model answer fully matches the reference answer in clinical reasoning and detail, with no significant omissions or errors. It clearly explains the implications of R0 resection and the rationale for adjuvant therapy, aligning with the reference."
  },
  "1273": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that further gene testing is not required for immunotherapy decision-making in this context, and provides appropriate justification without any major omissions or errors."
  },
  "1274": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately prioritizing Osimertinib over Durvalumab for this patient population, and provides additional guideline and evidence context without introducing errors or omissions."
  },
  "1275": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the impact of hepatic and renal dysfunction on chemotherapy eligibility, and emphasizing the need for individualized treatment rather than standard chemotherapy. No major omissions or errors are present."
  },
  "1276": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including the need to wait for molecular results, the rationale, guideline support, and exceptions for urgent cases, with no major omissions or errors."
  },
  "1277": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1278": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even adds relevant guideline references and practical considerations."
  },
  "1279": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides supporting references."
  },
  "1280": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and additional context without any major omissions or errors."
  },
  "1281": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of the need to differentiate between T4 disease and double primary lung cancers, but it overemphasizes the need to always consider double primaries and suggests a more complex diagnostic process than the reference answer, which states that such cases should generally be managed as T4 unless there is a contralateral lesion. This introduces some inaccuracy and partial deviation from the reference standard."
  },
  "1282": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately referencing guidelines and providing appropriate rationale, with no major omissions or errors."
  },
  "1283": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the contraindication to surgery due to poor lung function, and appropriately recommending non-surgical options with supporting guidelines. No major omissions or errors."
  },
  "1284": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1285": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and no major omissions or errors."
  },
  "1286": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why surgery is not preferred and detailing alternative treatments, with no major omissions or errors."
  },
  "1287": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately addresses the scenario, and provides additional relevant details without any major omissions or errors."
  },
  "1288": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the risks of concurrent chemoradiotherapy in severe pulmonary dysfunction, prioritizing systemic therapy, and emphasizing individualized assessment, with no major omissions or errors."
  },
  "1289": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the general recommendation for postoperative radiotherapy after breast-conserving surgery, the possibility of omitting radiotherapy in strictly selected low-risk cases, and the lack of indication for routine radiotherapy after mastectomy. No major omissions or errors are present."
  },
  "1290": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional guideline references and rationale supporting the recommendation."
  },
  "1291": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and supporting evidence for not recommending routine brain MRI in asymptomatic IIB (T3N0) NSCLC patients post-R0 resection, with no major omissions or errors."
  },
  "1292": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1293": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that DCIS (with or without Paget disease) alone is not an indication for systemic adjuvant therapy, and that the presence and molecular subtype of invasive cancer are the key determinants. No major omissions or errors are present."
  },
  "1294": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and addressing all key points without omissions or errors."
  },
  "1295": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it slightly overstates the interval for years 3–5 as \"每6-12个月\" instead of strictly \"每6个月\" per the reference, and does not explicitly mention the transition at year 4. Otherwise, it covers the key clinical content and rationale."
  },
  "1296": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed guideline and regulatory approval information, but it incorrectly states that Dabrafenib+Trametinib is supported by phase II (not phase III) data, missing the reference answer’s emphasis on phase III evidence. Otherwise, the clinical reasoning and recommendation are correct."
  },
  "1297": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing ROS1-targeted therapy, referencing guidelines, and appropriately addressing the management of pericardial effusion. No major omissions or errors are present."
  },
  "1298": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without any major omissions or errors."
  },
  "1299": {
    "score": 5.0,
    "explanation": "5: The model answer accurately reflects the reference answer, correctly stating that FDG-PET/CT is recommended when a new suspicious nodule appears postoperatively, and provides appropriate rationale and guideline support."
  },
  "1300": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the prioritization of reoperation over radiotherapy, the rationale, and relevant guidelines, with no significant omissions or errors."
  },
  "1301": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the metabolic concerns, toxicity risks, and guideline recommendations, with no major omissions or errors."
  },
  "1302": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating on guideline support and the rarity of co-mutations, with no major omissions or errors."
  },
  "1303": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately references multiple guidelines, and clearly explains why low-dose non-contrast CT is not standard for follow-up, matching the clinical content of the reference answer without omissions or errors."
  },
  "1304": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，明确指出不应常规考虑术后放疗，并详细解释了依据和指南，未有重要遗漏或错误。"
  },
  "1305": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of surgery due to significant pulmonary dysfunction and appropriately recommending non-surgical multimodal therapy, with no major omissions or errors."
  },
  "1306": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the need for comprehensive molecular testing before selecting amivantamab-vmjw and referencing relevant guidelines, with no major omissions or errors."
  },
  "1307": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "1308": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "1309": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of pathological confirmation before initial treatment, referencing guidelines, and addressing rare exceptions, with no major omissions or errors."
  },
  "1310": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the reference answer’s clinical content, correctly emphasizing the need to increase imaging frequency and individualize follow-up based on new or residual abnormalities, with no major omissions or errors."
  },
  "1311": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately describes the rationale, and even expands on guideline recommendations and multidisciplinary considerations without introducing errors or omissions."
  },
  "1312": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even provides additional relevant detail and justification."
  },
  "1313": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, fully addressing the question with no omissions or errors, and even provides supporting guideline references."
  },
  "1314": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of pathological examination despite negative clinical and imaging findings, with no major omissions or errors."
  },
  "1315": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and additional relevant details without any major omissions or errors."
  },
  "1316": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reiterates the necessity of pathological confirmation for N3 disease, and provides additional rationale and guideline references without any omissions or errors."
  },
  "1317": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and no major omissions or errors."
  },
  "1318": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing NTRK抑制剂, referencing guidelines, and addressing the role of PD-L1 and immunotherapy. The additional clarification about 瑞普特替尼 is accurate and does not detract from the core content."
  },
  "1319": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and appropriate exceptions, with no major omissions or errors."
  },
  "1320": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and emphasizing the necessity of preoperative pulmonary function testing before surgical evaluation, with no major omissions or errors."
  },
  "1321": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why repeat concurrent chemoradiotherapy is not recommended and appropriately suggesting palliative radiotherapy or stenting as first-line options, with no major omissions or errors."
  },
  "1322": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining that EGFR-TKI is the first-line treatment regardless of PD-L1 status, and provides supporting rationale and guideline references without any omissions or errors."
  },
  "1323": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，明确指出应优先选择支气管内激光治疗，并详细解释了原因，无明显遗漏或错误。"
  },
  "1324": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and clinically accurate, providing a detailed rationale for prioritizing SVC stenting (± RT) over immediate systemic therapy, but it places slightly more emphasis on SVC支架植入为首选而非与放疗并列，略有顺序差异。 Otherwise, there are no major omissions or errors."
  },
  "1325": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the reference answer's clinical content, elaborates on decision factors, and emphasizes individualized, guideline-based management without major omissions or errors."
  },
  "1326": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides additional guideline-based context and rationale."
  },
  "1327": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1328": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that routine FDG-PET/CT or brain MRI is not recommended in asymptomatic IIB (T3, N0) NSCLC patients post-surgery and adjuvant chemotherapy, and providing appropriate rationale and guideline references without omissions or errors."
  },
  "1329": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately distinguishes between EGFR and KRAS G12C mutations, details current guideline recommendations, and correctly states that KRAS G12C inhibitors are not first-line, matching the reference answer with no major omissions or errors."
  },
  "1330": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale for preferring sequential chemoradiotherapy and discusses relevant clinical considerations, but it inaccurately states that sequential therapy is generally preferred over concurrent chemoradiotherapy, which contradicts the reference answer's prioritization of concurrent chemoradiotherapy in suitable patients. This represents a significant omission and inaccuracy."
  },
  "1331": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing re-resection for R0 margins and recommending radiotherapy only if surgery is not feasible, with no major omissions or errors."
  },
  "1332": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the necessity of preoperative pulmonary function and PET-CT assessments, and provides clear reasoning without omissions or errors."
  },
  "1333": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and provides additional guideline-based justification without introducing inaccuracies."
  },
  "1334": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for preferring direct surgery over systemic therapy in the context of significant hepatic dysfunction, with no major omissions or errors."
  },
  "1335": {
    "score": 3.0,
    "explanation": "3: The model answer misunderstands the question, incorrectly stating that \"常规行 FDG-PET/CT 检查是合适的,\" while the reference answer clearly states that routine PET/CT is not appropriate unless there is evidence of recurrence or abnormal imaging findings. The model answer partially covers the rationale for using PET/CT in the context of suspicious findings, but it conflates routine use with targeted use, leading to a significant inaccuracy."
  },
  "1336": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of FDG-PET/CT and brain MRI before initiating treatment, and provides additional rationale and guideline support without any omissions or errors."
  },
  "1337": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the primacy of systemic therapy and the cautious use of local therapy in the context of poor pulmonary function. However, it places slightly more emphasis on the potential combination with local therapy than the reference answer, which clearly states systemic therapy as the first choice and local therapy as not preferred. Minor differences in prioritization prevent a perfect score."
  },
  "1338": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive guideline-based justification, relevant clinical trial data, and specific discussion of brain metastases, with no major omissions or errors."
  },
  "1339": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need for pathological confirmation, the limitations of imaging, the impact on treatment decisions, and guideline recommendations, with no major omissions or errors."
  },
  "1340": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the lack of efficacy of conventional EGFR-TKIs, guideline recommendations, superior efficacy of specific drugs, and appropriate clinical decision-making. No major omissions or errors are present."
  },
  "1341": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even adds relevant guideline references and clarifies indications for chemotherapy."
  },
  "1342": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating on the rationale and guidelines, with no major omissions or errors."
  },
  "1343": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale for prioritizing external beam radiotherapy (with or without SVC stenting) and correctly deferring concurrent chemoradiotherapy until after symptom relief, with no major omissions or errors."
  },
  "1344": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly emphasizes that adjuvant radiotherapy is not recommended as first-line local therapy in patients with severe pulmonary dysfunction due to increased risks. However, it omits the reference answer’s suggestion to consider reoperation as a priority before other options, which is a minor but relevant omission."
  },
  "1345": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and a clear conclusion with no major omissions or errors."
  },
  "1346": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, emphasizes the necessity of pathological confirmation, details appropriate diagnostic methods, and addresses exceptions and MDT discussion, fully aligning with the reference answer."
  },
  "1347": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a detailed explanation, correctly stating that single-agent immunotherapy cannot be chosen without PD-L1 testing, but notes that immunotherapy combined with chemotherapy can be considered without PD-L1 results. This is a minor expansion beyond the reference answer, but does not introduce errors; however, the reference answer does not mention the combination therapy option, so the model answer slightly exceeds the scope."
  },
  "1348": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that low-dose non-contrast CT alone is sufficient for early (术后1年) follow-up, which contradicts guidelines recommending contrast or non-contrast CT every 6 months in the first 2–3 years. This is a notable error, despite some correct rationale and supporting details."
  },
  "1349": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity and rationale for both PFTs and FDG-PET/CT prior to treatment, with no major omissions or errors."
  },
  "1350": {
    "score": 2.0,
    "explanation": "2: The model answer recommends immediate surgical excision, which contradicts the reference answer's emphasis on initial clinical follow-up and repeat biopsy before surgery. While the model provides some rationale, it overlooks the guideline to avoid unnecessary surgery and omits the stepwise approach, representing a notable error in clinical management."
  },
  "1351": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the role of high-risk factors, guidelines, and the selective use of adjuvant therapy versus observation, with no major omissions or errors."
  },
  "1352": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the required clinical content, accurately lists the necessary molecular tests and PD-L1, and provides appropriate rationale and references to guidelines, with no major omissions or errors."
  },
  "1353": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for surgery, the rationale, and the role of adjuvant therapy, with no major omissions or errors."
  },
  "1354": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It provides a thorough rationale, referencing pharmacokinetics, drug labeling, and guidelines, and reaches the same clinical conclusion."
  },
  "1355": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案在临床内容上完全一致，详细说明了随访频率、慢性肾功能不全患者应避免常规使用增强CT，并补充了指南依据，无明显遗漏或错误。"
  },
  "1356": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, accurately discusses the distinction between multiple primaries and metastases, and correctly concludes that management should follow the multi-focal (IIB/IIIA/IV) pathway, with no major omissions or errors."
  },
  "1357": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the need to await molecular and PD-L1 results before starting systemic therapy, and even adds guideline references and appropriate exceptions without introducing errors or omissions."
  },
  "1358": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that routine follow-up does not include FDG-PET/CT or brain MRI unless there are symptoms or abnormal findings, and it appropriately emphasizes standard follow-up methods."
  },
  "1359": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including follow-up intervals, imaging modality, and the impact of pulmonary dysfunction, with no major omissions or errors."
  },
  "1360": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, including the rationale, evidence basis, and specific recommendation to complete a full year of HER2-targeted therapy with trastuzumab if T-DM1 is discontinued. No major omissions or errors are present."
  },
  "1361": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and correctly emphasizes that surgery is not recommended due to both N3 staging and severe pulmonary dysfunction, but it omits the explicit mention of preoperative pulmonary function testing (PFTs) as a necessary assessment before considering surgery."
  },
  "1362": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing orthopedic fixation and palliative radiotherapy over bone-modifying agents in high-risk pathological fracture scenarios, with no major omissions or errors."
  },
  "1363": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1364": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including staging, mutation type, guideline recommendations, the role of brain MRI, and the appropriateness of EGFR-TKI therapy, with no major omissions or errors."
  },
  "1365": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides additional guideline references for completeness."
  },
  "1366": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of preoperative axillary pathological confirmation, the limitations of imaging, guideline recommendations, and appropriate steps if biopsy is inconclusive, with no major omissions or errors."
  },
  "1367": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, including standard recommendations, exceptions, and guideline references, with no major omissions or errors."
  },
  "1368": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，明确指出COPD增加肺癌风险，强调应按高风险人群管理，并详细列出具体随访建议，无明显遗漏或错误。"
  },
  "1369": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses drug metabolism, toxicity, guideline recommendations, and individualized treatment, with no major omissions or errors compared to the reference answer."
  },
  "1370": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and even elaborates on rationale and guidelines, fully supporting the recommendation for more frequent imaging."
  },
  "1371": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, correctly identifying concurrent chemoradiotherapy as the preferred option and discussing alternatives if not tolerated. However, it places slightly more emphasis on attempting concurrent chemoradiotherapy even in the context of severe pulmonary dysfunction, whereas the reference answer more clearly prioritizes patient safety and tolerance, suggesting individualized systemic therapy and delayed radiotherapy if concurrent chemoradiotherapy is not feasible."
  },
  "1372": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, guidelines, and sequence of interventions with no major omissions or errors."
  },
  "1373": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It covers all key points, provides guideline references, and clearly states that FDG-PET/CT and brain MRI are not routinely recommended except when clinically indicated."
  },
  "1374": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully aligning with the reference answer, and even elaborates on the rationale and exceptions without introducing errors or omissions."
  },
  "1375": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including rationale, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "1376": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the role of HER2 status in guiding HER2-targeted therapy and correctly stating that HR阳性、HER2阴性患者不应联合HER2靶向药物, with no major omissions or errors."
  },
  "1377": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a nuanced, guideline-based discussion, but it introduces additional complexity and conditional recommendations not present in the reference answer, which may cause minor confusion. The core message—that axillary lymph node dissection can often be omitted—is present, but the answer is less direct and omits the clear statement that additional surgery does not improve prognosis."
  },
  "1378": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It provides comprehensive reasoning, references key studies and guidelines, and reaches the same clear clinical conclusion."
  },
  "1379": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of axillary staging, the rationale, guideline support, and the consequences of omission, with no major omissions or errors."
  },
  "1380": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1381": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, guideline references, rationale, and specific follow-up recommendations without omissions or errors."
  },
  "1382": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with accurate reasoning and no major omissions or errors."
  },
  "1383": {
    "score": 4.0,
    "explanation": "4: The model answer covers nearly all key clinical content, including the rationale for neoadjuvant therapy in cT1cN0 triple-negative breast cancer and guideline recommendations, but it introduces nuance about neoadjuvant versus adjuvant options that slightly exceeds the reference answer’s directness, making it slightly less concise. No major omissions or errors."
  },
  "1384": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the recommended reduction in CT scan frequency and modality after 3 years without recurrence, and appropriately referencing relevant guidelines. No major omissions or errors are present."
  },
  "1385": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the rationale for using non-contrast low-dose CT and its appropriateness in severe renal insufficiency, with no significant omissions or errors."
  },
  "1386": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, citing guidelines, and emphasizing the contraindication due to cardiac toxicity, with no major omissions or errors."
  },
  "1387": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even expanding with guideline references and detailed rationale, with no major omissions or errors."
  },
  "1388": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，并补充了合理的循证依据和指南推荐，内容更为详实。"
  },
  "1389": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the inappropriateness of concurrent chemoradiotherapy in severe COPD with significant lung dysfunction, and suggesting appropriate alternative management options without omissions or errors."
  },
  "1390": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, with no major omissions or errors, and offers a thorough explanation consistent with current guidelines."
  },
  "1391": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and fully aligns with the reference answer, providing detailed rationale, guideline support, and relevant study evidence without any major omissions or errors."
  },
  "1392": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and accurate discussion of current evidence and guidelines, but it contradicts the reference answer by stating that KRAS G12C inhibitors are not the preferred option in squamous cell carcinoma, whereas the reference answer supports their use regardless of PD-L1 status. This represents a significant difference in clinical recommendation."
  },
  "1393": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of pathological confirmation, the limitations of imaging, and the rare exceptions, with no major omissions or errors."
  },
  "1394": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It fully addresses the appropriateness and priority of EGFR-TKI in EGFR-mutant squamous NSCLC, regardless of histology, and provides supporting rationale."
  },
  "1395": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including the preference for surgery in suitable patients, the role of MDT, and comparison with radiotherapy/SABR. However, it is more detailed and slightly less direct than the reference answer, with minor omissions in emphasizing surgery as the clear first choice when feasible."
  },
  "1396": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, referencing clinical trial data, guidelines, and risk-benefit considerations, with no major omissions or errors."
  },
  "1397": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining alternative imaging options and emphasizing that chronic renal insufficiency is not an absolute contraindication, with no major omissions or errors."
  },
  "1398": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of the evaluation process and acknowledges the role of PET/CT, but it overemphasizes the need for immediate PET/CT, which contradicts the reference answer's recommendation to prioritize high-resolution CT and reserve PET/CT for indeterminate or highly suspicious lesions. Some key nuances about imaging follow-up frequency and the non-routine use of PET/CT are omitted."
  },
  "1399": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale and guideline references but incorrectly states that PET/CT should be routinely performed, whereas the reference answer specifies that enhanced chest CT is the first-line evaluation and PET/CT or brain MRI are not routinely recommended unless recurrence or progression is suspected. This represents a significant deviation from the reference answer."
  },
  "1400": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides additional rationale and supporting evidence, but the core recommendation and reasoning are fully aligned."
  },
  "1401": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the rationale for trastuzumab monotherapy and the consideration of dual HER2 blockade. However, it places slightly more emphasis on monotherapy after pCR than the reference answer, which more strongly prioritizes dual therapy for node-positive patients, resulting in a minor omission regarding the preferred status of dual blockade in this specific high-risk group."
  },
  "1402": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering alternative imaging options, the rationale for assessment, and guideline flexibility, with no major omissions or errors."
  },
  "1403": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even adds guideline support and further details on efficacy and tolerability."
  },
  "1404": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，详细阐述了分期依据、处理原则，并补充了分子和病理学判断依据，无重大遗漏或错误。"
  },
  "1405": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer by stating the follow-up frequency is the same, whereas the reference answer clearly states they are different, with higher frequency for those who received radiotherapy."
  },
  "1406": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1407": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and structured response but contains a key inaccuracy: it incorrectly states that ERBB2靶向治疗不应在未完成PD-L1评估时直接推荐，而参考答案明确指出ERBB2靶向治疗的决策与PD-L1状态无关，可直接启动。此外，模型答案对指南推荐的时序也有一定混淆。"
  },
  "1408": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and provides additional supporting rationale and guideline references."
  },
  "1409": {
    "score": 3.0,
    "explanation": "3: The model answer provides a guideline-based rationale for omitting chest wall radiotherapy, but it omits the key clinical concern that a close (<1 mm) but negative margin still carries a risk of local recurrence, which is why the reference answer recommends considering radiotherapy. This is a significant omission affecting clinical decision-making."
  },
  "1410": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of the clinical considerations, including indications, risks, and decision-making for adjuvant radiotherapy in this scenario, with no major omissions or errors compared to the reference answer."
  },
  "1411": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and evidence for prioritizing adjuvant systemic therapy over observation, with no major omissions or errors."
  },
  "1412": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed guideline-based reasoning, but it slightly overemphasizes that brain MRI is not standard for all T1bN1 patients, whereas the reference answer more clearly states it is necessary for initial assessment in N1 (stage II) cases. Minor nuance differences prevent a perfect score."
  },
  "1413": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the increased surgical risk, guideline recommendations, and preference for non-surgical treatments, with additional detail and appropriate caveats for rare exceptions."
  },
  "1414": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points, including the prioritization of TKI therapy, rationale, guideline recommendations, and the role of whole-brain radiotherapy, with no major omissions or errors."
  },
  "1415": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and references guidelines, but it inaccurately states that osimertinib is not preferred for S768I, whereas the reference answer affirms its use as a preferred option. This represents a significant clinical inaccuracy."
  },
  "1416": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly stating that both radiotherapy and endocrine therapy are contraindicated during pregnancy and must be postponed until after delivery, with no major omissions or errors."
  },
  "1417": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and guideline-based justification, fully covering the clinical reasoning and threshold (≥0.6 cm/T1b) for recommending adjuvant chemotherapy plus trastuzumab, with no major omissions or errors."
  },
  "1418": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points with additional guideline references and rationale, without any major omissions or errors."
  },
  "1419": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the rationale for prioritizing immune checkpoint inhibitors, the irrelevance of HER2-targeted therapy in HER2-negative patients, and referencing current guidelines. No major omissions or errors are present."
  },
  "1420": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and correct standard-of-care recommendations without omissions or errors."
  },
  "1421": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points and providing additional, accurate rationale and caveats without introducing errors or omissions."
  },
  "1422": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and references relevant guidelines, but it does not clearly state that there is no strong clinical basis for continuing 6-monthly CT after 3 years, as the reference answer does. It also does not specify switching to annual low-dose, non-contrast CT after 3 years, which is a key detail."
  },
  "1423": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the primacy of ALK靶向治疗 for systemic disease control, the role of local interventions for complications, and the need for timely initiation of targeted therapy, with no major omissions or errors."
  },
  "1424": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides clear justification for the prioritization of airway intervention before systemic therapy."
  },
  "1425": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional appropriate detail regarding further investigations."
  },
  "1426": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even provides additional guideline context and practical considerations."
  },
  "1427": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the rationale for not prioritizing surgery, the role of concurrent chemoradiotherapy, and additional considerations such as consolidation immunotherapy. No major omissions or errors are present."
  },
  "1428": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the lack of evidence for EGFR TKI superiority, poor sensitivity of exon 20 insertions to standard TKIs, and the recommendation for chemotherapy as first-line treatment, with additional relevant details and guideline references."
  },
  "1429": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately prioritizing systemic therapy and appropriately discussing the role of local therapy in oligometastatic disease, with no major omissions or errors."
  },
  "1430": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, indications, and guideline recommendations, with no major omissions or errors."
  },
  "1431": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without any major omissions or errors."
  },
  "1432": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the necessity of systemic therapy, the rationale, guideline recommendations, and exceptions, with no major omissions or errors."
  },
  "1433": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant detail and justification."
  },
  "1434": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing reoperation and including all key points without omissions or errors."
  },
  "1435": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and appropriate exceptions, with no major omissions or errors."
  },
  "1436": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the question and providing additional guideline-based rationale without introducing errors or omissions."
  },
  "1437": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the inability to completely rule out distant or brain metastases, limitations of imaging, and the rationale for close follow-up. No major omissions or errors are present."
  },
  "1438": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing PD-L1-guided immunotherapy as first-line and reserving KRAS G12C inhibitors for later lines, with no major omissions or errors."
  },
  "1439": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the prioritization of local hemostatic interventions over systemic therapy, with no major omissions or errors."
  },
  "1440": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive justification, guideline references, and addressing all relevant aspects without omissions or errors."
  },
  "1441": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guidelines, and appropriate management approach without omissions or errors."
  },
  "1442": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the preference for single radiotherapy over repeat chemoradiotherapy, the role of SVC stenting, and individualized treatment. However, it introduces more detail than required and slightly overemphasizes the use of SVC stenting, which is not explicitly prioritized in the reference answer. Minor omissions and slight shifts in emphasis prevent a perfect score."
  },
  "1443": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the metabolic pathway, safety concerns, guideline recommendations, and clinical management, with no major omissions or errors."
  },
  "1444": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and references multiple guidelines, but it introduces some ambiguity regarding随访频率 (follow-up frequency) and does not clearly state that主流临床实践 generally recommends annual follow-up after 2–3 years, as in the reference answer. Minor omissions and lack of a definitive recommendation reduce the score."
  },
  "1445": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional guideline-based justification."
  },
  "1446": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, indications, and guidelines, with no major omissions or errors."
  },
  "1447": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, provides clear rationale, and cites relevant guidelines, with no major omissions or errors."
  },
  "1448": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive detail, guideline references, and even elaborating on rare exceptions, with no major omissions or errors."
  },
  "1449": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points, including the indication for T-DM1, the relevance of the KATHERINE study, and the lack of restriction based on initial clinical stage. No major omissions or errors are present."
  },
  "1450": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, correctly identifies SABR as the preferred curative treatment for inoperable/high-risk T1N0 NSCLC with severe COPD, and adds relevant guideline support and considerations without introducing errors or omissions."
  },
  "1451": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the indication, risks of pembrolizumab in the context of liver dysfunction, and guideline recommendations, with no major omissions or errors."
  },
  "1452": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and accurately explains the lack of indication for targeted therapy, but it introduces additional information about rare mutations and immunotherapy options, which, while relevant, goes slightly beyond the scope of the reference answer. Minor extraneous details prevent a perfect score."
  },
  "1453": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning and management steps outlined in the reference answer, with no major omissions or errors, and even provides additional guideline references and practical follow-up intervals."
  },
  "1454": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points, including follow-up intervals, imaging modality, and rationale, with no major omissions or errors."
  },
  "1455": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing SVC stent placement for rapid symptom relief and appropriately relegating radiotherapy to subsequent management, with no major omissions or errors."
  },
  "1456": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, citing guidelines, and making no significant omissions or errors."
  },
  "1457": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with comprehensive coverage and no major omissions or errors. It even provides additional relevant details and rationale, fully supporting the recommendation."
  },
  "1458": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage and includes relevant guidelines and reasoning, but it inaccurately suggests that routine PET/CT is not necessary postoperatively in all T1N0 R0 cases without high-risk features, which contradicts the reference answer's clear recommendation to perform PET/CT postoperatively if it was not done preoperatively, regardless of risk factors."
  },
  "1459": {
    "score": 4.0,
    "explanation": "4: The model answer is comprehensive and well-structured, providing detailed rationale and referencing guidelines, but it slightly overemphasizes that cT1cN0M0 TNBC is \"not a standard indication\" for neoadjuvant therapy, whereas the reference answer states both options are acceptable and within current treatment pathways. Minor nuance is missing regarding equal validity of both approaches."
  },
  "1460": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides additional guideline support and rationale, fully covering the key points."
  },
  "1461": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guideline recommendations, and treatment prioritization without omissions or errors."
  },
  "1462": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and includes all key clinical points without omissions or errors. It also provides guideline references and clarifies special situations, fully aligning with the reference content."
  },
  "1463": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, alternatives, and clinical recommendations without omissions or errors."
  },
  "1464": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the prioritization of local bleeding control over surgery, the need for preoperative pulmonary function assessment, and the use of radiotherapy or interventional methods as first-line measures. No major omissions or errors are present."
  },
  "1465": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately describing the timing of NTRK inhibitor use and the decision-making process, with no major omissions or errors. It also provides additional guideline references and rationale, enhancing completeness."
  },
  "1466": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the use of radiotherapy as a salvage treatment for positive margins after initial surgery, not limited to recurrence, and provides supporting guideline references without any major omissions or errors."
  },
  "1467": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need for adjuvant therapy rather than direct surveillance, and provides guideline-based justification without omissions or errors."
  },
  "1468": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing that EGFR-TKI therapy is based on molecular features rather than histology or metastasis, with no major omissions or errors."
  },
  "1469": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, accurately explains the rationale, references guidelines, and matches the reference answer with no major omissions or errors."
  },
  "1470": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that FDG-PET/CT and brain MRI are not included in routine surveillance, and provides additional guideline-based justification without introducing errors or omissions."
  },
  "1471": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately describes guideline recommendations, and clearly explains why the proposed follow-up is insufficient, with no major omissions or errors."
  },
  "1472": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content, aligns with guideline recommendations, and correctly justifies annual CT in the fourth year, with no major omissions or errors."
  },
  "1473": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guidelines, and clinical implications without omissions or errors. It even provides additional detail and clear structure, but all content is accurate and relevant."
  },
  "1474": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the prioritization of adjuvant systemic therapy, the rationale for omitting or delaying radiotherapy due to severe pulmonary dysfunction, and provides additional guideline references without introducing errors or omissions."
  },
  "1475": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides appropriate justification and guideline references."
  },
  "1476": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based reasoning, but it introduces nuanced conditions under which ALND may be omitted that are not reflected in the stricter reference answer, which states ALND cannot be omitted in this scenario. This represents a minor but important difference in clinical recommendation."
  },
  "1477": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, referencing key studies and guidelines, and clearly stating that ALND cannot be omitted when 3 positive sentinel nodes are found. No major omissions or errors."
  },
  "1478": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and even adds supporting evidence and guideline references."
  },
  "1479": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant details without any omissions or errors."
  },
  "1480": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including timing and safety of surgery and chemotherapy, with no major omissions or errors."
  },
  "1481": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the inadequacy of chest X-ray alone for follow-up, referencing guidelines, and emphasizing the necessity of regular chest CT, with no major omissions or errors."
  },
  "1482": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "1483": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale for prioritizing systemic therapy and discusses the role of local therapy, but it inaccurately states that systemic therapy should always be prioritized, whereas the reference answer emphasizes evaluating for local therapy first if feasible. This represents a significant omission in clinical approach."
  },
  "1484": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including the importance of PS assessment, the role of driver mutations, and guideline recommendations. However, it is more detailed than the reference and introduces additional considerations (e.g., molecular subtyping) that, while accurate, slightly expand beyond the core reference content."
  },
  "1485": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, evidence, and practical considerations found in the reference answer, with no major omissions or errors. It even adds relevant clinical trial data and bone health considerations, enhancing completeness."
  },
  "1486": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately recommending annual low-dose non-contrast chest CT for routine follow-up and providing appropriate rationale and guideline references, with no major omissions or errors."
  },
  "1487": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the indications for direct surgery, the rationale, and relevant guidelines, with no major omissions or errors."
  },
  "1488": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, recommendations, and supporting details without omissions or errors."
  },
  "1489": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including staging, surgical indications, pulmonary function assessment, and the need for thorough preoperative evaluation, with no major omissions or errors."
  },
  "1490": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the importance of HR status and referencing relevant guidelines, with no major omissions or errors."
  },
  "1491": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the indications for FDG-PET/CT and bronchoscopy, and the impact of severe pulmonary dysfunction on surgical candidacy. However, it slightly overemphasizes selective use of bronchoscopy in peripheral tumors, whereas the reference answer recommends routine use unless the patient cannot tolerate the procedure or results would not affect management."
  },
  "1492": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns closely with the reference answer, but it specifies 2 years for 6-monthly CTs rather than the 2–3 years range given in the reference, which is a minor omission."
  },
  "1493": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1494": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately citing both international and Chinese guidelines, and clearly states the appropriate adjustment in follow-up imaging frequency after 2 years."
  },
  "1495": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides additional supporting rationale consistent with guidelines and evidence."
  },
  "1496": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, indications, and exceptions for prioritizing concurrent chemoradiotherapy over radiotherapy alone, with no major omissions or errors."
  },
  "1497": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides additional rationale and references that reinforce the correct prioritization of RET-targeted therapy."
  },
  "1498": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the appropriateness of using Capmatinib or Tepotinib based solely on METex14跳跃突变, and provides additional guideline-based justification without any major omissions or errors."
  },
  "1499": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including the contraindication of standard concurrent chemoradiotherapy in patients with severe irreversible pulmonary dysfunction, the need for individualized risk assessment, and the consideration of alternative, safer treatment options."
  },
  "1500": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It clearly states that routine FDG-PET/CT or brain MRI is not recommended, specifies the appropriate follow-up methods, and provides guideline references."
  },
  "1501": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors."
  },
  "1502": {
    "score": 3.0,
    "explanation": "3: The model answer provides a more nuanced and guideline-based discussion, emphasizing MDT评估和寡转移概念，但与参考答案不同，主张优先局部治疗联合/后续全身治疗，而参考答案明确主张优先全身系统治疗，仅极少数病例考虑局部治疗，存在一定内容偏差。"
  },
  "1503": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines for not omitting postoperative radiotherapy, with no major omissions or errors."
  },
  "1504": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, supporting evidence, and guideline recommendations without any major omissions or errors."
  },
  "1505": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately prioritizing palliative radiotherapy for severe symptoms and timely initiation of systemic therapy, with no major omissions or errors. It also adds appropriate detail and context without deviating from the core guidance."
  },
  "1506": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, guideline recommendations, and specific follow-up intervals, with no major omissions or errors."
  },
  "1507": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the inapplicability of I–IIIA initial treatment for N3M0 NSCLC, and further elaborates on appropriate treatment strategies without any major omissions or errors."
  },
  "1508": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the need for shortened follow-up and further evaluation in the presence of new imaging abnormalities, with no major omissions or errors."
  },
  "1509": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and even elaborates on rationale and guidelines without introducing inaccuracies."
  },
  "1510": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion and references guidelines, but it incorrectly suggests that FDG-PET/CT is routinely recommended for any new imaging abnormality, whereas the reference answer emphasizes individualized assessment and that PET/CT or brain MRI are not routine but reserved for suspected recurrence/metastasis. This represents a significant deviation from the reference answer."
  },
  "1511": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need to await molecular testing before systemic therapy, referencing guidelines, and appropriately noting exceptions for urgent cases. No major omissions or errors are present."
  },
  "1512": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that follow-up should match stage III patients and not be reduced to stage I–II frequency, with appropriate justification and guideline references. No major omissions or errors are present."
  },
  "1513": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, but it adds biopsy as an initial step, which is not mentioned in the reference, and slightly overemphasizes immediate further evaluation rather than prioritizing intensified imaging follow-up first. Minor differences in sequencing and emphasis account for the deduction."
  },
  "1514": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content, accurately explains the rationale, and has no major omissions or errors. It matches the reference answer in detail and reasoning."
  },
  "1515": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides clear justification for the recommended approach."
  },
  "1516": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately prioritizes surgery over radiotherapy, and provides detailed, guideline-based justification without any major omissions or errors."
  },
  "1517": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant justification and guideline support."
  },
  "1518": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including guideline support, rationale, and appropriate patient selection, with no major omissions or errors."
  },
  "1519": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately addressing the role of combined systemic therapy and radiotherapy, the need for individualized assessment in the context of impaired lung function, and alternative strategies if radiotherapy is not tolerated. No major omissions or errors are present."
  },
  "1520": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the question, and provides detailed guideline-based justification without any major omissions or errors."
  },
  "1521": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating with guideline support and rationale, without introducing any errors or omissions."
  },
  "1522": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "1523": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning and recommendations in the reference answer, with additional detail and no major omissions or errors."
  },
  "1524": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion and references guidelines, but it inaccurately states that TRK抑制剂通常在免疫治疗失败后启用，而参考答案明确指出应优先转为TRK抑制剂，未强调需等待免疫治疗失败，存在一定的临床决策偏差。"
  },
  "1525": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including the need to distinguish between independent primary tumors and metastasis, and the approach to treatment. However, it introduces additional details (e.g., MDT evaluation, guidelines) and slightly complicates the answer, which, while accurate, goes beyond the concise focus of the reference answer. Minor omissions include not explicitly stating that the default principle is to treat as two primaries if both are potentially curable."
  },
  "1526": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content from the reference answer, with accurate staging interpretation, guideline support, and rationale for neoadjuvant therapy in cT1cN0M0 TNBC patients, without omissions or errors."
  },
  "1527": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale and guideline support without any major omissions or errors."
  },
  "1528": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, sequence, and guidelines for prioritizing local treatment before systemic therapy, with no major omissions or errors."
  },
  "1529": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant explanation without introducing inaccuracies."
  },
  "1530": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the rationale, guideline recommendations, and rare exceptions for surgery, with no significant omissions or errors."
  },
  "1531": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and patient-specific analysis with no major omissions or errors."
  },
  "1532": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer by stating that EGFR-TKIs (erlotinib, gefitinib, dacomitinib) are not recommended, whereas the reference answer affirms their use as first-line therapy in this setting. The model answer is largely incorrect in the context of the reference answer."
  },
  "1533": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and practical recommendations without any major omissions or errors."
  },
  "1534": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including the indication for adjuvant pembrolizumab regardless of BRCA1/2 status, and the role of olaparib. No major omissions or errors are present."
  },
  "1535": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully addressing the staging, the concept of oligometastatic disease, and the rationale for considering local therapy, matching the reference answer without major omissions or errors."
  },
  "1536": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including guideline recommendations, rationale, and appropriate indications for omitting radiotherapy. No major omissions or errors are present."
  },
  "1537": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and well-justified, but it places greater emphasis on systemic therapy as the initial priority due to N3 involvement, whereas the reference answer suggests local therapy should be prioritized if oligometastatic criteria are met and the patient is fit. The model answer’s approach is defensible but omits the nuance that local therapy can be considered first in select oligometastatic cases."
  },
  "1538": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale, guidelines, and specific recommendations for axillary biopsy and marking before neoadjuvant therapy in cN0, early triple-negative breast cancer. No major omissions or errors are present."
  },
  "1539": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including imaging, pathology, MDT discussion, guideline support, and justification for proceeding with systemic therapy without invasive biopsy. No major omissions or errors are present."
  },
  "1540": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It provides comprehensive reasoning, guideline references, and a clear conclusion consistent with current recommendations."
  },
  "1541": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the contraindication of neoadjuvant anti-HER2 therapy in severe hepatic impairment, and provides detailed rationale and management suggestions consistent with the reference answer, with no major omissions or errors."
  },
  "1542": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects all key clinical points from the reference answer, and provides additional relevant details without introducing errors or omissions."
  },
  "1543": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and even provides guideline references and rationale."
  },
  "1544": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of brain MRI before surgery, the limitations of FDG-PET/CT, and the impact on treatment decisions, with no major omissions or errors."
  },
  "1545": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends more frequent CT scans than the reference answer, which specifies every 6 months (not 3–6 months) for the first 2–3 years and only more frequent scans for those with prior radiotherapy or higher stage. This is a notable error in clinical guidance, despite some correct background information."
  },
  "1546": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides additional relevant justification."
  },
  "1547": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate details, fully covering the differences in follow-up frequency and imaging modalities between the two patient groups, with no major omissions or errors."
  },
  "1548": {
    "score": 2.0,
    "explanation": "2: The model answer contains notable errors, as it incorrectly suggests that pathological mediastinal lymph node evaluation can proceed without first performing bronchoscopy, which contradicts the reference answer's emphasis on bronchoscopy as an essential initial step. It also misrepresents the sequence of diagnostic procedures recommended in guidelines for this clinical scenario."
  },
  "1549": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline citations, and practical recommendations without any major omissions or errors."
  },
  "1550": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating with guideline references and rationale, with no major omissions or errors."
  },
  "1551": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical reasoning, but it introduces additional considerations (such as the need for further evidence and MDT discussion) and nuances not explicitly stated in the reference answer, making it slightly more complex but not omitting major content."
  },
  "1552": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides clear rationale and guideline support for prioritizing MET抑制剂 over immunotherapy."
  },
  "1553": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the appropriateness of dabrafenib plus trametinib in this context, and even provides additional guideline support and practical considerations without introducing errors or omissions."
  },
  "1554": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and emphasizing the importance of PET/CT in staging and treatment planning, with no major omissions or errors."
  },
  "1555": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of molecular marker testing and multidisciplinary evaluation before proceeding with local thoracic treatment, with no major omissions or errors."
  },
  "1556": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and provides clear justification for the treatment sequence."
  },
  "1557": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing surgery and appropriately contrasting it with SRS, with no major omissions or errors."
  },
  "1558": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the inappropriateness of pemetrexed in squamous NSCLC, the impact of severe hepatic dysfunction, and the prioritization of targeted therapy. It also adds relevant, accurate details about alternative regimens and drug metabolism, with no major omissions or errors."
  },
  "1559": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the question, and includes all key points from the reference answer without omissions or errors. It also provides additional guideline-based rationale and practical recommendations, fully aligning with the reference answer."
  },
  "1560": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, supporting evidence, and guideline recommendations, with no major omissions or errors."
  },
  "1561": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed and guideline-based rationale but incorrectly states that routine driver gene testing is not recommended for all squamous cell carcinoma patients, whereas the reference answer recommends comprehensive molecular profiling for all. This is a significant omission, though PD-L1 testing is correctly addressed."
  },
  "1562": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately states that routine FDG-PET/CT or brain MRI is not needed for all patients, details the recommended follow-up, and cites relevant guidelines."
  },
  "1563": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, guideline recommendations, and correct management without omissions or errors."
  },
  "1564": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the contraindication to surgery due to severe cardiopulmonary dysfunction and appropriately recommending non-surgical management, with no major omissions or errors."
  },
  "1565": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed rationale for prioritizing pathological confirmation of N3 disease before completing PFTs or PET/CT, which contradicts the reference answer stating that these assessments must be completed first. This represents a notable error in clinical sequencing, despite the answer's thoroughness."
  },
  "1566": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer by stating that routine pathological mediastinal lymph node evaluation is not needed, whereas the reference answer affirms its necessity. This is a major error in clinical content."
  },
  "1567": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the indications, evidence, and risks of PORT in this scenario, and emphasizes individualized decision-making, with no major omissions or errors."
  },
  "1568": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including drug metabolism, safety data, and dose adjustment, with no major omissions or errors."
  },
  "1569": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline citations, and no major omissions or errors."
  },
  "1570": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of EGFR exon 20 insertion mutation and treatment considerations, but it diverges from the reference answer by emphasizing the need to wait for all molecular results, which contradicts the reference's clear recommendation to proceed based on the known EGFR exon 20 result. This introduces some inaccuracy and partial coverage of the key clinical decision point."
  },
  "1571": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, provides accurate rationale, and contains no major omissions or errors."
  },
  "1572": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even provides additional guideline support and rationale."
  },
  "1573": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and recommendations without omissions or errors."
  },
  "1574": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough discussion of the evidence, guidelines, and clinical considerations, but it does not emphasize as clearly as the reference answer that current mainstream opinion still does not recommend omitting axillary dissection after mastectomy, and it leans more toward \"can consider omitting\" rather than \"not recommended.\""
  },
  "1575": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, guideline basis, and specific recommendation to avoid contrast-enhanced CT in chronic renal insufficiency, matching the reference answer with no major omissions or errors."
  },
  "1576": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the impact of reduced lung function on treatment choice, discusses guideline recommendations, and emphasizes the need for individualized assessment—matching the reference answer in all key aspects without major omissions."
  },
  "1577": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining the necessity of confirming BRCA1/2 germline mutation before using olaparib, and appropriately referencing guidelines and studies. No major omissions or errors are present."
  },
  "1578": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage but contains a key inaccuracy—it recommends FDG-PET/CT for new imaging abnormalities even in asymptomatic patients, whereas the reference answer states it is not routinely recommended unless there is high suspicion or symptoms. The answer is otherwise detailed and references guidelines, but this over-recommendation is a significant deviation."
  },
  "1579": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, supporting evidence, and guideline recommendations without omissions or errors."
  },
  "1580": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides a thorough explanation consistent with current guidelines."
  },
  "1581": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and a clear conclusion without any major omissions or errors."
  },
  "1582": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the indications for surgery, the need for tissue diagnosis, symptom relief, and guideline recommendations, with no major omissions or errors."
  },
  "1583": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including the need for pathological confirmation due to imaging limitations, its impact on staging and treatment, and guideline recommendations, with no major omissions or errors."
  },
  "1584": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that FDG-PET/CT and brain MRI are not recommended for routine surveillance in asymptomatic patients and should only be used if recurrence is suspected. No major omissions or errors are present."
  },
  "1585": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points including the need for histological confirmation, patient suitability for surgery, and guideline recommendations, with no major omissions or errors."
  },
  "1586": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the high surgical risk, the need to assess resectability and lung function, and the recommendation for non-surgical multimodal therapy. No major omissions or errors are present."
  },
  "1587": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and even expands with guideline references and rationale, without any major omissions or errors."
  },
  "1588": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the reference answer’s key points, adds relevant clinical reasoning, and provides guideline-based recommendations without introducing errors or omissions."
  },
  "1589": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the appropriateness of FDG-PET/CT and biopsy in high-risk patients with COPD, and adds relevant details about decision-making, risks, and guidelines without introducing errors or omissions."
  },
  "1590": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and guideline-based reasoning, covering all key points from the reference answer with no major omissions or errors."
  },
  "1591": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content from the reference answer, accurately describes the criteria for Oncotype DX testing, and provides appropriate justification without omissions or errors."
  },
  "1592": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and provides additional guideline-based rationale supporting the recommendation."
  },
  "1593": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and appropriate exceptions, with no major omissions or errors."
  },
  "1594": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides clear justification for the preferred treatment strategy."
  },
  "1595": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing molecular targeted therapy and appropriately positioning bone-targeted therapy as adjunctive, with no major omissions or errors."
  },
  "1596": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage, including drug examples, guideline recommendations, and supporting evidence, with no major omissions or errors."
  },
  "1597": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers主要随访频率和方式的差异，但对具体时间节点（如3年后每6个月、5年后每年）和低剂量无增强CT的强调略有不足，且未明确提及H&P（病史和查体）。"
  },
  "1598": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough, nuanced explanation, including diagnostic criteria and clinical decision-making. However, it introduces additional detail not present in the reference answer and slightly complicates the core message, which may cause minor deviation from the reference's straightforward recommendation for aggressive treatment if considered as two primaries."
  },
  "1599": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately explaining the rationale for omitting radiotherapy and emphasizing endocrine therapy, with no major omissions or errors."
  },
  "1600": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of axillary evaluation, guideline recommendations, and the rationale for not skipping pathological assessment, with no major omissions or errors."
  },
  "1601": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing staging, surgical risks, the necessity of pulmonary function assessment, and the preference for non-surgical treatment, with no major omissions or errors."
  },
  "1602": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，无重大遗漏或错误，准确说明了放疗耐受性对方案选择的决定性作用，并指出需重新评估治疗策略。"
  },
  "1603": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the timing of radiotherapy, guideline recommendations, and the rationale for preferring mastectomy, with no major omissions or errors."
  },
  "1604": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive detail, supporting evidence, and guideline references without any major omissions or errors."
  },
  "1605": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the preference for surgery, the rationale, and the role of radiotherapy only when surgery is contraindicated. No major omissions or errors are present."
  },
  "1606": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating with guideline references and rationale, without any major omissions or errors."
  },
  "1607": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points and providing additional guideline support without introducing errors or omissions."
  },
  "1608": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical content from the reference answer, with additional relevant guideline details and no major omissions or errors."
  },
  "1609": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately describes follow-up intervals, and cites relevant guidelines, with no major omissions or errors."
  },
  "1610": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical reasoning, covers all key points from the reference answer, and includes additional relevant details without any major omissions or errors."
  },
  "1611": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It accurately reflects current guidelines and provides appropriate reasoning for not routinely recommending FDG-PET/CT or brain MRI in this scenario."
  },
  "1612": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and alternative treatment options without any major omissions or errors."
  },
  "1613": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including drug names, guideline recommendations, and the rationale for prioritizing BRAF V600E-targeted therapy, with no major omissions or errors."
  },
  "1614": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough discussion, including the limitations of non-contrast CT and alternative strategies, but it overemphasizes the reduction in accuracy compared to the reference answer, which states that non-contrast CT is sufficient for standard follow-up without significant impact on accuracy or feasibility."
  },
  "1615": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects current guidelines, and covers all key points from the reference answer, including the preference for concurrent chemoradiotherapy, the role of osimertinib as consolidation, and the limited scenarios for EGFR-TKI monotherapy."
  },
  "1616": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the indication, evidence basis, and EGFR mutation considerations, with no major omissions or errors."
  },
  "1617": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points, rationale, and guideline recommendations without omissions or errors."
  },
  "1618": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity to exclude distant metastasis before proceeding with systemic or concurrent chemoradiotherapy, and provides appropriate rationale and supporting details without omissions or errors."
  },
  "1619": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the need to prioritize HER2-targeted therapy in combination with endocrine therapy, and not recommending endocrine therapy alone. It also provides supporting evidence and guideline references without any major omissions or errors."
  },
  "1620": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly prioritizing emergency management of life-threatening hemoptysis over routine imaging, and only recommending full staging once the patient is stabilized. No major omissions or errors are present."
  },
  "1621": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, including the prioritization of re-resection, the role of radiotherapy as a secondary option, and referencing current guidelines. No major omissions or errors are present."
  },
  "1622": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including evidence basis, guideline recommendations, and the rationale for omitting ALND. However, it introduces some additional background and nuances (e.g., referencing TAD and guidelines in more detail) that, while accurate, slightly diverge from the concise reference answer and may introduce minor ambiguity regarding the strictness of the criteria."
  },
  "1623": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the necessity of pathological confirmation before local treatment and explaining the rationale, with no major omissions or errors."
  },
  "1624": {
    "score": 3.0,
    "explanation": "3: The model answer provides a comprehensive discussion of alternative treatments and individualized decision-making but omits the key point that, in the absence of available TRK抑制剂,系统化疗应作为一线优先选择, as stated in the reference answer. This constitutes a significant omission regarding the standard treatment sequence."
  },
  "1625": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It clearly prioritizes orthopedic stabilization and palliative radiotherapy before systemic therapy, and provides appropriate rationale and guideline references."
  },
  "1626": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points without omissions or errors. It clearly explains why targeted therapy is not preferred and outlines the appropriate standard treatment options."
  },
  "1627": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately explaining that further routine testing for ALK, ROS1, BRAF is unnecessary for first-line treatment decisions in this context, and adds minor guideline and clinical rationale without introducing errors or omissions."
  },
  "1628": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points from the reference answer, and provides additional relevant details without any major omissions or errors."
  },
  "1629": {
    "score": 2.0,
    "explanation": "2: The model answer provides a reasonable discussion but contains a notable error by recommending best supportive care as the primary management, rather than systemic therapy, which is the guideline-based first-line treatment for this scenario. It also incorrectly states that systemic therapy is not prioritized, which contradicts the reference answer."
  },
  "1630": {
    "score": 2.0,
    "explanation": "2: The model answer contradicts the reference answer by recommending routine follow-up without increased imaging, despite the presence of a new radiological abnormality. This is a notable error and does not align with standard post-operative surveillance recommendations for this scenario."
  },
  "1631": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to avoid routine enhanced CT in patients with moderate chronic kidney disease and recommending non-contrast low-dose CT, with no major omissions or errors."
  },
  "1632": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points with additional relevant details and no major omissions or errors."
  },
  "1633": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the recommendation to use ALK inhibitors in ALK-rearranged squamous cell carcinoma, and provides additional supporting rationale without any omissions or errors."
  },
  "1634": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that brain MRI is mandatory for all T2aN0 peripheral NSCLC patients, whereas guidelines consider it optional in asymptomatic cases. This represents a notable error and overstates the requirement, missing the nuance in the reference answer."
  },
  "1635": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points with additional relevant explanation and no major omissions or errors."
  },
  "1636": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points in the reference answer, including the use of liquid biopsy (ctDNA) when tissue biopsy is not feasible, and emphasizes the importance and guideline support for molecular testing to guide systemic therapy. No major omissions or errors are present."
  },
  "1637": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, relevant staging, and the need for MDT assessment, with no major omissions or errors."
  },
  "1638": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with comprehensive coverage and no major omissions or errors. It provides clear rationale and guideline support for prioritizing EGFR-TKI over immunotherapy in this scenario."
  },
  "1639": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the importance of adjuvant radiotherapy for R1 margins, the limitations of systemic therapy alone, and guideline recommendations, with no major omissions or errors."
  },
  "1640": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive, accurate, and guideline-based reasoning, correctly concluding that single endocrine therapy is preferred and chemotherapy is not routinely recommended for this patient profile, matching the reference answer in clinical content with no major omissions or errors."
  },
  "1641": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and appropriate recommendations without omissions or errors."
  },
  "1642": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly covering all key points without omissions or errors, and provides clear justification and guideline support."
  },
  "1643": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for prioritizing interventional procedures over radiotherapy in acute airway obstruction, with no significant omissions or errors."
  },
  "1644": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，无重大遗漏或错误，并补充了指南依据和ALK重排在鳞癌中的罕见性，内容更为详实。"
  },
  "1645": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, relevant details, and no major omissions or errors."
  },
  "1646": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional guideline-based justification without introducing inaccuracies."
  },
  "1647": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including drug recommendations, timing, guideline support, and rationale, with no major omissions or errors."
  },
  "1648": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical content, including guideline recommendations and the rationale for molecular testing. However, it omits mention of PD-L1 testing, which is included in the reference answer as part of comprehensive assessment for systemic therapy."
  },
  "1649": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, exceptions, and guideline support for not routinely recommending invasive N3 confirmation in this patient population, with no major omissions or errors."
  },
  "1650": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully addressing the distinction between metastatic disease and synchronous primary lung cancers, and appropriately recommends considering curative treatment when both lesions are potentially resectable. There are no major omissions or errors."
  },
  "1651": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the limitations of the current workup and the necessity of FDG-PET/CT and brain MRI, with no major omissions or errors."
  },
  "1652": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and practical considerations without any major omissions or errors."
  },
  "1653": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need for strict assessment, the non-routine recommendation of combined therapy, and the importance of individualized decision-making based on lung function. It also adds relevant clinical considerations without introducing errors or omissions."
  },
  "1654": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and provides additional relevant justification."
  },
  "1655": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, guideline references, rationale, and specific follow-up recommendations without omissions or errors."
  },
  "1656": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional guideline-based justification without introducing inaccuracies."
  },
  "1657": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with comprehensive coverage, no major omissions, and accurate emphasis on the necessity of combining bone-protective agents with radiotherapy for optimal management."
  },
  "1658": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points with no major omissions or errors, and even provides additional guideline support and rationale."
  },
  "1659": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，无重大遗漏或错误，并补充了指南依据和具体理由，内容完整。"
  },
  "1660": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately addresses the metabolic risks, guideline recommendations, and alternative management in Child-Pugh C patients, and contains no major omissions or errors compared to the reference answer."
  },
  "1661": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns well with the reference answer, providing appropriate follow-up intervals and rationale. However, it introduces slightly different time frames (e.g., 2–5 years, 5 years after) and additional details not specified in the reference, which could be considered minor deviations."
  },
  "1662": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and aligns with the reference answer, but it provides a slightly different (and more detailed) follow-up interval and omits explicit mention of H&P (history and physical) as part of the follow-up. Otherwise, the clinical content is accurate and appropriate."
  },
  "1663": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and addressing the impact of steroid use, with no major omissions or errors."
  },
  "1664": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including standard indications, risks, guideline recommendations, and the need for individualized assessment and alternative options in the context of severe hepatic dysfunction."
  },
  "1665": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive clinical reasoning, includes all key points from the reference answer, and adds relevant details about diagnostic criteria and guidelines, with no major omissions or errors."
  },
  "1666": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points, including patient performance status, tumor pathology, severity of SVCS, and treatment tolerability. However, it introduces additional details not present in the reference answer and does not explicitly state that concurrent chemoradiation is preferred if the patient has not received prior chemoradiation, which is a key point in the reference."
  },
  "1667": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant detail supporting the same conclusion."
  },
  "1668": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline-based recommendations without omissions or errors."
  },
  "1669": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive, guideline-based reasoning that matches the reference answer in clinical content, with no major omissions or errors. It clearly states that endocrine therapy alone is insufficient and that standard care includes chemotherapy plus trastuzumab, aligning fully with the reference."
  },
  "1670": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale and references key studies, but it incorrectly states that radiotherapy should not be omitted, whereas the reference answer supports omission based on current criteria. This represents a significant clinical inaccuracy despite otherwise comprehensive coverage."
  },
  "1671": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing all key considerations (lung function, tumor location, risks of surgery, and advantages of SABR), and even provides guideline support without introducing errors or omissions."
  },
  "1672": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "1673": {
    "score": 5.0,
    "explanation": "5: The model answer accurately addresses the question, clearly stating that there is insufficient evidence to support continued use of HER2-targeted agents after progression, and provides detailed, guideline-based reasoning consistent with current clinical standards."
  },
  "1674": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the scenario, rationale, and necessary caveats, with no major omissions or errors."
  },
  "1675": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need for increased imaging frequency upon new radiological findings, even in asymptomatic patients, and provides appropriate rationale and guideline references without omissions or errors."
  },
  "1676": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant details supporting the reasoning."
  },
  "1677": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately distinguishing stage IIIb/IIIC from stage IV, correctly prioritizing concurrent chemoradiotherapy, and providing appropriate caveats and references without any major omissions or errors."
  },
  "1678": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, thoroughly explaining the rationale and referencing guidelines, with no major omissions or errors."
  },
  "1679": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the main points of the reference answer, including the use of无增强胸部CT and maintaining standard follow-up intervals. However, it introduces additional options (MRI, PET/CT) that are not routinely recommended for follow-up per the reference, making the answer slightly broader than required. Minor omissions include not explicitly stating that PET/CT and脑MRI are not routinely recommended."
  },
  "1680": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, risks, and guideline recommendations, matching the reference answer in content and rationale with no major omissions or errors."
  },
  "1681": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and provides additional guideline-based rationale without introducing errors or omissions."
  },
  "1682": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, guideline-based, and fully aligns with the reference answer, with no major omissions or errors. It clearly explains the rationale and appropriate indications for advanced imaging, matching the reference content."
  },
  "1683": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and addressing special circumstances without any major omissions or errors."
  },
  "1684": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，明确指出高龄且严重肺功能不全患者追加放疗风险大，通常不被视为合理选项，并补充了指南依据，无明显遗漏或错误。"
  },
  "1685": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends routine FDG-PET/CT for all such cases, which contradicts the reference answer stating it should not be routine but reserved for specific situations. While the answer provides some relevant rationale, it contains a notable error in clinical recommendation."
  },
  "1686": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, referencing guidelines, and providing appropriate clinical recommendations without omissions or errors."
  },
  "1687": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with comprehensive coverage and no major omissions or errors. It even provides additional guideline references and practical considerations, fully supporting the recommendation."
  },
  "1688": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant details supporting the rationale for PD-L1 testing."
  },
  "1689": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the indications for stent placement and radiotherapy, the need for individualized assessment after prior chemoradiotherapy, and the role of symptom palliation. It provides additional detail without introducing errors or omissions."
  },
  "1690": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the need to prioritize local control of hemoptysis before systemic therapy, and provides additional relevant details without any omissions or errors."
  },
  "1691": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, correctly emphasizing the need to increase imaging follow-up frequency in the presence of new or residual abnormalities, and provides additional guideline context without any major omissions or errors."
  },
  "1692": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects guideline recommendations, and covers all key points from the reference answer without omissions or errors."
  },
  "1693": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and emphasizing the necessity of systematic mediastinal evaluation beyond a single lymph node biopsy, with no major omissions or errors."
  },
  "1694": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the necessity of biomarker testing before systemic therapy, guideline recommendations, and exceptions for urgent cases, with no major omissions or errors."
  },
  "1695": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, aligns fully with the reference answer, and provides additional guideline-based justification without any omissions or errors."
  },
  "1696": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate coverage of both follow-up strategies, clearly explains the rationale and differences in patient populations and treatment modalities, and aligns closely with the reference answer without major omissions or errors."
  },
  "1697": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline references, with no major omissions or errors."
  },
  "1698": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need for individualized risk assessment, the fact that COPD is not an absolute contraindication, and the importance of balancing risks and benefits. It also adds relevant details about perioperative management and alternative treatments, with no major omissions or errors."
  },
  "1699": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed, guideline-based reasoning, but it introduces a distinction between PD-L1 1–49% and ≥50% that is not present in the reference answer, which more simply states that immunotherapy monotherapy is recommended for all PD-L1 ≥1% cases. This extra nuance, while accurate, constitutes a minor omission relative to the reference answer's broader recommendation."
  },
  "1700": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional relevant details without introducing inaccuracies."
  },
  "1701": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough analysis and covers most clinical aspects, but it introduces significant nuance and caution regarding the high-risk nature of micropapillary carcinoma, suggesting possible consideration of adjuvant therapy, which is not supported by the reference answer. This introduces some inaccuracy and partial deviation from the guideline-based recommendation."
  },
  "1702": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale for SRS preference, guideline support, and the limited indications for WBRT, with no major omissions or errors."
  },
  "1703": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the requirement for confirmed ERBB2（HER2） mutation positivity before using fam-trastuzumab deruxtecan-nxki, with no omissions or errors."
  },
  "1704": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It covers all key points, including the rationale, guideline references, and the role of SABR as an alternative."
  },
  "1705": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, sequence, and guideline recommendations without omissions or errors."
  },
  "1706": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, correctly emphasizing that in patients unable to tolerate systemic therapy, postoperative radiotherapy alone (not concurrent chemoradiotherapy) is appropriate, and supports this with guideline references. No major omissions or errors are present."
  },
  "1707": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, criteria, and management distinctions outlined in the reference answer, with no major omissions or errors. It provides a comprehensive, guideline-based explanation consistent with the reference."
  },
  "1708": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, indications, and exceptions for treatment choice, with no major omissions or errors."
  },
  "1709": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately addressing the indication for T-DM1 based on ypN≥1 and providing supporting evidence from the KATHERINE study without any major omissions or errors."
  },
  "1710": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the question, and provides guideline-based justification without any major omissions or errors."
  },
  "1711": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with no major omissions or errors. It even provides additional guideline and study references, enhancing its completeness."
  },
  "1712": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional detail on guidelines and clinical considerations, and contains no major omissions or errors."
  },
  "1713": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1714": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining why observation alone is not appropriate and detailing recommended interventions, with no major omissions or errors."
  },
  "1715": {
    "score": 3.0,
    "explanation": "3: The model answer misunderstands the question, recommending routine brain MRI for all such patients, whereas the reference answer specifies MRI is only indicated when new neurological symptoms appear. The model answer provides relevant rationale for symptomatic patients but incorrectly supports routine imaging, leading to a partial but inaccurate response."
  },
  "1716": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the impact of severe restrictive ventilatory impairment on surgical candidacy and emphasizing the preference for non-surgical multimodal therapy, with no major omissions or errors."
  },
  "1717": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of pathological confirmation before initiating stage III treatment, with no major omissions or errors."
  },
  "1718": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, providing comprehensive justification, guideline citations, and a clear conclusion with no major omissions or errors."
  },
  "1719": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable follow-up schedule and rationale but overstates the need for shorter intervals (every 3–6 months) and suggests more intensive surveillance than current evidence supports, missing the key point that there is no evidence for shorter intervals even with positive margins."
  },
  "1720": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and provides clear justification and guideline references."
  },
  "1721": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the indications for axillary lymph node dissection and referencing relevant guidelines, with no major omissions or errors."
  },
  "1722": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a thorough understanding, but it introduces additional details (如SBRT、观察等) not explicitly mentioned in the reference answer and slightly shifts emphasis toward局部放疗, whereas the reference answer更强调辅助系统治疗为可行选择且不建议直接放化疗。整体内容一致，细节略有扩展。"
  },
  "1723": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the recommendation, rationale, and appropriate indications for FDG-PET/CT or brain MRI, with no major omissions or errors."
  },
  "1724": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the inappropriateness of perioperative treatment in patients with poor lung function and emphasizing non-surgical options, with no major omissions or errors."
  },
  "1725": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, including the rationale for continued annual low-dose non-contrast chest CT follow-up, the lack of contraindication due to renal insufficiency, and guideline support. No major omissions or errors are present."
  },
  "1726": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the insufficiency of preoperative assessment without FDG-PET/CT and the risk of missing distant metastases, with no major omissions or errors."
  },
  "1727": {
    "score": 3.0,
    "explanation": "3: The model answer provides partial coverage, referencing guidelines and discussing individualized follow-up, but it omits the clear recommendation from the reference answer that imaging frequency should be increased in the presence of any suspicious radiological abnormality, even if asymptomatic. This is a significant omission."
  },
  "1728": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional guideline references and rationale."
  },
  "1729": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support without omissions or errors."
  },
  "1730": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the reference answer’s key points, including correct staging as M1b, the inapplicability of M0 treatment principles, and the need for oligometastatic (not widespread) management. It adds guideline references and further detail without introducing errors or omissions."
  },
  "1731": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key points from the reference answer, and provides additional relevant rationale without introducing errors or omissions."
  },
  "1732": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of treatment options and rationale but incorrectly prioritizes systemic therapy over chest radical chemoradiotherapy after local control of brain metastasis, which is inconsistent with the reference answer and current recommendations for potentially curable chest disease. There are some accurate points, but the treatment sequence and emphasis are not fully aligned."
  },
  "1733": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even expands with guideline references and rationale, fully supporting the correct approach."
  },
  "1734": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and even adds relevant details such as specific PFT parameters."
  },
  "1735": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the rationale for not recommending neoadjuvant systemic therapy due to early stage, drug contraindications, and safety concerns, and suggests surgery as the primary option. There are no major omissions or errors."
  },
  "1736": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining that BRAF V600E is a clear indication for targeted therapy regardless of PD-L1 status, and provides appropriate guideline-based justification with no major omissions or errors."
  },
  "1737": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly advises delaying systemic therapy until molecular results are available, which contradicts the reference answer’s emphasis on not delaying treatment for metastatic disease. While it provides some relevant rationale, this constitutes a notable error in clinical management."
  },
  "1738": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage, guideline support, and a clear conclusion that these high-risk factors constitute an indication for regional nodal irradiation. No major omissions or errors are present."
  },
  "1739": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the necessity, rationale, and guideline support for FDG-PET/CT before definitive chemoradiotherapy, with no major omissions or errors."
  },
  "1740": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale and references guidelines, but it incorrectly concludes that chemotherapy can be directly excluded without 21-gene testing, whereas the reference answer emphasizes the necessity of considering 21-gene testing for decision-making in this group. This represents a significant clinical omission."
  },
  "1741": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and no major omissions or errors."
  },
  "1742": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a nuanced understanding of current evidence and guidelines, but it introduces some ambiguity regarding the availability and efficacy of new EGFR-TKIs and does not clearly state that EGFR-TKI should be prioritized when available, as the reference answer does."
  },
  "1743": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and supporting evidence without omissions or errors. It even expands with guideline and study data, but does not introduce inaccuracies or irrelevant content."
  },
  "1744": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing concurrent chemoradiotherapy and appropriately addressing the role of systemic therapy, with no major omissions or errors."
  },
  "1745": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines, with no major omissions or errors."
  },
  "1746": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing staging, surgical indications, comorbidities, and standard treatment, with no major omissions or errors."
  },
  "1747": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly recommends routine FDG-PET/CT and brain MRI for any imaging abnormality during follow-up, which contradicts guidelines that reserve these tests for cases with clear evidence or suspicion of recurrence. While the answer provides rationale, it demonstrates a notable error in clinical decision-making."
  },
  "1748": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and even examples of targeted drugs, with no major omissions or errors."
  },
  "1749": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need to address liver dysfunction before systemic therapy, the risks of chemotherapy with liver impairment, and alternative management strategies. No major omissions or errors are present."
  },
  "1750": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, fully addressing the indications for adjuvant systemic therapy versus postoperative radiotherapy, and appropriately references current guidelines and evidence, with no major omissions or errors."
  },
  "1751": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides nuanced reasoning, but it overstates the appropriateness of systemic chemotherapy for ECOG 3 patients, whereas guidelines generally do not recommend standard initial chemotherapy for this group except in very select cases. The reference answer is more definitive in recommending supportive and palliative care as first-line."
  },
  "1752": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, supporting evidence, and guideline recommendations without omissions or errors."
  },
  "1753": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details about specific endocrine regimens and current recommendations, and no major omissions or errors."
  },
  "1754": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional guideline context without introducing inaccuracies."
  },
  "1755": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including the rationale, guideline recommendations, and appropriate imaging choices, with no major omissions or errors."
  },
  "1756": {
    "score": 1.0,
    "explanation": "1: The model answer directly contradicts the reference answer, stating that it is not necessary to wait until completion or interruption of current therapy before switching, whereas the reference answer says it is necessary. This is a major clinical error."
  },
  "1757": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable discussion of both systemic therapy and whole-brain radiotherapy, but it incorrectly prioritizes systemic chemotherapy as the first-line treatment in the context of extensive brain metastases, whereas the reference answer clearly states that palliative whole-brain radiotherapy should be prioritized to address neurological symptoms and improve quality of life. This represents a significant clinical inaccuracy."
  },
  "1758": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional guideline support and rationale without introducing inaccuracies."
  },
  "1759": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for not recommending repeat radiotherapy, outlining standard management, and mentioning rare exceptions, with no major omissions or errors."
  },
  "1760": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the requirement that surgical treatment presupposes resectability, and even elaborates on R0 resection and patient operability without introducing errors or omissions."
  },
  "1761": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects current guidelines and evidence, and addresses the specific scenario of renal insufficiency, with no major omissions or errors compared to the reference answer."
  },
  "1762": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, including the indication, risks in severe renal impairment, the need for monitoring and supplementation, and the rationale for use when bisphosphonates are contraindicated, with no major omissions or errors."
  },
  "1763": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the contraindication of trastuzumab due to heart failure, the need to avoid HER2-targeted therapy, and the recommendation to use alternative regimens with lower cardiac toxicity. It also provides guideline references and additional detail without introducing errors or omissions."
  },
  "1764": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a detailed, guideline-based rationale, but it introduces additional discussion about low-risk features and high-risk factors not explicitly mentioned in the reference answer, and is more conservative regarding chemotherapy. It does not fully align with the reference answer’s more direct recommendation for adjuvant chemotherapy in the absence of 21-gene testing, resulting in a minor omission."
  },
  "1765": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "1766": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the indications and rationale for not routinely recommending FDG-PET/CT or brain MRI, with no major omissions or errors."
  },
  "1767": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale and guideline-based recommendation but omits the option of completing the current first-line and maintenance therapy, which is also considered acceptable per the reference answer. It presents only one approach as preferred, missing the nuance of individualized decision-making based on disease progression and tolerance."
  },
  "1768": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content, accurately explains the rationale, and references relevant guidelines, with no major omissions or errors."
  },
  "1769": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning, recommendations, and supporting guidelines, with no major omissions or errors compared to the reference answer."
  },
  "1770": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and demonstrates a strong understanding of the clinical context, including drug indications, evidence basis, and guideline recommendations. However, it is more detailed than necessary and does not explicitly and concisely state that amivantamab-vmjw should not be prioritized as first-line therapy, as the reference answer does. Minor omissions include not directly stating its role as a post-line rather than first-line agent."
  },
  "1771": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale but incorrectly states that fam-trastuzumab deruxtecan-nxki is not recommended for squamous NSCLC with ERBB2 mutation, which contradicts the reference answer. It also introduces an additional organizational subtype prerequisite not required by the reference, resulting in partial accuracy with notable omissions."
  },
  "1772": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects guideline recommendations, and covers all key points from the reference answer without omissions or errors."
  },
  "1773": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and even cites relevant guidelines to support the recommendations."
  },
  "1774": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，详细阐述了随访频率的指南依据及与放疗人群的区别，无重大遗漏或错误。"
  },
  "1775": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of FDG-PET/CT before local treatment and providing detailed, accurate reasoning without omissions or errors."
  },
  "1776": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides comprehensive justification, guideline references, and clinical evidence, fully covering the required content."
  },
  "1777": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale against surgery, referencing guidelines, and recommending appropriate alternative treatments for symptom control and hemostasis. No major omissions or errors are present."
  },
  "1778": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need for prioritizing local salvage therapy over direct imaging follow-up, and provides appropriate rationale and guideline references without major omissions or errors."
  },
  "1779": {
    "score": 3.0,
    "explanation": "3: The model answer provides a nuanced, guideline-based approach and covers relevant considerations, but it partially contradicts the reference answer by suggesting that routine follow-up may be appropriate if the imaging abnormality lacks malignant features, whereas the reference answer recommends increased imaging frequency for any new abnormality. This represents a significant omission relative to the reference standard."
  },
  "1780": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, clearly stating that axillary imaging is essential and cannot be omitted, while axillary biopsy is only needed if imaging is suspicious. There are no major omissions or errors."
  },
  "1781": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and even provides additional guideline references and clarifications."
  },
  "1782": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical decision points, but introduces a conditional approach based on symptom severity, which is not explicitly stated in the reference answer. The reference answer prioritizes local radiotherapy for any significant local symptoms, while the model answer allows for immediate systemic therapy if symptoms are not severe, representing a minor deviation."
  },
  "1783": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "1784": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1785": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering the exclusion of distant metastasis, the standard of concurrent chemoradiotherapy, the non-recommendation of surgery, and the need for multidisciplinary evaluation, with no major omissions or errors."
  },
  "1786": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient selection, rationale (local control, toxicity), and guideline recommendations, with no major omissions or errors."
  },
  "1787": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical reasoning and recommendations in the reference answer, with no major omissions or errors, and provides additional guideline context and practical steps."
  },
  "1788": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the necessity of whole-body staging with FDG-PET/CT and brain MRI, the rationale, guideline support, and the impact of staging on treatment decisions, with no major omissions or errors."
  },
  "1789": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It clearly prioritizes orthopedic fixation and palliative radiotherapy before systemic targeted therapy, and provides sound reasoning consistent with the reference."
  },
  "1790": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, including the limitations of PET/CT, the need for alternative imaging, and the relative sensitivities of different modalities."
  },
  "1791": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional guideline support and practical considerations, without any major omissions or errors."
  },
  "1792": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical considerations, and aligns fully with the reference answer, with no major omissions or errors."
  },
  "1793": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and appropriately referencing guidelines."
  },
  "1794": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points, including the rarity of ALK rearrangement in SCC, guideline recommendations, efficacy evidence, and the rationale for prioritizing ALK inhibitors over chemotherapy or immunotherapy. No major omissions or errors are present."
  },
  "1795": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the ECOG 3 contraindication, discusses relevant trial populations, and provides appropriate nuance and references, fully matching the reference answer with no major omissions or errors."
  },
  "1796": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and additional relevant considerations without any major omissions or errors."
  },
  "1797": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable approach but omits the guideline-based recommendation for ongoing routine cessation support for all patients, regardless of current smoking status, as emphasized in the reference answer. It inaccurately limits intervention to only those with relapse risk, missing the preventive aspect."
  },
  "1798": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately recommending concurrent chemoradiotherapy and providing appropriate justification without omissions or errors."
  },
  "1799": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the prioritization of non-surgical local therapies in patients with severe pulmonary dysfunction, and provides appropriate rationale and guideline support without omissions or errors."
  },
  "1800": {
    "score": 3.0,
    "explanation": "3: The model answer provides a thorough discussion of staging, oligometastatic disease, and treatment options, but it incorrectly prioritizes immediate systemic therapy over local control of the primary and regional disease, which contradicts the reference answer's emphasis on local treatment first in this specific scenario."
  },
  "1801": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points, including the preference for non-surgical approaches, rationale, and guideline support, but it introduces an \"exception\" about surgery that is not mentioned in the reference answer, making it slightly less direct and potentially less aligned with the reference's clear recommendation against surgery as first choice."
  },
  "1802": {
    "score": 5.0,
    "explanation": "5: The model answer provides all key clinical content from the reference answer, including the necessity of PET/CT and brain MRI for accurate staging, the rationale for not proceeding without these, and guideline recommendations, with no major omissions or errors."
  },
  "1803": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the rationale, recommended regimen, and relevant guidelines, with no major omissions or errors."
  },
  "1804": {
    "score": 5.0,
    "explanation": "5: The model answer provides all the key clinical content from the reference answer, with accurate explanation and no major omissions or errors."
  },
  "1805": {
    "score": 5.0,
    "explanation": "5: The model answer provides all the key clinical content from the reference answer, with no major omissions or errors, and even elaborates on the rationale and guidelines, fully supporting the conclusion."
  },
  "1806": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key points from the reference answer, including the limitations of PET/CT, the need for caution regarding understaging, and practical recommendations. However, it is more detailed and slightly expands on the reference, with minor omissions such as not explicitly stating the risk of missing small metastases as concisely as the reference answer."
  },
  "1807": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully explaining the rationale for not recommending adjuvant endocrine therapy and covering all key points without omissions or errors."
  },
  "1808": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional detail and no major omissions or errors. It accurately reflects current guidelines and the nuanced decision-making process."
  },
  "1809": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the risks, rationale, and alternative strategies, with no major omissions or errors."
  },
  "1810": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, correctly emphasizing the need for 6-monthly imaging follow-up and suggesting non-contrast CT as an alternative, with no major omissions or errors."
  },
  "1811": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage, rationale, guideline support, and practical recommendations without any major omissions or errors."
  },
  "1812": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key points, including the preference for endocrine therapy with ovarian suppression and the exceptions for endocrine resistance or visceral crisis. However, it introduces some nuance about endocrine resistance that, while accurate, slightly complicates the clear prioritization stated in the reference answer. Minor differences in emphasis prevent a perfect score."
  },
  "1813": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers the clinical content of the reference answer, accurately describing the rationale, guideline support, and considerations for using radiotherapy as a local salvage treatment in this scenario, with no major omissions or errors."
  },
  "1814": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and provides additional guideline-based justification without introducing inaccuracies."
  },
  "1815": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately covers all key clinical points from the reference answer, and provides detailed justification for the necessity of both FDG-PET/CT and bronchoscopy in preoperative decision-making for NSCLC. No major omissions or errors are present."
  },
  "1816": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion but inaccurately states that a tumor size of just over 1 cm is not a standard indication for neoadjuvant therapy in triple-negative breast cancer, which contradicts the reference answer and current guidelines. There are some correct elements, but the main clinical recommendation is incorrect."
  },
  "1817": {
    "score": 3.0,
    "explanation": "3: The model answer provides guideline-based recommendations supporting a higher frequency of CT (every 3–6 months), which contradicts the reference answer stating every 6 months is sufficient for this group. While the answer is detailed and references guidelines, it omits the key point that increased frequency is not necessary for IB stage patients without postoperative radiotherapy, leading to a significant inaccuracy."
  },
  "1818": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, clearly prioritizing bone stabilization and local radiotherapy before systemic therapy, with no major omissions or errors."
  },
  "1819": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors. It clearly prioritizes targeted therapy over repeat radiotherapy, provides appropriate rationale, and references guidelines, fully aligning with the reference answer."
  },
  "1820": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant detail supporting the recommendation against surgery."
  },
  "1821": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of pulmonary function testing before perioperative assessment and referencing relevant guidelines, with no major omissions or errors."
  },
  "1822": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline support, and evidence for prioritizing Fam-trastuzumab deruxtecan-nxki, with no major omissions or errors."
  },
  "1823": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, guidelines, and evidence for prioritizing immunotherapy over KRAS G12C inhibitors as first-line treatment, with no major omissions or errors."
  },
  "1824": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the need to wait for molecular results before initiating targeted therapy, and provides appropriate rationale and guideline references without omissions or errors."
  },
  "1825": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers all key clinical points, including trial data, drug labeling, and guideline recommendations, but it is slightly more permissive than the reference answer regarding use in moderate hepatic impairment, suggesting possible use with caution rather than generally not recommending routine use. Minor differences in emphasis account for the deduction."
  },
  "1826": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline-based recommendations without omissions or errors."
  },
  "1827": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional relevant details and guideline references."
  },
  "1828": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, with no major omissions or errors, and even adds relevant details about patient assessment and supportive care."
  },
  "1829": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant detail supporting the necessity of preoperative pulmonary function testing."
  },
  "1830": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, including the absolute contraindication of trastuzumab in severe cardiac dysfunction, the risks of chemotherapy, and alternative management considerations, with no major omissions or errors."
  },
  "1831": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately reflects the reference answer, and includes all key points without major omissions or errors. It also appropriately emphasizes the need for local treatment as the first choice and clarifies the indications for systemic therapy."
  },
  "1832": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including the contraindication of standard concurrent chemoradiotherapy in severe pulmonary dysfunction, the increased risk of complications, and alternative treatment options. There are no major omissions or errors."
  },
  "1833": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline citations, and no major omissions or errors."
  },
  "1834": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately addresses both the evidence for capecitabine and the contraindication in moderate hepatic impairment, and provides appropriate clinical reasoning and references, fully matching the reference answer with no major omissions or errors."
  },
  "1835": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable rationale for starting systemic therapy without waiting for molecular results, but it omits the guideline-recommended priority of obtaining molecular testing before initiating treatment and underestimates the importance of individualized therapy based on mutation status. This is a significant omission compared to the reference answer."
  },
  "1836": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including indications for endocrine therapy, patient selection, and drug options, with no major omissions or errors."
  },
  "1837": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional relevant details, and contains no major omissions or errors."
  },
  "1838": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional guideline references and rationale."
  },
  "1839": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the impact of significant liver dysfunction on neoadjuvant therapy, emphasizing the need to correct liver abnormalities before systemic treatment, and providing appropriate clinical reasoning and references."
  },
  "1840": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable summary of guideline recommendations and discusses the use of low-dose CT, but it inaccurately states that annual low-dose CT after 2 years is within standard boundaries, whereas the reference answer clearly states this is premature and may risk missing early recurrence. This represents a significant omission regarding the timing and frequency of imaging."
  },
  "1841": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content, accurately reflects guideline recommendations, and provides appropriate justification without omissions or errors."
  },
  "1842": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately reflecting guideline recommendations and providing clear rationale without omissions or errors."
  },
  "1843": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurately reflects the reference answer, and provides additional detail without introducing errors or omissions. It clearly states that FDG-PET/CT and brain MRI are not routinely indicated unless there are suspicious findings or symptoms, fully aligning with the reference answer."
  },
  "1844": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key points from the reference answer, including rationale, guideline recommendations, and appropriate exceptions, with no major omissions or errors."
  },
  "1845": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining that immunotherapy monotherapy is not recommended and providing appropriate guideline-based alternatives without omissions or errors."
  },
  "1846": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and recommendations without omissions or errors."
  },
  "1847": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key points from the reference answer, including guideline recommendations, the lack of necessity for adjuvant therapy, the importance of considering drug toxicity in renal insufficiency, and the need for individualized decision-making."
  },
  "1848": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, provides additional relevant details, and accurately reflects current guidelines without any major omissions or errors."
  },
  "1849": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale for concurrent chemoradiotherapy as the preferred option, referencing guidelines, and correctly distinguishing indications for systemic therapy. No major omissions or errors are present."
  },
  "1850": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully addressing the scenario, providing rationale, and citing guidelines, with no major omissions or errors."
  },
  "1851": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that routine FDG-PET/CT or brain MRI is not recommended during follow-up unless there are new symptoms or imaging abnormalities, and provides appropriate guideline-based justification."
  },
  "1852": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even adds relevant guideline support and practical considerations for SABR in central tumors."
  },
  "1853": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a nuanced, guideline-based approach, but it introduces additional stratification (stable vs. progressive changes) not explicitly mentioned in the reference answer, which simply recommends increased imaging for any residual or new abnormality. This adds minor complexity but does not omit major clinical content."
  },
  "1854": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that more intensive follow-up is required solely due to the presence of COPD, which contradicts current guidelines that do not recommend increased surveillance for solid nodules <6 mm even in high-risk individuals. This represents a notable error in clinical content."
  },
  "1855": {
    "score": 3.0,
    "explanation": "3: The model answer provides a reasonable summary of guideline recommendations and addresses the question, but it inaccurately states that III期患者的随访频率与I期患者相同, missing the reference answer's emphasis that III期患者推荐的随访频率应高于I期，并且每半年一次为最低要求，实际临床常建议更密集随访。"
  },
  "1856": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering all key points with no major omissions or errors, and even provides additional guideline-based rationale without introducing inaccuracies."
  },
  "1857": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive rationale, guideline context, and appropriate recommendations without omissions or errors."
  },
  "1858": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even supporting evidence from guidelines, with no major omissions or errors."
  },
  "1859": {
    "score": 3.0,
    "explanation": "3: The model answer provides detailed information about guidelines and the importance of preoperative pulmonary function testing, but it incorrectly states that surgery should not proceed without such testing, which contradicts the reference answer that allows surgery if the patient is clinically operable, though it is not ideal. This represents a significant inaccuracy."
  },
  "1860": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors. It provides a clear recommendation for TKI, includes rationale, and references relevant guidelines, fully covering the required content."
  },
  "1861": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It clearly explains the rationale for surgery as the initial treatment and appropriately addresses the role of adjuvant therapy."
  },
  "1862": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional rationale and guideline references."
  },
  "1863": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale, indications, and guideline recommendations for MRI in this scenario, with no major omissions or errors."
  },
  "1864": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a detailed, nuanced discussion, but it introduces additional considerations and exceptions not present in the reference answer, which could be seen as minor omissions or overcomplications relative to the more straightforward recommendation against re-irradiation."
  },
  "1865": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately prioritizing systemic therapy and correctly describing the supportive role of bone-protective agents, with no major omissions or errors."
  },
  "1866": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the need to adjust imaging frequency based on the nature of the abnormality, the rationale for closer monitoring, and specific criteria for decision-making, with no major omissions or errors."
  },
  "1867": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the criteria and rationale, with no major omissions or errors."
  },
  "1868": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale, alternative treatments, and referencing guidelines, with no major omissions or errors."
  },
  "1869": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, clearly explaining why perioperative therapy is not preferred and emphasizing the need to prioritize non-surgical options due to severe pulmonary dysfunction, with no major omissions or errors."
  },
  "1870": {
    "score": 5.0,
    "explanation": "5: The model answer fully covers all key clinical points from the reference answer, elaborates on the rationale, and includes relevant guideline recommendations without any major omissions or errors."
  },
  "1871": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points, rationale, and guideline support, with no major omissions or errors."
  },
  "1872": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, including guideline recommendations, efficacy evidence, and the limited predictive value of PD-L1 in this context, with no major omissions or errors."
  },
  "1873": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, correctly prioritizing immunotherapy (with or without chemotherapy) and stating that further molecular screening is unnecessary, with no major omissions or errors."
  },
  "1874": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the prioritization of骨科手术和放疗 over NTRK靶向治疗, with no major omissions or errors. It even provides additional rationale and guideline references, fully aligning with the reference answer’s intent and content."
  },
  "1875": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive coverage with no major omissions or errors, and even adds relevant guideline references and clinical reasoning."
  },
  "1876": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the correct sequencing of surgery and chemotherapy, and clearly explaining why chemotherapy should not precede surgery in late pregnancy, with no major omissions or errors."
  },
  "1877": {
    "score": 2.0,
    "explanation": "2: The model answer incorrectly states that the follow-up frequency after definitive radiotherapy is the same as after surgery, missing the key point that radiotherapy patients require more frequent imaging (every 3–6 months). This is a notable error in clinical content."
  },
  "1878": {
    "score": 5.0,
    "explanation": "5: The model answer is identical in clinical content to the reference answer, with no major omissions or errors, and even provides additional relevant details and guideline references."
  },
  "1879": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with additional relevant details and no major omissions or errors."
  },
  "1880": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically comprehensive, accurately addresses the question, and includes all key points from the reference answer, with additional supporting evidence and guideline references. There are no major omissions or errors."
  },
  "1881": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed rationale for prioritizing systemic therapy, but it contradicts the reference answer, which recommends local resection of the brain metastasis first in this specific scenario. The model answer omits the option of initial local control for a single, resectable brain lesion and overemphasizes systemic therapy, leading to a significant clinical inaccuracy."
  },
  "1882": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, accurately describing the indication, rationale, and considerations for radiotherapy as a salvage option, with no major omissions or errors."
  },
  "1883": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容完全一致，详细阐述了同步放化疗的适应证、COPD的评估及注意事项，无重大遗漏或错误。"
  },
  "1884": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors, and even provides additional guideline references for completeness."
  },
  "1885": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with no major omissions or errors, and provides additional relevant detail and justification."
  },
  "1886": {
    "score": 5.0,
    "explanation": "5: The model answer accurately covers all key clinical points from the reference answer, including the increased surgical risk, the recommendation against surgery as first-line treatment, and the preference for SBRT or other non-surgical local therapies, with no major omissions or errors."
  },
  "1887": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing concurrent chemoradiotherapy, referencing guidelines, and clearly explaining why systemic therapy alone is not preferred. No major omissions or errors are present."
  },
  "1888": {
    "score": 3.0,
    "explanation": "3: The model answer provides a detailed discussion but over-recommends FDG-PET/CT for all patients with new imaging findings, whereas the reference answer states that neither brain MRI nor PET/CT should be routinely added unless recurrence or metastasis is suspected. This represents a partial but not fully accurate alignment with the reference."
  },
  "1889": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the necessity of FDG-PET/CT and brain MRI before SRS, and covers all key points without omissions or errors."
  },
  "1890": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the contraindication of ICI in active autoimmune disease, providing rationale, alternative recommendations, and referencing guidelines, with no major omissions or errors."
  },
  "1891": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key point that frequent enhanced CT suggests high-risk factors, listing several plausible high-risk features. However, it omits the specific recommendation that routine follow-up should be with low-dose, non-contrast CT annually, as emphasized in the reference answer."
  },
  "1892": {
    "score": 2.0,
    "explanation": "2: The model answer contains notable errors, as it incorrectly states that erlotinib, gefitinib, and dacomitinib should not be prioritized, which contradicts the reference answer and current evidence. While it provides some rationale and alternative recommendations, it omits the fact that these drugs are considered effective for S768I and can be used as first-line therapy."
  },
  "1893": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the indications, necessity of KRAS G12C mutation, and patient selection criteria, with no major omissions or errors."
  },
  "1894": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the need to assess surgical tolerance, the risks of surgery with poor lung function, and the recommendation for SBRT or other non-surgical options if surgery is not tolerated. No major omissions or errors."
  },
  "1895": {
    "score": 5.0,
    "explanation": "5: The model answer provides comprehensive and accurate clinical content, covering all key considerations from the reference answer and expanding with relevant details, without any major omissions or errors."
  },
  "1896": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the need for increased imaging frequency, rationale, and guideline support, with no major omissions or errors."
  },
  "1897": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, fully covering the recommendation to prioritize BRAF-targeted therapy and providing additional, accurate details without any major omissions or errors."
  },
  "1898": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the risks, guideline recommendations, and alternative management for patients with poor lung function, with no major omissions or errors."
  },
  "1899": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and including all key points without omissions or errors."
  },
  "1900": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including patient selection, guideline recommendations, and the rationale for SABR as the preferred curative option, with no major omissions or errors."
  },
  "1901": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a thorough discussion, but it slightly underemphasizes that辅助化疗联合曲妥珠单抗“可以考虑”，而不是“通常不推荐”，与参考答案的推荐力度略有不同，属于轻微遗漏。"
  },
  "1902": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and covers all key clinical points from the reference answer, with no major omissions or errors. It provides detailed reasoning, guideline references, and a clear conclusion consistent with the reference."
  },
  "1903": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the indications, rationale, and guideline recommendations, with no major omissions or errors."
  },
  "1904": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points regarding trastuzumab continuation, pertuzumab consideration for node-positive patients, and the necessity of endocrine therapy, with no major omissions or errors."
  },
  "1905": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points with no major omissions or errors. It clearly states that surgery is preferred if feasible, with radiotherapy as an alternative only if surgery is not possible, and provides appropriate guideline references."
  },
  "1906": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately describing the timing and modality adjustment for imaging surveillance, with no major omissions or errors."
  },
  "1907": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately addressing staging, the implications of the satellite nodule, and the appropriateness of surgery, with no significant omissions or errors."
  },
  "1908": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately explaining the rationale and providing appropriate follow-up recommendations without omissions or errors."
  },
  "1909": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, with no major omissions or errors, and even provides additional supporting evidence and practical considerations."
  },
  "1910": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, accurately recommends annual low-dose non-contrast chest CT after 3 years, and provides additional guideline-based rationale without any major omissions or errors."
  },
  "1911": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline support, and practical considerations without any major omissions or errors."
  },
  "1912": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the rationale for prioritizing surgical intervention over systemic therapy in the absence of extrathoracic disease, and referencing relevant guidelines. No major omissions or errors are present."
  },
  "1913": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides a nuanced, guideline-based discussion, but it omits the clear statement that adjuvant chemotherapy is the standard choice for triple-negative breast cancer even with small tumors, as emphasized in the reference answer. It instead leans toward observation as the preferred option, which is a minor deviation from the reference standard."
  },
  "1914": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addressing the need for intensified surveillance and early imaging in the context of R2 resection and new symptoms, with no major omissions or errors."
  },
  "1915": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly explaining the rationale and guidelines, with no major omissions or errors."
  },
  "1916": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical reasoning, but it introduces additional nuance about risk stratification and the possibility of omitting chemotherapy in low-risk cases, which is not explicitly mentioned in the reference answer. This is a minor omission in directness but does not contain major errors."
  },
  "1917": {
    "score": 5.0,
    "explanation": "5: The model answer contains all the key clinical content of the reference answer, with additional detail and no major omissions or errors. It fully addresses the indication for surgery, the importance of patient selection, and guideline recommendations."
  },
  "1918": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately covering all key points without omissions or errors, and even provides additional clarification consistent with current guidelines."
  },
  "1919": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides strong justification and references, but it omits that both continuing current therapy or switching to ROS1-targeted therapy are guideline-accepted options, with a preference for early switch; it presents switching as the only correct approach, missing the nuance in the reference answer."
  },
  "1920": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and covers the key clinical considerations, including the standard recommendation for radiotherapy, the need for individualized assessment in high-risk patients, and possible alternatives. However, it omits the specific suggestion of partial breast irradiation as an alternative, which is present in the reference answer."
  },
  "1921": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing all key points and even elaborating with guideline references and rationale, without any major omissions or errors."
  },
  "1922": {
    "score": 5.0,
    "explanation": "5: The model answer contains all key clinical content from the reference answer, with no major omissions or errors, and even expands with guideline references and clinical reasoning."
  },
  "1923": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points including the rationale for waiting, exceptions for urgent cases, and relevant guidelines, with no major omissions or errors."
  },
  "1924": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning and no major omissions or errors. It fully addresses the need for routine pulmonary function testing in this scenario."
  },
  "1925": {
    "score": 3.0,
    "explanation": "3: The model answer provides a well-reasoned argument for sequential chemoradiotherapy and cites guidelines, but it directly contradicts the reference answer, which prioritizes concurrent chemoradiotherapy for eligible patients. The model omits the reference's emphasis on improved local control and survival with concurrent therapy and does not mention that sequential therapy is reserved for those with poor performance status or comorbidities."
  },
  "1926": {
    "score": 5.0,
    "explanation": "5: The model answer covers all key clinical points from the reference answer, including the prioritization of reoperation, the role of radiotherapy as a secondary option, and the rationale for each. It also adds appropriate detail without introducing errors or omissions."
  },
  "1927": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the scenario, and provides guideline-based justification without omissions or errors."
  },
  "1928": {
    "score": 2.0,
    "explanation": "2: The model answer provides a detailed discussion but contradicts the reference answer's key point—namely, that local palliative therapy should be prioritized even with mild symptoms if imaging shows significant progression. The model instead suggests systemic therapy first, which is a notable error."
  },
  "1929": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly covering the preferred treatment sequence and the main tumor characteristics influencing the decision, with no major omissions or errors."
  },
  "1930": {
    "score": 4.0,
    "explanation": "4: The model answer is nearly complete and provides detailed information about afatinib's use, including pharmacokinetics and monitoring recommendations, but it slightly downplays the caution needed due to potential toxicity and does not explicitly mention considering alternative EGFR-TKIs with lower toxicity as in the reference answer."
  },
  "1931": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, providing comprehensive reasoning, guideline references, and appropriate recommendations without omissions or errors."
  },
  "1932": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, covering all key points without omissions or errors, and even provides additional guideline references for completeness."
  },
  "1933": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, accurately stating that routine FDG-PET/CT or brain MRI is unnecessary in asymptomatic patients and providing appropriate justification without omissions or errors."
  },
  "1934": {
    "score": 5.0,
    "explanation": "5: The model answer is comprehensive, accurate, and includes all key clinical content from the reference answer, with additional supporting evidence and rationale, and no major omissions or errors."
  },
  "1935": {
    "score": 5.0,
    "explanation": "5: The model answer is clinically identical to the reference answer, thoroughly addresses the risks of contrast in renal insufficiency, and clearly recommends non-contrast CT as first choice, with appropriate caveats for exceptions. No major omissions or errors."
  },
  "1936": {
    "score": 5.0,
    "explanation": "5: 模型答案与参考答案临床内容一致，无重大遗漏或错误，并补充了无对比CT的敏感性及其他替代影像学方法，内容完整。"
  }
}